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Abstract 
 
 
Haematopoietic stem cell transplantation (HSCT) is currently the only curative 
treatment for many patients with malignant and non-malignant haematological diseases.  
However, its success is greatly reduced by the development of complications, including 
graft-versus-host disease (GVHD), infection and relapse.  Human leukocyte antigen 
(HLA)-matching of patients and donors is essential in HSCT, but does not completely 
prevent such complications.  Thus, it is extremely likely that non-HLA genes also have 
an impact.   
 
Naturally occurring polymorphisms within non-HLA genes have been suggested to 
contribute to some of the genetic disparity that exists between transplant patients and 
donors, consequently, they may have the potential to influence HSCT outcome.  As a 
result, this study investigated the significance of non-HLA polymorphisms in HSCT.  
 
Polymorphisms in the genes of interleukin (IL) 2 (IL2, -330 T/G), 4 (IL4, -590 C/T), 6 
(IL6, -174 G/C) and 10 (IL10, -592 A/C, -1082 G/A), IL-1 receptor antagonist (IL-1Ra 
(IL1RN), intron 2 VNTR), tumour necrosis factor α (TNFα (TNFA), intron 3 (GA)n), 
TNF receptor II (TNFRII (TNFRSF1B), -196 M/R), interferon γ (IFNγ (IFNG), intron 1 
(CA)n), vitamin D receptor (VDR, intron 8 A/C, exon 9 T/C) and oestrogen receptor 
(ESR1, intron 1 A/G, intron 1 C/T) have been studied extensively in HLA-matched 
sibling transplantation, however, relatively little is known about their role in unrelated 
donor HSCT.  This study therefore examined these polymorphisms in the unrelated 
donor setting.  VDR intron 8 A/C, IFNG intron 1 (CA)n and IL6 -174 G/C were found to 
associate with GVHD in our cohort.  The VDR intron 8 A,A and IFNG intron 1 3,3 
genotypes correlated with severe acute GVHD (grades III-IV), whilst the IL6 -174 G,G 
genotype correlated with chronic GVHD.  No genetic associations were demonstrated 
with any other clinical outcome.  
 
This study also examined the +2044 G/A polymorphism in the gene encoding IL-13 
(IL13), an immunoregulatory cytokine that has been implicated in GVHD.  This 
polymorphism has been widely studied for disease associations; however, its role in 
HLA-matched sibling and unrelated donor HSCT is currently unknown.  In our 
transplant cohort the IL13 +2044 A allele was found to correlate significantly with both 
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acute and chronic GVHD.  Higher IL-13 expression was also observed in patients with 
these conditions, although this altered expression could not be directly attributed to IL13 
+2044 G/A.  The prognostic significance of pre-transplant IL-13 serum levels was also 
investigated.  No associations were observed between IL-13 expression and GVHD.  
Elevated pre-transplant IL-13 serum levels did, however, correlate with post-transplant 
relapse and Hodgkin disease in two independent cohorts.  Again, this altered expression 
could not be directly attributed to the IL13 +2044 G/A polymorphism. 
 
This study clearly demonstrates that non-HLA polymorphisms influence the outcome of 
both HLA-matched sibling and unrelated donor HSCT.  Thus, in the future, genotyping 
with respect to a panel of non-HLA polymorphisms may be used to complement HLA 
typing, increase the ability to predict the risk of transplant complications and allow 
post-transplant treatment strategies to be tailored to an individual.   
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Chapter 1. Introduction 
 
Haematopoietic stem cells (HSCs) are immature blood cells found in the bone marrow, 
from which all other types of blood cells evolve and differentiate.  Due to their ability to 
self-renew, a small number of HSCs can expand and generate a very large number of 
progeny HSCs.  This phenomenon is employed in haematopoietic stem cell 
transplantation (HSCT) to reconstitute the haematopoietic system of a transplant patient 
in order to overcome a functional deficit (Wodnar-Filipowicz 2008).  
 
HSCT is currently the only curative treatment for many malignant and non-malignant 
haematological diseases.  Despite this, a high transplant-related mortality (TRM) is 
associated with the procedure and its success is greatly limited by the development of 
complications, such as graft-versus-host disease (GVHD), infection and relapse 
(Appelbaum 2007).  Although significant advances have been made in the field of 
transplantation it is still uncertain which patients will develop such complications.  As a 
result, the identification of methods that permit the prediction of HSCT outcome prior 
to transplantation is becoming important.  As transplant complications are 
immunologically mediated, naturally occurring variations (polymorphisms) within 
genes associated with an individual’s capability to mount an immune response have 
emerged as possible predictive markers and are currently being studied for associations 
with complication development and thus transplant outcome.  Due to the complexity of 
HSCT it is unlikely that a single predictive genetic marker will exist.  The ultimate goal 
of this research is therefore the identification of a profile of genetic markers that can be 
used in combination with identified clinical risk factors (prognostic index) prior to 
transplantation to inform on HSCT outcome, so that patients at high risk of 
complications can be identified early and treatment strategies can be tailored to the 
individual or adjusted accordingly.  Such research may also lead to the identification of 
potential novel targets for future treatment modalities.         
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1.1 Haematopoietic Stem Cell Transplantation 
 
The atomic bomb essentially marked the beginning of interest in HSCT, with the 
detonation and subsequent effects of nuclear devices provoking great interest in the 
effects of irradiation on humans; particularly on bone marrow function (Perry and Linch 
1996; Baron and Storb 2004).  However, the era of HSCT actually began with the 
landmark observation by Jacobson et al, (1949) that the lethal effects of ionizing 
radiation on bone marrow could be prevented by shielding the spleens of mice with lead 
(Jacobson et al. 1949).  In 1951 it was demonstrated that this protection could also be 
conferred by intravenous infusion of bone marrow (Lorenz et al. 1951).  It was not 
however, until the mid-1950s that the protective effect of bone marrow was attributed to 
HSCs within the infusion (Barnes and Loutit 1954; Main and Prehn 1955).  This 
discovery and subsequent studies in mouse models led to the initial attempts at human 
HSCT (Thomas et al. 1957).  Although these transplants were largely unsuccessful they 
did provide firm evidence that the infusion of stem cells from one individual to another 
was possible.  Research continued, and eventual progress made in studies of primates 
and canines renewed hope that patients with haematological diseases could be treated by 
HSCT (van Bekkum 1977; Storb and Thomas 1985).  Finally, in the late-1960s/early-
1970s the first successful stem cell transplants were reported (Bach et al. 1968; Thomas 
et al. 1975).  Nowadays, HSCT is routinely used to treat diseases, such as acute and 
chronic leukaemias, lymphomas, anaemias and immunological deficiencies.           
 
Since these initial studies there has been a substantial growth in HSCT (Figure 1.1), 
with a dramatic increase in both the annual number of HSCT procedures and the 
number of diseases for which HSCT is considered appropriate.  Current estimates 
suggest that 55-60,000 transplants are undertaken worldwide each year and HSCT now 
offers a potential for cure or long-term control of a number of diseases where other 
treatment options fail (Wingard et al. 2002; Appelbaum 2007; Eapen and Rocha 2008).  
A better understanding of the underlying disease, transplant strategy and supportive care 
has permitted this escalation and consequently changed the role of HSCT from a 
desperate therapeutic manoeuvre to a curative treatment modality (Baron and Storb 
2004). 
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Figure 1.1 Annual numbers of allogeneic and autologous HSCT performed 
worldwide 1970-2005. Adapted from (Appelbaum 2007).  
 
 
 
HSCT may be autologous (stem cells from the patient), syngeneic (stem cells from a 
genetically identical donor) or allogeneic (stem cells from a genetically distinct donor).  
An autologous transplant involves the reinfusion of the patient’s own cells to provide a 
therapeutic benefit.  This process has inherently fewer complications than allogeneic 
transplantation, although there is a risk that the stem cell graft may contain residual 
tumour cells that can cause disease relapse (Bjorkstrand et al. 1996; Lowenberg and 
Voogt 1996).  Sibling donors that are genetically identical (syngeneic) are the ideal in 
HSCT, however, since few people have identical twins, this transplant type is relatively 
rare.  Patients without a genetically identical relative have the option of an allogeneic 
HSCT from a suitably matched family member, usually a sibling or from an unrelated 
donor.  This thesis concentrates on allogeneic HSCT from HLA-matched sibling or 
unrelated donors.  Autologous and syngeneic transplantation are not covered in this 
current study  
 
Allogeneic HSCT is initiated with a period of conditioning that prepares the patient for 
transplantation.  Traditionally, this has involved the administration of total body 
irradiation (TBI) alone or in combination with chemotherapeutic agents such as 
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cyclophosphamide, melphalan and busulphan (target proliferating cells) at a level that 
destroys all lymphoid and myeloid cells of the body (myeloablative conditioning, 
MAC).  The conditioning regimen has three main objectives: creation of space for the 
incoming graft, immunosuppression to prevent rejection of the donor cells by any 
residual host immune system and disease eradication.  Whilst conditioning is necessary 
for HSCT, myeloablative regimens are associated with considerable toxic side effects 
involving the gastrointestinal tract, liver and kidneys, that are responsible for the 
majority of TRM (Bacigalupo et al. 2000; Gratwohl 2008).   Thus, more recently there 
has been an emergence of HSCT using low intensity conditioning.  Such regimens aim 
to reduce the complications associated with myeloablation by employing smaller doses 
of radiation and chemotherapy.  Low intensity conditioning is based mainly on the 
chemotherapeutic agent fludarabine (induces lymphocyte apoptosis) and is considered 
as either non-myeloablative (fludarabine + low dose irradiation (2 Gray (Gy)) or 
reduced intensity (RIC, fludarabine + cyclophosphamide, melphalan or 
busulphan)(Gratwohl 2008).  Unlike conventional myeloablative preparations, low 
intensity regimens are primarily immunosuppressive, run lower risks of serious 
infections and TRM, but depend purely on the graft for disease eradication.  These 
newer transplant strategies are therefore employed mainly for the elderly and other 
patients who would otherwise be considered too weak to withstand myeloablation 
(Copelan 2006; Gratwohl 2008). 
 
The transplant procedure itself involves the infusion of HSCs into the peripheral blood, 
where, after briefly circulating in the bloodstream, they migrate to the bone marrow 
cavity and engraft (> 0.5x10
9 
neutrophils/L and > 50x10
9 
platelets/L for 3 consecutive 
days) (de Lima and Champlin 2001).  After several weeks of growth in the marrow, the 
expansion of stem cells is sufficient to normalize the blood count and reconstitute the 
immune system.  Stem cells from the haematopoietic system are the progenitors of 
subsequent blood cell lineages, that are able to self-renew and differentiate into many 
different cell types and can be obtained from a variety of sources; bone marrow, 
peripheral blood and cord blood (Wodnar-Filipowicz 2008).  Traditionally, stem cells 
for HSCT were obtained from the bone marrow, harvested from the rear of the pelvis 
(iliac crests) via needle aspiration under general anaesthetic.  Nowadays however, stem 
cells from the peripheral blood are most commonly employed in HSCT.  Peripheral 
blood stem cells (PBSC) are isolated and collected at the bed side through a process 
known as apheresis.  Growth factors such as granulocyte colony-stimulating factor (G-
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CSF) mobilise stem cells from the marrow cavity into the peripheral circulation and 
thus are used to boost the yield of PBSCs collected (Larghero et al. 2008).  Compared 
with marrow, PBSC collections are less invasive and associated with a more rapid 
haematologic recovery (engraftment), but they have been linked with late complications 
of HSCT (Jansen et al. 2005).  The third source of stem cells in transplantation is the 
blood from the umbilical cord and placenta.  Cord blood is enriched with stem cells, but 
the small quantity of blood normally collected makes this source more suitable for 
paediatric transplants.  Techniques such as ex-vivo expansion and the use of two or 
more cord blood units from different donors are being explored in order to permit the 
routine use of cord blood transplants in adults (Piacibello et al. 1998; Majhail et al. 
2006).  This thesis concentrates on allogeneic HSCT undertaken using stem cells from 
bone marrow or peripheral blood.  Cord blood transplants are not covered in this current 
study. 
 
1.2 The Major Histocompatibility Complex 
 
A major advancement in the success of HSCT came with the discovery of the major 
histocompatibility complex (MHC).  The first HSCT performed based on knowledge of 
the MHC was carried out in 1968 to treat an infant with severe combine 
immunodeficiency (Gatti et al. 1968).  The earliest animal models of solid organ 
transplant used skin grafts to demonstrate that rejection occurred due to lymphocytic 
infiltration of the foreign tissue if organs were transplanted across strain barriers 
(Medawar 1944).  The immunological problems associated with allo-grafting were 
shown to result from genetically encoded differences in tissue type initiating an immune 
(T cell) response.  This led to the characterisation of the MHC.  
 
The MHC is a tightly linked cluster of genes encoding cell surface glycoproteins, which 
can present foreign antigens to circulating T-cells resulting in a highly specific 
mechanism for T cell activation (Goulmy 1988).  The human MHC is located on the 
short arm of chromosome 6 and spans 3.6 million base pairs of DNA (Consortium 
1999).  With over 200 genes identified, the MHC is the most gene-dense region in the 
genome and encodes some of the most polymorphic proteins.  Polymorphisms within 
the MHC are thought to be driven by the continuous response of the immune system to 
infectious pathogens (Parham 1999).  
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The MHC is divided into three regions, class I, class II and class III.  Class I and class II 
molecules are closely related in both structure and function and are encoded by the 
human leukocyte antigen (HLA) genes.  This large cluster of genes were originally 
defined in transplantation experiments by their ability to promote vigorous rejection of 
grafts between different members of the same species (Snell 1948).  Both HLA class I 
and class II molecules have two domains that resemble immunoglobulin domains and 
two domains that fold together to create a peptide-binding cleft.  Both play a role in the 
binding of foreign peptides for recognition by the immune system. However, 
differences in their structure allow them to serve distinct functions in antigen 
presentation to different T cell subsets (Janeway et al. 1999).  HLA Class I molecules 
are present on all nucleated cells and accommodate intracellular derived peptides of 8-
11 residues, which when bound are recognised by CD8+ (cytotoxic) T cells and natural 
killer (NK) cells (York and Rock 1996).  HLA class II molecules accommodate larger 
extracellular derived peptides of 10-30 residues, which when bound are recognised by 
CD4+ (T-helper) T cells.  The expression of class II molecules is restricted primarily to 
antigen presenting cells (APCs), such as B cells, dendritic cells (DC) and macrophages 
(Boss 1997). 
 
HLA class I and class II genes are the most polymorphic genes present in the genome. 
For some HLA genes over 500 different alleles have been identified.  The high degree 
of allelic variants between individuals has significant implications in transplantation, 
since the chance of a complete match between a patient and an unrelated donor is 
extremely low and the degree of HLA disparity correlates closely with the rate of 
mortality after HSCT (Anasetti et al. 1995; Szydlo et al. 1997).  To date ten HLA class 
I genes have been described: HLA-A, -B, -C, -E, -F, -G, -H, -J, -K, and –L.  Of these, 
only HLA-A, -B. -C, -E, -F and -G are translated into proteins, the remaining four are 
pseudogenes.  Characterisation of HLA-A, -B, and -C has demonstrated extensive 
polymorphisms for these genes and their encoded proteins.  The expression of HLA-E, -
F, and -G however, is more discriminate and these genes are significantly less 
polymorphic (Table 1.1) (Klein and Sato 2000).   Five groups of HLA class II genes 
have also been described: HLA-DR, -DQ, -DP, -DM and -DO.  Of these, HLA-DR, - 
DQ and -DP are the most polymorphic and associate with peptides for presentation 
(Klein and Sato 2000).  In terms of matching individuals for HSCT, the polymorphic 
nature of HLA class I and II genes has great implications.  Traditionally, only HLA-A, -
B, and HLA-DR were considered as these were easier to identify and thought to be the 
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most polymorphic.  More recently however, the application of DNA-based typing 
methods has highlighted the need to consider other genes which are also extensively 
polymorphic, such as HLA-C, -DQ, and -DP (Little and Madrigal 1999; Flomberg et al. 
2004; Shaw et al. 2007). 
 
 
 
 
 
 
 
 
 
 
Table 1.1 Number of identified HLA class I alleles as of January 2009. (Data obtained from 
IMGT-HLA database http://www.ebi.ac.uk/imgt/hla/).  HLA, Human Leukocyte 
Antigen 
 
 
 
The class III MHC region, which is flanked by the class I and II regions contains no 
HLA genes, but 57-60 structural genes that span 654-759kb of genomic DNA.  This 
region encodes molecules that are critical to immune function, but they have very little 
in common structurally and functionally with class I and II molecules (Goldsby et al. 
2003).  Class III region products include the complement components C4, C2 and BF 
and the inflammatory cytokines tumour necrosis factor (TNF), lymphotoxin and heat-
shock proteins.  Other genes within the class III MHC region include essential genes 
involved in growth, development and differentiation and enzymes involved in 
metabolism (Klein and Sato 2000).  The physiological roles of the majority of the genes 
within the class III region are yet to be determined; however, many autoimmune, 
neurological, reproductive and malignant disorders have been associated with the MHC.  
 
 
 
 
 
 
HLA Class I Number of Alleles 
 
HLA-A 
 
767 
HLA-B 1178 
HLA-C 439 
HLA-E 9 
HLA-F 21 
HLA-G 
 
43 
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1.3 Graft versus Host Disease 
 
GVHD is an immunologically mediated disease that is the major limitation to the 
success of allogeneic HSCT.  Despite progress in the understanding of GVHD and 
advances in HLA typing techniques, conditioning regimens and post-transplant 
prophylaxis strategies, the disease still occurs in 30-60% of transplants and most 
patients who develop severe manifestations succumb to it or to treatment related 
complications (Barret 1987; Goker et al. 2001; Vogelsang et al. 2003). 
 
GVHD affects multiple target organ systems and occurs when immunologically 
competent T cells are introduced into an immunologically incompetent host.  T cells 
within bone marrow or PBSC transplants recognise mismatched major (HLA) and/or 
minor (mHag) histocompatibility antigens of the transplant patient as foreign, become 
activated and initiate an immune response (allo-response) (Gale 1985; Goker et al. 
2001).   
 
The first description of GVHD came from animal experiments documenting 
haematopoietic reconstitution following lethal marrow irradiation.  Mice that received 
syngeneic stem cell transplants recovered from radiation toxicity, ‘primary disease’; 
whereas mice that received stem cells from different murine strains recovered from their 
primary disease but went on to develop ‘secondary disease’.  This condition was 
characterised by weight loss, diarrhoea, liver abnormalities and eventual death (Barnes 
et al. 1956).  The occurrence of human GVHD was first demonstrated in 1963, when 
Mathe et al (1963) reported the development of severe dermatitis, weight loss and 
diarrhoea in a patient transplanted for leukaemia (Mathe et al. 1963).  Following this, in 
1966 Billingham outlined three prerequisites for the development of GVHD 
(Billingham 1966):            
 
1) A graft containing a sufficient number of immunologically competent cells. 
2) Histoincompatibility between the recipient and donor. 
3) A host immune system that is incapable of mounting an effective immune 
response against the graft. 
 
Although there have been slight modifications to these factors since their proposal, the 
basic principles still apply. 
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GVHD occurs in two forms; acute and chronic.  The distinction between the two 
conditions was traditionally based on the time of onset; less or more than 100 days post 
transplant.  However, since acute GVHD can present beyond 100 days when low 
intensity conditioning is employed or when immunosuppression is withdrawn, 
characteristics of chronic GVHD can occur before day 100 and symptoms common to 
both forms of the disease exist; this distinction is no longer plausible (Ringden and 
Deeg 1997; Devergie 2008).  Nowadays, acute and chronic GVHD are determined by 
specific clinical and histological characteristics rather than by time of onset alone (Table 
1.2). 
 
 
 
 
Table 1.2 Definition of acute and chronic GVHD (Devergie 2008).  GVHD, graft-versus-host 
disease 
 
     
 
1.3.1 Acute GVHD 
 
Acute GVHD usually occurs within weeks of transplantation (< 100 days) and ranges 
from mild and self-limiting to an extremely severe and potentially fatal disorder.  It is 
currently responsible for 15-40% of mortality and is the major cause of morbidity 
following allogeneic HSCT.  Acute GVHD is characterised by damage primarily to the 
skin, liver and gastrointestinal tract, but it can also affect the reconstitution and 
functioning of the patient’s now donor-derived immune system due to immune 
mediated destruction of the bone marrow stroma.  The onset of acute GVHD often 
coincides with engraftment (Vogelsang et al. 1988; Hart and Fearnley 1997; Sun et al. 
2007). 
 
Category Time of 
manifestation 
Acute GVHD 
features 
Chronic GVHD 
features 
Acute GVHD    
Classic ≤ 100 days Yes No 
Pesistent, recurrent, late onset 
 
> 100 days 
 
Yes No 
Chronic GVHD    
Classic No time limit No Yes 
Overlap syndrome No time limit Yes Yes 
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Clinical Manifestations and Grading 
 
An itchy erythematous maculopapular rash is usually the earliest clinical manifestation 
of acute GVHD (Figure 1.2).  The rash initially involves the palms, soles, face and 
trunk, but if the GVHD advances it spreads and can cover the entire body surface.  
Lesions are tight and pruritic, and in severe disease the skin may blister and become 
intensely painful.  Surface area desquamation can occur, that leads to denudation and 
protein loss (Glucksberg et al. 1974; Vogelsang et al. 2003; Devergie 2008).  Liver 
involvement is characterised by cholestatic hepatopathy with or without jaundice.  
Onset of liver GVHD usually coincides with a rise in serum levels of bilirubin, alkaline 
phosphatase and transaminases, and symptoms including fatigue, easy bruising and 
confusion are often indications of hepatic dysfunction.  In extreme cases of GVHD, 
hepatic failure can occur (Crawford 1997; Vogelsang et al. 2003; Devergie 2008).  
Acute GVHD of the gastrointestinal tract usually presents at the same time as or shortly 
after the onset of skin GVHD and primarily manifests as nausea, vomiting and watery 
diarrhoea.  Advanced GVHD is often associated with severe abdominal pain, bloody 
diarrhoea and massive enteral fluid loss.  Diarrhoea results from water and protein 
exudation across a damaged mucosa and in severe disease may have a stringy 
appearance due to sloughing of intestinal mucosa (Mowat 1997; Vogelsang et al. 2003; 
Devergie 2008).        
 
Concomitant signs of acute GVHD include fever, weight loss and a decrease in 
performance status.  Lymphoid organs, mucous membranes, endocrine glands and the 
bronchi may also be involved in the disease, but these are not included in the clinical 
staging and grading (Devergie 2008).   
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Figure 1.2 Clinical appearance of acute GVHD involving the skin and upper intestinal mucosa.  
Left: The diffuse erythematous maculopapular rash typical of acute GVHD of the skin.  
Right: An oedematous and reddened mucosa seen in GVHD of the gastrointestinal tract.  
(Riddell and Appelbaum 2007). 
 
 
 
The first clinical grading system for acute GVHD was developed in 1974 (Glucksberg 
et al. 1974), however, in recognition of it’s limitations this system was later modified in 
a consensus conference on acute GVHD grading (Table 1.3) (Przepiorka et al. 1995).  
Overall acute GVHD grade is based on the extent of skin, liver and gastrointestinal tract 
damage and ranges from I to IV, with the severity of acute GVHD increasing with 
grade.  In brief, grade I denotes mild disease and a good clinical prognosis; grade II 
indicates moderately severe disease and grade III and IV are the most severe life-
threatening stages, with multi-organ involvement and increased mortality.   
 
 
 
 
Table 1.3 Consensus conference grading of acute GVHD.  Clinical acute GVHD overall is 
assessed by the minimum organ involvement required to confer that grade (Przepiorka 
et al. 1995).  
 
 
 Extent of organ involvement 
 Skin Liver Gut 
Stage    
1 Rash on <25% of skin Bilirubin 2-3mg/dl Diarrhea >500ml/day or 
persistent nausea 
2 Rash on 25-50% of skin Bilirubin 3-6mg/dl Diarrhea >1000ml/day 
3 Rash on >50% of skin Bilirubin 6-15mg/dl Diarrhea>1500 ml/day 
4 Generalised erythroderma 
with bullous formation 
Bilirubin >15mg/dl Severe abdominal pain 
with or without ileus 
Grade    
I Stage 1-2 None None 
II Stage 3 or Stage 1 or Stage 1 
III - Stage 2-3 or Stage 2-4 
IV Stage 4 or Stage 4 - 
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Histopathological Features 
 
The characteristic histological appearance of acute GVHD is apoptosis of epithelial 
cells in the skin, liver and gastrointestinal tract.  GVHD lesions in these target organs 
are the same, consisting of apoptotic cells associated with immune cell infiltrates 
(satellite cell necrosis) (Devergie 2008).  In the skin, the dermo-epidermal junction is 
the most severely affected, with epidermal and basal cell vacuolisation and necrosis.  In 
patients with severe skin GVHD sub-epidermal cleft formation and/or complete dermal-
epidermal separation may occur (Vogelsang et al. 2003).  Pathological changes in the 
liver primarily affect the epithelium of the biliary canal and include lymphocytic 
infiltration and degenerative necrosis that leads to bile duct damage or loss, whilst in the 
gastrointestinal tract, necrosis around the basal crypts results in abscess formation and 
epithelial desquamation (McCarthy 1998; Devergie 2008). 
 
In the first few weeks following HSCT the microscopic lesions induced by 
chemotherapy or conditioning regimens may be very similar to the lesions associated 
with GVHD, consequently acute GVHD is often difficult to diagnose early in the post-
transplant period (Devergie 2008).   
     
Pathophysiology 
 
Murine transplant models have permitted the elucidation of the mechanisms involved in 
acute GVHD and the roles of particular cell types and soluble mediators implicated in 
the process.  The pathophysiology of acute GVHD is considered to occur in three 
phases (Figure 1.3); the first of which is instigated by pre-transplant conditioning 
regimens, which damage host tissues and activate inflammatory cytokines.  The second 
phase is initiated by the infusion of allogeneic stem cells and consists of donor T cell 
activation, proliferation and differentiation.  Finally, the third phase is the effector 
phase, where the histopathological changes of acute GVHD become apparent (Chao 
1997; Ferrara et al. 1999).       
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Figure 1.3 The pathophysiology of acute GVHD.  Acute GVHD development is considered as a 
three phase process: (1) injury to host tissues by the conditioning regimen, resulting in 
the release of inflammatory cytokines; (2) infusion of the stem cell graft followed by 
donor T cell activation, proliferation and differentiation and (3) cellular and 
inflammatory attack, producing skin, liver and gastrointestinal tract damage.  APC, 
antigen presenting cells; CTL, cytotoxic T lymphocyte; TH, T helper; Mac, macrophage; 
NK, natural killer cell; IL, interleukin; IFN-γ, interferon γ; TNF-α, tumour necrosis 
factor α; LPS, lipopolysaccharide (Devetten and Vose 2004)  
 
 
 
Phase I: Conditioning Regimen 
 
The earliest phase in the development of acute GVHD begins when conditioning 
regimens employed to prepare the patient for transplantation, cause profound tissue 
damage and activation of the immune response in host tissues, including the intestinal 
mucosa and the epithelial surfaces of the skin and liver.  Underlying disease and 
infections may also contribute to this damage.  Activated host cells respond to the tissue 
damage by secreting considerable amounts of inflammatory cytokines, such as tumour 
necrosis factor α (TNFα), interleukin-1 (IL-1) and interleukin-6 (IL-6) (Xun et al. 
1994).  This cytokine release increases the expression of adhesion molecules (ICAM-1), 
costimulatory molecules and HLA antigens in the host (Pober et al. 1986; Leeuwenberg 
et al. 1988; Norton and Sloane 1991; Thornhill et al. 1991).  These are essential for the 
localisation and activation of immune cells.  The secretion of inflammatory cytokines 
also activates host APCs; which present foreign antigens to T cells and thus are vital for 
the development of GVHD.  In murine models, cytokine release results in the activation 
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of host APCs, and the complete abolition of GVHD is possible by inactivation of these 
cells (Shlomchik et al. 1999).  Host cells also secrete chemokines, which aid in the 
migration of other immune cells, including neutrophils and monocytes to the sites of 
tissue damage.   
 
Damage to the gastrointestinal tract by conditioning regimens is also important in the 
initiation of GVHD, as irradiation and chemotherapeutic agents increase the 
permeability of the intestinal mucosa and allow the translocation of immuno-
stimulatory microbial products, such as lipopolysaccharide (LPS) into the circulation 
(Johansson et al. 2001).  LPS further enhances the activation of host APCs and 
stimulates host macrophages and other tissues to produce excessive amounts of 
inflammatory cytokines, particularly TNFα.  Administration of a synthetic analogue that 
inhibits LPS-mediated NF-κB activation decreases the amount of TNFα produced and 
reduces intestinal injury in murine models of GVHD (Cooke et al. 2001). 
 
An increased risk of GVHD has been correlated with intensive (myeloablative) 
conditioning regimens that cause extensive tissue damage and the excessive release of 
inflammatory cytokines.  This relationship has been demonstrated in both human HSCT 
and animal transplant models (Gale et al. 1987; Clift et al. 1990; Hill et al. 1997).  
Moreover, delaying the infusion of donor stem cells until well after the administration 
of intensive conditioning regimens appears to decrease the risk of acute GVHD 
(Johnson et al. 1993; Johnson and Truitt 1995; Barrett et al. 1998). 
 
Phase II: Donor T cell activation, proliferation and differentiation 
    
Activation of an allo-response begins when T cells within the infused stem cell graft 
interact with APCs and become activated through the recognition of allo-antigens bound 
to HLA molecules (Figure 1.4) (Sun et al. 2007).  After allogeneic HSCT, both host and 
donor derived APCs are present in the patient.  Donor T cells can recognise allo-
antigens on either host (direct presentation) or donor (indirect presentation) APCs, 
however, direct presentation is vital for the initiation of GVHD (Shlomchik et al. 1999).  
When a transplant patient and donor are not HLA-identical, donor T cells recognise host 
HLA molecules as foreign and a profound graft-versus-host reaction ensues.  In HLA-
identical transplants, GVHD occurs through donor T cell recognition of mHag 
differences (immunogenic peptides derived from polymorphic intracellular proteins and 
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presented on MHC class I and class II molecules) (Vogelsang et al. 2003).  T cell 
recognition and activation involves the interaction between alloantigen-HLA complexes 
on the surface of APCs and antigen specific T cell receptors (TCRs) (Sakihama et al. 
1995).  Upon activation, donor T cells produce interleukin-2 (IL-2), which stimulates 
allo-reactive T cells to proliferate and differentiate into effector cells.   
 
 
 
 
Figure 1.4 Donor T cell interaction with host APC.  Molecular diagram of a CD4+ donor T cell 
recognising a foreign protein antigen (allo-antigen) via the T cell receptor in the context 
of a HLA class II molecule.  TCR, T cell receptor; HLA, human leukocyte antigen; 
APC, antigen presenting cell 
 
 
 
Donor T cell activation requires two signals, TCR-alloantigen-HLA binding and a 
costimulatory signal from APCs that requires cell to cell contact.  This costimulatory 
signal determines the outcome of the activation sequence; if the signal is delivered T 
cells become activated, however, if it is absent tolerance (anergy) to the allo-antigen 
develops (Goker et al. 2001).  Several molecules can provide costimulation to T cells, 
but the B7 antigens are currently the best characterised.  Theses antigens (B7-1 (cluster 
of differentiation (CD) 80) and B7-2 (CD86)) bind to two T cell surface receptors, 
CD28 and CTLA-4.  CD28 supplies a positive signal and if it is absent anergy develops.  
Conversely, CTLA-4 provides a negative signal; if it is not delivered, T cell activation 
occurs with uncontrolled cytokine production and T cell proliferation (Freeman et al. 
1993; Green et al. 1994).  Experimental data from murine HSCT models suggest that 
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the blockade of positive costimulatory molecules reduces GVHD, whereas antagonism 
of negative signals exacerbates the severity of the disease (Blazar et al. 1997; Blazar et 
al. 2003).  Blockade of the B7-CD28 interaction with CTLA4-Ig has been demonstrated 
to prevent T cell activation and inhibit both acute and chronic GVHD (Blazar et al. 
1994; Ogawa et al. 2001).                   
 
Activated donor T cells that secrete IL-2 and interferon-gamma (IFNγ) steer the 
subsequent immune response in the T-helper1 (TH1) pro-inflammatory direction; 
activating cytotoxic (CD8+) T cells and NK cells, and enhancing IL-1 and TNFα 
production by host macrophages (Nestel et al. 1992).  Both of these cytokines have 
been demonstrated clinically and experimentally to be important mediators of acute 
GVHD (Theobald et al. 1992; Allen et al. 1993; Via and Finkelman 1993; Szebeni et al. 
1994).  On the other hand, interleukin-10 (IL-10) and interleukin-4 (IL-4) secreting 
donor T cells enhance the proliferation of T-helper2 (TH2) cells and drive an anti-
inflammatory immune response.  High spontaneous production of IL-10 by PBMCs 
prior to HSCT has be shown to associate with a decreased incidence of acute GVHD 
and transplantation of polarised TH2 cell populations fail to induce acute GVHD to 
HLA class I or II antigens (Krenger et al. 1995; Holler et al. 2000).  Consequently, the 
balance between TH1 and TH2 cytokines is critical for the development or prevention of 
acute GVHD. 
 
Regulatory T cell subsets (Treg, Tr1 and NK1.1
+
) may also help determine the response 
of donor T cells to allo-antigens.  These cells can control immune responses by inducing 
anergy or by suppressing the expansion of allo-reactive T cells, and as a result of their 
actions have emerged as possible regulators of the GVHD pathway (Ferrara et al. 1999; 
Sun et al. 2007). 
 
Phase III: Effector phase – target organ damage 
 
The third phase of acute GVHD is perhaps the most complex and has only recently 
becoming appreciated.  Initially it was thought that the cytolytic function of cytotoxic T 
cells directly caused the majority of damage in acute GVHD.  However, it has now 
become apparent that several effector mechanisms are more likely to cause the damage 
observed.  Target tissue damage can be caused directly through inflammatory 
mediators, in particular TNF- and IL-1 secreted from monocytes and macrophages 
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(Piquet et al. 1987; Abhyanker et al. 1993).  TNF- can cause direct tissue damage by 
inducing necrosis of target cells or by initiating tissue destruction via apoptosis 
commonly mediated through the TNF--Fas antigen pathway (Laster et al. 1988).  The 
critical role of cytokines in the pathogenesis of acute GVHD has also been highlighted 
in a study that demonstrated the occurrence of severe acute GVHD as a result of 
inflammatory cytokines in the absence of allo-antigen expression on host target tissue 
(Teshima et al. 2002).  Syngeneic HSCT was utilised to generate mice in which all cells 
except marrow-derived APCs lacked either HLA class I or class II molecules, a further 
allo-graft from a mismatched donor resulted in 100% mortality due to acute GVHD.  
Further studies have demonstrated an increase in cytokine expression in the skin and 
PBMCs with subsequent increase in the severity of acute GVHD (Abhyanker et al. 
1993; Tanaka et al. 1993). 
 
Although cytokines clearly play a key role in the morbidity and mortality of acute 
GVHD, the tissue damage observed in GVHD target organs is not adequately explained 
by the systemic release of cytokines alone; intravenous infusion of TNFα and IL-1 fail 
to produce the immune cell infiltration of the liver and skin seen in acute GVHD.  As 
cytotoxic T cells have the ability to kill virtually all nucleated cells, cell-mediated 
cytotoxicity is thought to contribute to the destruction of these target organs.  T cells 
exert their cytotoxic effects by either the release of soluble mediators such as TNF- or 
by direct contact with the target cell via receptor-ligand interactions (Ferrara et al. 
1999).  Contact-dependent cytotoxicity can occur through perforin/granzyme B-
mediated cytolysis or Fas/Fas Ligand (FasL)-mediated apoptosis.  Both of these 
pathways result in cell death through the activation of the caspase cascade (Figure 1.5) 
(Lowin et al. 1994; Via et al. 1996).   
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Figure 1.5 Perforin/granzyme B and Fas/FasL Pathways.  Contact-dependent cytotoxicity through 
the perforin/granzyme B and Fas/FasL pathways results in cell death via the activation 
of the caspase cascade (Modified from (Ferrara et al. 1999).  FADD, Fas-associated 
protein with death domain; CAD, caspase-activated DNase  
 
 
 
Although perforin/granzyme B- and Fas/FasL-mediated pathways are important in 
effective cell-mediated cytotoxicity, they are not the sole effector mechanisms involved 
in GVHD.  Significantly higher morbidity and mortality is observable in transplanted 
FasL-deficient B6.lpr mice compared with control B6 mice (van den Brink et al. 2000).  
Transplantation of perforin-deficient T cells results in a marked delay in the onset of 
GVHD, however all signs of the disease are still induced (Levy et al. 1995; Baker et al. 
1996).  Also, T cells from perforin/granzyme and FasL cytotoxic double deficient (cdd) 
mice are capable of inducing significant GVHD after transplantation into MHC-
mismatched recipients conditioned with lethal TBI (Jiang et al. 1998; Martin et al. 
1998) and GVHD target damage is observable in mice that lack allo-antigen expression 
on the epithelium (Maeda et al. 2005).  Consequently, the actions of other effector 
molecules, such as the death receptor (DR) ligands TRAIL (TNF-related apoptosis-
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inducing ligand) and TWEAK (TNF-like weak inducers of apoptosis) are currently 
being explored.   
 
While cell-mediated tissue damage results mainly from the cytolytic actions of 
cytotoxic T cell, other effector cells, such as NK and TH17 cells may also contribute to 
GVHD damage (Klingemann 2000; Carlson et al. 2009).  
 
1.3.2 Chronic GVHD 
 
Chronic GVHD is the most common late complication of HSCT; occurring in 
approximately 60-80% of patients and apart from disease relapse is the major cause of 
late death post-transplant (Socie et al. 1999).  This form of GVHD is still primarily a T 
cell-mediated disease, but is a much more pleiotropic syndrome (Shulman et al. 1980; 
Ratanatharathorn et al. 2001; Horwitz and Sullivan 2006).   
 
Clinical Manifestations and Grading 
 
Chronic GVHD can present itself in three ways; progressing as a continuation of pre-
existing acute GVHD, developing as a separate entity after complete resolution of acute 
GVHD or de novo without any previous indication of acute GVHD (Sullivan et al. 
1981; Flowers et al. 1999).  It is a multi-system disease, but mainly affects the skin and 
mucous membranes.  Clinically, chronic GVHD can often resemble non-specific 
autoimmune diseases such as Sjogrens syndrome or systemic sclerosis.  Early stages of 
the condition present as a lichen planus-like rash, with later stages closely resembling 
scleroderma with skin atrophy and ulceration (Aractingi and Chosidow 1998).  Dryness 
of the eyes and oral ulcers are also common.  Chronic GVHD of the liver typically 
presents with cholestatis, whilst the involvement of the gastrointestinal tract results in 
dyspepsia and weight loss (Horwitz and Sullivan 2006).  In addition to these specific 
organ system effects, chronic GVHD has profound effects on the immune system.  
Involution of thymic epithelium has been observed along with loss of secondary 
germinal centres in lymph nodes (Ghayur et al. 1990).  Functionally, cellular immunity 
is affected by the disease with reduced B cell proliferation, reduced antibody responses 
to antigenic stimuli and defects in CD4+ cell numbers and functions (Ferrara and Deeg 
1991b; Ratanatharathorn et al. 2001).  Consequently, patients with chronic GVHD 
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experience long periods of immunosuppression and are therefore highly susceptible to 
opportunistic infection. 
 
The staging of chronic GVHD has traditionally been based on observations made in a 
Seattle study involving 20 patients (Table 1.4) (Shulman et al. 1980).  The presence of 
chronic GVHD is recorded as limited or extensive depending on clinical observations.  
Although this system is crude, it is helpful in delineating those patients that require 
treatment (extensive chronic GVHD) from those who can be managed expectantly 
(limited chronic GVHD) (Vogelsang 2001).  To aid grading the Karnovsky score can be 
added into the assessment (Atkinson et al. 1989).  This grading system does however 
pose problems in terms of capturing the depth and degree of affected organs.  An 
updated grading system has been introduced that arranges patients into categories based 
on their clinical characteristics at the time of diagnosis.  The additional factors for 
chronic GVHD grading in this system include: extensive skin involvement (>50% of 
body surface), thrombocytopenia (<100,000 platelets/mcl), progressive onset of chronic 
GVHD and Karnovsky performance status of less than 50% at primary treatment failure 
(Akpek et al. 2001; Akpek et al. 2003).  Another potential advancement in chronic 
GVHD grading has been proposed by Filipovich et al. (2005).  This grading system is 
based on the number of organs involved and the severity within each organ system 
(mild/moderate/severe).  Despite the recommendations, current clinical practice 
however continues to support the use of the limited versus extensive grading system.   
 
 
 
Limited Chronic GVHD Extensive Chronic GVHD 
 
Either or both 
Localised skin involvement 
Hepatic dysfunction 
 
 
Generalised skin involvement 
and/or 
hepatic dysfunction  
and one more of 
i) chronic aggressive hepatitis 
ii) eye involvement 
iii) oral mucosa involvement 
iv) another target organ involvement 
 
 
 
Table 1.4 Chronic GVHD grading system (Shulman et al. 1980).  GVHD, graft-versus-host 
disease 
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Histopathological Features 
 
Many of the histological changes of cutaneous chronic GVHD resemble those of acute 
GVHD.  These include lymphocytic infiltration in the superficial dermis, vacuolisation, 
epidermal cell necrosis and apoptosis of basal keratinocytes.  The diagnosis of chronic 
GVHD is often on the basis of hypergranulosis and hyperkeratosis (Horn et al. 1997).  
In the later stages of the disease sclerodermatous type changes become apparent with 
epidermal atrophy and progressive destruction of skin appendages (Aractingi and 
Chosidow 1998). 
 
Pathophysiology 
 
The mechanisms involved in chronic GVHD are still largely unclear.  Despite advances 
in the understanding of acute GVHD, the same advances have not been made with the 
chronic form of the disease.  The possible explanation for this is the lack of in vitro and 
animal models that resemble the condition.  Although, allo-reactivity forms the basis for 
the pathogenesis of chronic GVHD, the exact phenotype and origination of the allo-
reactive cells is still unclear.  It is also unclear whether these cells are patient specific or 
simply react as a result of common epitopes shared by the graft and the patient (Claman 
et al. 1985; Horwitz and Sullivan 2006).  The latter fits with the clinical symptoms of 
systemic sclerosis and would support the theory of chronic GVHD being an 
autoimmune phenomenon.  The presence of allo-reactive T cells in lesions of chronic 
GVHD, the clinical similarities with autoimmune disorders and the increased number of 
auto-antibodies observed in patients have led to the investigation of possible altered 
thymic selection in the disease process (Quaranta et al. 1999).  In both experimental and 
clinical studies of chronic GVHD, thymic atrophy, lymphocyte depletion and loss of 
thymic epithelial secretory function has been demonstrated.  Thus, abnormal 
thymopoiesis resulting in the retention of auto-reactive clones may occur (Atkinson et 
al. 1982; Beschorner et al. 1982; Tutschka et al. 1982; Weinberg et al. 2001). 
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1.3.3 Clinical Risk Factors of GVHD 
 
The first steps in the prevention of GVHD, where possible are to minimise risk factors 
associated with the development of the disease.  There are several clinical parameters 
that affect the rate of GVHD. 
 
Acute GVHD 
 
It is well documented that the degree of HLA-mismatch between a donor and patient 
increases the rate of acute GVHD.  The incidence of acute GVHD with only one 
haplotype mismatch increases as much as three-fold compared to fully HLA-matched 
transplants (Beatty et al. 1985).  In unrelated donor HSCT, HLA disparity is of 
particular importance, as complete matching between patients and their unrelated 
donors is extremely low.  Since the use of DNA-based typing, it is now known that only 
a single mismatch at HLA-A, -B, -C, -DRB1 or –DPB1 is required to substantially 
increase the risk of both GVHD and post-transplant mortality in this setting (Sasazuki T 
1998; Flomberg et al. 2004; Chalandon et al. 2006; Lee et al. 2007; Shaw et al. 2007).  
Despite HLA-matching, acute GVHD can still occur as a result of mHag differences 
between patients and donors (Simpson et al. 2002).  The incidence of acute GVHD has 
been shown to be significantly increased with greater than one mHag mismatch 
(Goulmy et al 1996).  mHags located on the Y chromosome are male specific and have 
been shown to be targets for T cell-mediated killing of male cells and involved in 
GVHD (Vogt et al 2002).  It therefore follows that sex mismatch between the patient 
and the donor is a risk factor for acute GVHD, with female donor-derived T cells 
recognising Y chromosome associated mHags of a male patient (Weisdorf et al. 1991; 
Gratwohl et al. 2001).  Other mHags that are important in HSCT are HA-1, HA-2, HA-
3, HA-4 and HA-5.  Mismatches at these antigens have been shown to be responsible 
for acute GVHD following HLA-matched transplantation (Goulmy et al. 1996; Nesci et 
al. 2003).     
 
Older age of an allogeneic HSCT patient has frequently been associated with an 
increased risk of GVHD (Weisdorf et al. 1991; Gratwohl et al. 1998; Cavet et al. 2001).  
Several possible reasons have been suggested including an increased susceptibility to 
infection, slower repair of damaged tissue and the reduced ability of the thymus to 
educate incoming donor T cells (Gluckman et al 1997).  Older age of a donor, 
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particularly in the unrelated donor HSCT setting may also increase the risk of acute 
GVHD, however, currently data is conflicting (Goker et al. 2001; Hahn et al. 2008). 
 
Other well documented clinical parameters associated with an increased rate of acute 
GVHD are myeloablative (high intensity) conditioning regimens, cytomegalovirus 
(CMV) positivity and low intensity GVHD prophylaxis strategies (Gratwohl et al. 1998; 
Hahn et al. 2008; Ljungman 2008).     
 
Chronic GVHD 
 
The most important risk factor for the development of chronic GVHD is the presence of 
prior acute GVHD (Perez-Simon et al. 2006).  However, other factors, such as HLA 
disparity and unrelated donor HSCTs are also associated with a higher incidence of this 
condition (Ratanatharathorn et al. 2001).  The incidence of chronic GVHD has been 
demonstrated to be as high as 80% in one antigen HLA-mismatched unrelated donor 
transplants (Horwitz and Sullivan 2006).  As with acute GVHD, older patient age is 
associated, in fact recent studies have highlighted patient age as an independent risk 
factor for chronic GVHD (Carlens et al. 1998; Zecca et al. 2002).  Among patients of 
HLA-identical HSCT the probability of developing chronic GVHD was significantly 
higher in adults over the age of 20 (Sullivan et al. 1991).  The use of PBSCs in 
transplantation is now on the whole regarded to increase the incidence of chronic 
GVHD (Storek et al. 1997; Scott et al. 1998; Solano et al. 1998; Vigorito et al. 1998; 
Champlin et al. 2000; Snowden et al. 2000; Morton et al. 2001).  This is be due to 
PBSC preparations having a significantly higher T and NK cell content than stem cells 
grafts taken directly from the bone marrow (Bensinger and Storb 2001).  Conflict does 
however still exist, as a few studies have shown PBSC transplants to restore blood 
counts faster than bone marrow, without increasing the risk of GVHD (Powles et al. 
2000; Bensinger et al. 2001).   
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1.3.4 Prevention and Treatment of GVHD 
 
The primary approach in the treatment of acute GVHD is in prevention via the 
administration of prophylactic drugs.  GVHD prophylaxis primarily involves 
immunosupression using cyclosporine A (CsA) alone or in combination with 
methotrexate (MTX) or mycophenolate mofetil (MM).  
 
CsA has been used for acute GVHD prophylaxis since 1976 (Borel et al. 1976) and 
works by inhibiting T cell activation through the blockage of cytokine gene 
transcription (Herold et al. 1986).  CsA binds with high affinity to cyclophilin, a 
ubiquitous cytosolic protein in T cells that is responsible for protein folding (Schmid 
1995).  The CsA-cyclophilin complex can associate with another cytosolic protein, 
calcineurin.  In normal circumstances the engagement of the T cell receptor causes 
calcineurin to dephosphorylate transcription factors which are involved in the 
transcriptional activation of genes encoding cytokines including IL-2 (Timmerman et al. 
1996).  The direct association of the CsA-cyclophilin complex with calcineurin prevents 
the dephosphorylation of transcription factors and the subsequent expression and 
secretion of IL-2 in T cells.  Inhibition of IL-2 production inhibits the clonal expansion 
of allo-reactive T cells. 
 
MTX is a folate antagonist first developed for the treatment of malignancies in 1956 
(Farber et al. 1956) and was subsequently the first GVHD prophylactic drug to be used 
as immunosuppression, after its efficacy was demonstrated in a canine model (Thomas 
et al. 1975).  MTX exhibits both anti-inflammatory and immunosuppressive properties.  
MTX is converted to polyglutamate forms intracellularly by directly binding two to five 
polyglutamate groups (Fry et al. 1982).  The polyglutamate derivatives of MTX inhibit 
dihydrofolate reductase (DHFR), which results in a depletion of thymidylate synthase; 
an enzyme that is essential in the production of pyrimidine nucleotides for de novo 
DNA synthesis (Chu et al 1990).  MTX therefore interferes with DNA replication in 
dividing cells, including activated donor T cells.  This leads to premature apoptosis and 
a reduced allo-response. 
 
Several studies have been carried out comparing CsA and MTX as monotherapy for 
GVHD prophylaxis (Backman et al. 1988; Storb et al. 1988), with both drugs found to 
be equivalent in the likelihood of acute GVHD, chronic GVHD and overall survival.  
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Combination therapy with CsA and MTX has been compared to CsA monotherapy and 
was found to associate with reduced rates of acute GVHD and improved overall 
survival (Mrsic et al. 1990).  
 
MM is the pro-drug of the potent immune-suppressant mycophenolic acid, a non-
competitive reversible inhibitor of inosine monophosphate dehydrogenase; an enzyme 
that blocks de novo synthesis of guanosine nucleotides (Lipsky 1996).  Lymphocytes 
depend on this pathway because they do not possess the salvage pathway of other cells.  
The toxicity profile of MM, particularly its lack of renal toxicity and cross-reactivity 
with CsA makes it an attractive prophylaxis candidate, however, a recent study has 
demonstrated that the addition of MM to CsA does not offer any benefit over CsA and 
MTX (Nash et al. 2005).  Thus, CsA and MTX are typically the drugs of choice for 
combination therapy.  
 
Immunosuppressive prophylaxis for GVHD effectively reduces the severity of the 
disorder in most individuals, but in doing so increases infection and decreases the 
beneficial graft-versus-leukaemia (GVL) effect, which helps to prevents relapse.  
Consequently, in many of the cases of GVHD associated death, the cause of death is 
infection or relapse rather than the GVHD itself (Goker et al. 2001). 
 
Alternatively, acute GVHD can be prevented by T cell depletion.  This can be achieved 
in vitro by physiological and immunological methods or in vivo with the use of 
antibodies such as Campath-1H (anti-CD52) and anti thymocyte globulin (ATG) (Hale 
et al. 1998; Bacigalupo 2007).  These T cell antibodies not only allow the host immune 
response to be reduced; which favours engraftment, but as they are still in the 
circulation at the time of transplantation they also down-regulate donor T cells and thus 
reduce GVHD (Bacigalupo 2007).  The removal of donor T cells is the most effective 
strategy for the prevention of GVHD; however, it is associated with significant 
complications including: an increased risk of relapse, an increase risk of engraftment 
failure and an increase risk of post-transplant infections (Hale et al. 1988).  T cell 
depletion is therefore often only used for patients considered to be at a high risk of 
severe acute GVHD, such as older patients and those receiving transplants from an 
unrelated donor. 
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Despite the use of immunosuppressive prophylaxis and T cell depletion as preventative 
measures against acute GVHD, it is still highly likely that the condition will develop.  
Addition of corticosteroid therapy to the GVHD prophylaxis regimen is standard first-
line treatment in such cases.  Typically, methylprednisone is administered at a dose of 
2mg/kg/day; however, a higher does (10mg/kg/day) can be used for patients who 
develop severe acute GVHD (grades III-IV) (Bacigalupo 2007; Morris and Hill 2007).  
Steroid treatment is usually given over a five day course, as this is normally sufficient to 
identify responsive and steroid-refractory (partial/non-responsive) patients.  
Methylprednisone therapy can be tapered in responders, whereas additional (second-
line) therapeutic strategies are required for steroid-refractory patients (Bacigalupo 
2007).  ATG alone or in combination with methylprednisone is one second-line 
treatment option.  Some encouraging results have come from phase II trials (Roy et al. 
1992; Aschan, 1994); especially when ATG was administered early after GVHD 
diagnosis (MacMillan et al. 2002), however, evidence that this treatment improves 
survival is still lacking.  Other second-line strategies include additional 
immunosuppression with MM and antibody therapy against IL-2 (denileukin difitox, 
inolinomab, basiliximab and daclizuman), TNF (infliximab) or the TNF receptor 
(etanercept) (Bacigalupo 2007).  A more novel second-line procedure is extracorporeal 
photopheresis (ECP).  This is an immunotherapeutic modality that involves the 
treatment of blood mononuclear cells with 8-methoxypsoralen activated by UV light.  
This chemical binds irreversibly to the DNA of T cells, damaging them and thus down 
regulating the allo-response in GVHD.  Greinix et al. (2002) have reported a 82% 
response rate for patients with severe skin acute GVHD treated with ECP and steroids, 
61% for gastrointestinal involvement and 61% for liver involvement.  However, 
responses were not observed until 12 weeks after treatment.                         
 
Although there is no specific prophylaxis for chronic GVHD the incidence of previous 
acute GVHD is a risk factor for the subsequent onset of the chronic form of the disease. 
However, acute GVHD prophylaxis in several early studies has shown no effect on the 
rate of chronic GVHD (Storb et al. 1986; Storb et al. 1989).  T cell depletion is 
associated with reduced rates of the condition, but as previously discussed the problems 
associated with this method prevents widespread use of this application (Hale et al. 
1988).  The main focus therefore is on the treatment of chronic GVHD rather than the 
prevention of the disease.  The nature of chronic GVHD as a multi-system disorder and 
its association with immunosuppression means that the disease is difficult to manage.  
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The standard first-line therapy for chronic GVHD is a combination of CsA 
(10mg/kg/day) and prednisolone (1mg/kg/day).  This approach has achieved a degree of 
success and is considered to have a survival advantage (Sullivan et al. 1988).  More 
recently tacrolimus has been used interchangeably with CsA, although no direct 
comparison has been performed (Fraser and Baker 2007).  The duration of therapy is 
determined by response, but typically is prolonged, continuing for close to 12 months 
even in those achieving complete resolution.  As with acute GVHD, steroid and 
immunosuppressive therapies can be tapered in responders.  So far, the addition of other 
immunosuppressive agents, such as thalidomide, to this standard first-line therapy has 
not led to any significant difference in chronic GVHD response rates or survival (Koc et 
al. 2000; Arora et al. 2001).   
 
Approximately 15% of transplant patients receiving standard first-line therapy for 
chronic GVHD fail to achieve complete resolution and require further treatment (Koc et 
al. 2002).  Currently however, there is no standard second-line therapy for steroid-
refractory chronic GVHD, thus management of these patients is extremely problematic.  
MM is probably the most commonly used second-line treatment, although other 
therapeutic agents do exist.  Several phase II trials of thalidomide treatment have been 
performed.  The largest study (80 patients) reported overall response rates of 26%, but 
36% of patients had to discontinue the drug because of side-effects (Parker et al. 1995).  
Other studies have however demonstrated more encouraging data, with both complete 
and partial responses being observed (Vogelsang et al. 1992; Kulkarni et al. 2003).  
Switching from CsA to tacrolimus in the setting of steroid-refractory disease has also 
been reported, but with varying success (Carnevale-Schiana et al. 2000; Kanamaru et al. 
1995).  Sirolimus has been used in combination with calcineurin inhibitors and 
corticosteroids.  Relatively high overall response rates (complete and partial) have been 
documented following this treatment strategy, although only a very small number of 
patients were able to discontinue all immunosuppressive therapies and adverse effects 
were quite common (Couriel et al. 2005; Johnston et al. 2005).  Other studied possible 
second-line treatments for chronic GVHD include hydroxychloroquine, pravastatin, 
ECP and monoclonal antibodies, such as rituximab (anti-CD20), daclizumab (IL-2 
receptor inhibitor) and infliximab (TNFα inhibitor).  Again, good overall response rates 
have been associated with these therapies, although the majority of responders achieved 
partial rather than complete resolution (Fraser and Baker 2007).             
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1.4 Infection 
 
Infection is another major complication of HSCT and occurs mainly as a result of 
intensive pre-transplant conditioning.  Myeloablative regimens cause prolonged 
neutropenia, immunodeficiency and damage to mucosal tissue such as the mouth, 
gastrointestinal tract and the skin (Bacigalupo et al. 2000; Gratwohl 2008).  This creates 
the ideal environment for opportunistic bacterial, fungal and viral pathogens.  Measures 
that can be taken against these infections include isolation of the patient in a clean room, 
gut decontamination or prophylaxis with antibiotic, antifungal or antiviral drugs.  The 
most common source of viral infection following HSCT is infection with CMV, which 
can lead to potentially life threatening CMV disease and is caused primarily by viral 
reactivation in seropositive patients.  Clinical trials of the drug glanciclovir and its oral 
derivative valganciclovir have proved effective in the pre-emptive treatment of CMV 
disease, however, CMV remains an issue for seropositive HSCT patients, especially 
after mismatched or unrelated transplants (Ljungman 2008).  
 
1.5 Disease Relapse 
Disease relapse can occur when small numbers of residual leukaemic cells evade 
destruction.  These cells are able to grow unchecked in most patients because the 
immune system does not recognise them as foreign (Kolb 2008).  The observation that 
disease relapse occurs more frequently after T cell depletion of the donor, lead to the 
realisation that some of the therapeutic effects of HSCT was due to an anti-tumour or 
‘GVL’ effect.  Barnes and Loutit (1956) first suggested GVL after experiments in mice 
showed that allogeneic HSCT recipients had a lower incidence of leukaemic death than 
syngeneic recipients.  GVL occurs when T cells from an allogeneic donor recognise 
foreign mHags or tumour-specific antigens expressed by leukaemic cells within the 
patient and generate an immune response to eliminate them (Horowitz et al. 1990).  
Disease relapse following allogeneic HSCT can be reversed by infusing more of the 
donor’s lymphocytes (donor-lymphocyte infusion, DLI), as the T cells within the 
infusion restore the GVL effect.  Due to the presence of mature T cells within the 
infusion DLI is however associated with an increased incidence of GVHD (Kolb 2008).  
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1.6 Non-HLA Polymorphisms 
In HSCT, complications including GVHD, infection, disease relapse and TRM can 
occur even when transplant patients and donors are HLA-matched.  As a result, it is 
extremely likely that non-HLA genes also have an impact.  Naturally occurring 
polymorphisms within such genes have been suggested to contribute to some of the 
genetic disparity that exists in HSCT and may therefore have the potential to influence 
transplant outcome.   
 
Polymorphisms within the 5′ or 3′ regulatory sequences of genes, such as single-
nucleotide polymorphisms (SNPs), microsatellites or variable number of tandem repeats 
(VNTRs), can alter transcription factor binding, and hence the level of protein 
produced.  Such polymorphisms in the genes of cytokines can result in individuals 
producing higher or lower cytokine levels (Bidwell et al. 1998; Bidwell et al. 1999).  
Their impact therefore affects both the quality and quantity of, for example, the 
cytokine or cytokine receptor, and in the transplant setting, may influence the ‘cytokine 
storm’ associated with GVHD.  Cytokine gene polymorphisms have been investigated 
in a number of diseases where there is an immune pathology, such as autoimmune 
diseases, cancer and transplantation.  Immunosuppressed solid-organ transplant patients 
with a ‘high-producer’ TNFα (TNFA) genotype and ‘low-producer’ IL-10 (IL10) 
genotype have been shown to be more likely to reject their graft (Turner et al. 1997).  
These findings led to studies in the HSCT field, with TNFA and IL10 gene 
polymorphisms being the first to be investigated for associations with transplant 
outcome.  In recent years, the number of different polymorphisms studied has increased 
and expanded to encompass other immune molecules as well as cytokines.  The vast 
amount of research performed to date has demonstrated a role for non-HLA genes in 
transplantation and highlighted their potential use as predictive markers of HSCT 
outcome.     
 
The following sections will summarise non-HLA polymorphism results concerning 
cytokines and other immune molecules.  However, the remainder of this thesis will 
focus mainly on the roles of cytokines and cytokine genes in HSCT. 
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1.6.1 Cytokine and Cytokine Receptor Genes 
 
Tumour Necrosis Factor α 
 
TNFα is a multifunctional pro-inflammatory cytokine produced mainly by monocytes 
and macrophages, which has the ability to up-regulate adhesion and MHC molecule 
expression and can directly induce cell death.  It also possesses anti-tumour activity and 
plays a major role in the GVHD immune response (Lichtman et al. 1996).  The gene 
encoding TNFα (TNFA) is highly polymorphic and located within the class III region of 
the MHC complex on chromosome 6, close to the HLA region and lymphotoxin and 
heat shock protein (HSP) genes. 
 
TNFA polymorphisms have been widely studied with respect to HSCT outcome, 
particularly in the HLA-matched sibling setting.  One of these polymorphisms is a SNP 
within the gene promoter region at position –308 (TNFA –308 G/A).  This SNP has 
been linked with a diverse number of diseases and inconsistently associated with 
GVHD following HLA-matched sibling transplantation.  Several small studies have 
reported a positive association with acute GVHD (Takahashi et al. 2000; Wang et al. 
2002)); however, the majority of the larger studies found no such association 
(Middleton et al. 1998; Socié et al. 2001; Nordlander et al. 2002; Rocha et al. 2002; Lin 
et al. 2003; Mullighan et al. 2004)).  TNFA –308 G/A, along with the TNFB +1069 C/T 
polymorphism, has also been linked with toxic complications, with the highest 
incidence of such complications in TNFA and/or TNFB heterozygous patients (Bogunia-
Kubik et al. 2003). 
 
Another SNP within TNFA is located at position +488 (TNFA +488 G/A).  The A allele 
of this SNP has been associated with GVHD in two independent HLA-matched sibling 
cohorts.  Patients with this allele developed significantly higher grades of acute GVHD 
than TNFA +488 A-negative patients.  The same allele has also been associated with 
chronic GVHD and early death (Mullighan et al. 2004).  
 
A number of microsatellite polymorphisms occur within TNFA: TNFa, TNFb, TNFc, 
TNFd and TNFe (Nedospasov et al. 1991; Udalova et al. 1993; Holzinger et al. 1995). 
The TNFd3 and TNFa2 alleles have been associated with higher TNFα production, 
whereas the TNFa6 allele correlates with decreased production (Pociot et al. 1991; 
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Turner et al. 1995; Turner et al. 1997).  In terms of HSCT, the TNFd3 homozygous 
genotype is associated with an increased incidence of acute GVHD and early death 
following HLA-matched sibling transplantation (Middleton et al. 1998; Cavet et al. 
1999), whereas the TNFd4 allele correlates with the development of moderate to severe 
acute GVHD in this setting (Nordlander et al. 2002).  Spink et al (2003) however, has 
recently reported the existence of sub-alleles of the TNFd polymorphism (contain slight 
sequence differences) and demonstrated that a high proportion of TNFd alleles have 
been incorrectly assigned as d3 rather than one of these sub-alleles.  This finding has 
major implications for existing disease associations with TNFd3, but as of yet these 
have not been investigated further. 
  
An important factor potentially influencing any association between TNFA 
polymorphisms and GVHD is the location of the gene within the MHC class III region. 
TNFA polymorphisms are in linkage disequilibrium with HLA class I and class II 
genotypes.  As certain HLA genotypes are known to influence HSCT outcome, 
association with TNFA genotype may be secondary to or interact with the HLA 
associations (Mullighan and Bardy 2004; Shaw et al. 2004).  TNFA –863 C/A and –857 
C/T polymorphisms in donors and/or patients have been correlated with a higher 
incidence of GVHD and a lower rate of relapse.  By restricting the analysis to HLA A-, 
HLA B- and DRB1-matched pairs, the effect of HLA linkage disequilibrium with TNFA 
was revealed. GVHD outcome was still linked with patient genotype; however, the 
association with relapse was no longer observed (Ishikawa et al. 2002a). 
 
TNFA polymorphisms have also been examined in the unrelated donor HSCT setting.  
The TNFd microsatellite polymorphism has been associated with several transplant 
outcomes, including GVHD, TRM and survival (Keen et al. 2004; Bettens et al. 2006). 
TNFα serum levels and TNFd genotypes have been correlated with acute GVHD, with 
patients homozygous for the TNFd3 or TNFd4 alleles having significantly higher TNFα 
levels during conditioning and more frequently developing acute GVHD (Remberger et 
al. 2003).  More recently, TNFd has been associated with TRM rather than GVHD 
(Keen et al. 2004).  The presence of the d4 allele in conjunction with the TNFA 1031C 
allele in either patients or donors significantly increased the incidence of TRM.  A 
further allele associated with the TNFd4/1031C haplotype, TNFa5, is also linked to 
increased TRM.  TNFd has also been associated with HSCT survival.  A proportional 
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decrease in survival rates has been reported for transplant patients possessing TNF 
d3/d3, d4 and d5 respectively compared to TNFd1/d2d3 genotypes (Bettens et al. 2006). 
 
The actions of TNF are mediated by two receptors; a type I (TNFRI) receptor and a 
type II receptor (TNFRII).  The second of these receptors is found on most cell types, 
but is more abundant on endothelial and haematopoietic cells and on TNF binding 
induces apoptosis amongst CD8+ cells and stimulates haematopoietic cell (particularly 
T cell) proliferation (Zheng et al. 1995; Stark et al. 2003).  The TNFRII (TNFRSF1B) 
gene is located on chromosome 1 at position 1p36.  A SNP occurs within exon 6 of this 
gene at codon 196 that results in an amino acid substitution, methionine (M)→arginine 
(R).  Consequently, two alleles for this polymorphism exist; M and R.  Research 
performed to date has shown that the R allele is linked to the development of systemic 
lupus erythematosus (SLE) and in both the HLA-matched sibling and unrelated donor 
HSCT settings is associated with an increased incidence of acute and chronic GVHD 
(Morita et al. 2001; Ishikawa et al. 2002b; Stark et al. 2003). 
 
Interleukin-10   
 
IL-10 is a potent inhibitor of T-cell proliferative responses and suppresses pro-
inflammatory cytokine production.  The gene of this cytokine maps to chromosome 1 
(1q31-32) and is highly polymorphic, containing numerous microsatellites and five 
SNPs, that have been resolved into conserved haplotypes representing high-level 
(GCC), intermediate-level (ATA) and low-level (ACC) producers of IL-10 (Edwards-
Smith et al. 1999).  
 
Several studies have examined the role of IL10 polymorphisms in HSCT; however, at 
present, the data is conflicting.  Initial studies demonstrated that the ACC haplotype and 
the longer IL10 –1064 (CA)n microsatellite (>12) alleles associated with the 
development of severe acute GVHD (grade III–IV) in HLA-matched sibling transplant 
patients treated with CsA alone or CsA plus MTX (Middleton et al. 1998; Cavet et al. 
1999).  While in a larger HLA-matched sibling transplant cohort the ATA/ATA 
diplotype in the patient has been shown to decrease the risk of acute GVHD (Lin et al. 
2003).  A further study has demonstrated that the presence of IL10 diplotypes 
(ACC/ACC vs ATA/ATC vs ATA/ATA) increase the incidence of chronic GVHD and 
individuals possessing the ATA haplotype required longer immunosuppression and 
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were more susceptible to invasive pulmonary aspergillosis (Kim et al. 2005; Seo et al. 
2005).  Several other studies have also reported differing associations between IL10 
polymorphisms and the risk of GVHD (Socié et al. 2001; Rocha et al. 2002; Mullighan 
and Bardy 2004).  
 
In unrelated donor HSCT, an association between allele length at the IL10 -1064 (CA)n 
microsatellite and survival has been reported: longer patient IL10 alleles (>12) 
correlated with decreased survival (Bettens et al. 2006).  In addition, in a mixed HLA-
matched sibling and unrelated donor transplant cohort, the donors of chronic GVHD 
patients frequently possessed a greater number of CA repeats (allele 13 or above) 
(Takahashi et al. 2000).  There also appears to be a significant link between TRM and 
the IL10 GCC haplotype in this transplant setting.  Presence of the donor R2-GCC 
haplotype has been shown to increase the incidence of TRM, while possession of the 
R3-GCC haplotype (donor-derived) decreases the risk (Keen et al. 2004).  This finding 
conflicts with current HLA-matched sibling studies, as the majority of these have found 
associations with GVHD rather than TRM (Cavet et al. 1999; Ishikawa et al. 2002a; Lin 
et al. 2003). 
 
Interferon γ 
 
IFN is a pleiotropic cytokine with potent pro-inflammatory actions that is important in 
both the innate and adaptive immune response, and is essential for the induction and 
regulation of antimicrobial and anti-tumour immunity (Yang et al. 2005).  Within the 
first intron of the IFNG gene on chromosome 12q14-15 there is a (CA)n microsatellite 
polymorphism.  This polymorphism has two common alleles, 2 and 3, both of which 
exhibit differential IFN production in vitro.  Allele 2 is associated with increased levels 
of IFN, whereas allele 3 has been linked with decreased production.  IFNG 
microsatellite alleles have also been linked with a variety of immunological diseases 
and, in addition, in HLA-matched sibling transplantation an association between patient 
intron 1 (CA)n 3,3 homozygosity and an increased risk of acute GVHD has been 
reported (Cavet et al. 2001).  Other studies have also shown an association between the 
possession of the intron 1 (CA)n 3,3 genotype or the lack of the intron 1 (CA)n  2,2 
genotype and acute or chronic GVHD in this transplant setting (Mlynarczewska et al. 
2004; Bogunia-Kubik et al. 2005).  The mechanism behind these associations is 
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currently unknown, but may be explained if IFN has a negative feedback regulatory 
role, as seen in some murine models of GVHD (Brok et al. 1993).  Possession of the 
IFNγ intron 1 (CA)n 3,3 genotype  has also been associated with an increased risk of 
Epstein-Barr virus (EBV) reactivation following HLA-matched sibling or unrelated 
donor HSCT (Bogunia-Kubik et al. 2006). 
 
Interleukin-1 Family 
 
There are ten members in the IL-1 family, of these IL-1α and IL-1β (IL1A and IL1B) are 
agonists, and IL-1RA (IL1RN) is a specific receptor antagonist; which is relatively 
unique in cytokine biology.  Binding of IL-1 to its receptor leads to induction of a wide 
range of genes including other cytokines, chemokines, nitric oxide synthase and type 2 
cyclooxygenase, all of which are involved in the inflammatory response and stimulation 
of lymphocytes.  The IL1 family and its polymorphisms have therefore been associated 
with a wide range of inflammatory diseases (Cullup and Stark 2005). 
 
The IL1A -889 C/T and IL1RN intron 2 VNTR polymorphisms have been extensively 
investigated in HLA-matched sibling transplantation.  Possession of the IL1RN intron 2 
VNTR allele 2 by transplant donors has been shown to down-regulate IL-1 production 
and consequently correlate with less-severe acute GVHD.  In contrast, the same allele in 
the patient has been correlated with the development of acute GVHD (Cullup et al. 
2001; Rocha et al. 2002).  The presence of the IL1RN intron 2 VNTR allele 2 or the 
IL1A –889 C allele in the donor has also been correlated with chronic GVHD (Cullup et 
al. 2003).  IL1 polymorphism research in the unrelated donor setting is extremely 
limited; only one study performed on a small paediatric cohort has been reported to 
date.  In this study, the presence of the IL1A –889 T allele in either the patient or donor 
was associated with significantly improved survival and decreased TRM.  No 
association with acute GVHD was demonstrated; however, trends were observed 
between the incidence of chronic GVHD and the IL1A –889 C allele and allele 2 of the 
IL1RN intron 2 VNTR (MacMillan et al. 2003a).  
 
Interleukin-2 
 
IL-2 is a pro-inflammatory cytokine that plays a key role in immune response 
production; particularly in T cell activation, proliferation and differentiation, and has 
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been implicated in the initiation and maintenance of GVHD (Ferrara and Deeg 1991a). 
A T/G SNP exists within the IL2 gene promoter region at position –330.  The G allele 
of this polymorphism associates with early and sustained elevation of IL-2 production 
(high-producer genotype) and an increased risk for acute GVHD after unrelated donor 
HSCT (MacMillan et al. 2003b). 
 
Interleukin-6 
 
IL-6 is a pro-inflammatory cytokine that plays a central role in immune, inflammatory 
and acute phase responses. It is produced by numerous cell types, induces the 
development of cytotoxic T cells in the presence of IL-2 and synergises with IL-13 to 
promote haematopoietic stem cell differentiation and maturation.  Consequently, IL-6 
plays a major role in the biology of GVHD and HSCT (Lichtman et al. 1996).   
 
The IL6 gene is located on chromosome 7p21 and, like many other cytokine genes, has 
been found to be polymorphic, containing both microsatellites and SNPs (Terry et al. 
2000; Ferrari et al. 2003).  A G/C SNP exists in the promoter region at position –174.  
In both normal and HSCT populations, the G allele of this SNP correlates with higher 
serum IL-6 levels (Fishman et al. 1998).  Several studies have also found the IL6 -174 
G,G genotype to be associated with both acute GVHD and chronic GVHD following 
HLA-matched sibling transplantation (Cavet et al. 2001; Socié et al. 2001; Mullighan 
and Bardy 2004; Karabon et al. 2005). 
 
Interleukin-7 Receptor, Interleukin-18 and Interleukin-13 
 
More recently studied cytokine gene polymorphisms include those within the IL7 
receptor and IL18 genes.  IL-7 is a 25kDa glycoprotein that plays an important role in 
the regulation of lymphopoiesis and signals through IL-7 receptors (IL-7R).  These 
receptors consist of a γc and an α chain.  Sequencing of the α chain has revealed the 
existence of four SNPs (+510 C/T, +1237 A/G, +2087 T/C and +3110 A/G), all of 
which result in amino-acid substitutions.  In a recent study of 75 unrelated donor 
transplant pairs the IL7R +1237 A/G SNP within donors was shown to associate with 
survival and TRM, with the highest mortality being linked to the G,G genotype.  No 
associations were observed in the HLA-matched sibling setting.  Considering the 
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functions of IL-7, these findings seem to suggest a possible role for this SNP in T cell 
and immune reconstitution following unrelated donor HSCT (Shamim et al. 2006).   
 
IL-18, a pro-inflammatory cytokine that induces Th1-type lymphocyte differentiation 
and cytotoxic T lymphocyte function has three polymorphisms at positions -137 G/C, -
607 C/A and -656 G/T within its promoter region.  Three main haplotypes exist, GCG, 
CAT and GAT.  Cardoso et al (2004) have shown that the GCG haplotype in HSCT 
patients associated with a decreased risk of TRM at day 100, at 1 year post-transplant 
and with improved survival.  IL18 haplotypes had no effect on acute GVHD in this 
unrelated donor cohort (Cardoso et al. 2004).  Associations between IL-18 and acute 
GVHD have, however, been demonstrated by well-established murine BMT models.  
Reddy et al (2003) have shown that neutralisation of IL-18 by antibodies increased 
acute GVHD-related mortality while administration of the cytokine significantly 
improved survival and reduced the pathological features of acute GVHD (Reddy et al. 
2003) 
 
Interleukin-13 (IL-13) is an immunoregulatory cytokine produced by B cells, mast cells, 
basophils, NK cells and DCs, but is predominantly secreted by activated Th2 CD4+ T 
cells (Brown et al. 1989; de Vries et al. 1996).  It has many diverse functions, including 
the promotion of proliferation, immunoglobulin E (IgE) class switching and MHC class 
II expression in B cells (Punnonen et al. 1993; Chomarat and Banchereau 1998), the 
enhancement of monocyte and macrophage antigen presenting ability (Zurawski and de 
Vries 1994; de Vries 1998), the up-regulation of IgE receptor (CD23) expression on 
APCs (de Vries 1998) and the inhibition of pro-inflammatory cytokine production from 
monocytes and macrophages (de Waal Malefyt et al. 1993).  In addition to these 
physiological roles, IL-13 has also been implicated in several pathological conditions.  
Most notably, in asthma; where it is capable of independently producing the entire 
asthmatic phenotype (Grunig et al. 1998; Wills-Karp et al. 1998; Shirakawa et al. 2000; 
Walter et al. 2001) and in allergy; where it up-regulates IgE production through the 
promotion of isotype class switching in B cells (Punnonen et al. 1993; Minton 2008).  
IL-13 has also been reported to play a role in several other pathological conditions, 
including inflammatory bowel disease (Kucharzik et al. 1996; Kadivar et al. 2004), 
parasitic worm infections (Urban et al. 1998; Chiaramonte et al. 1999), HIV infection 
(Montaner et al. 1993; Papasavvas et al. 2005) and chronic obstructive pulmonary 
disease (COPD) (Barnes 2000; van der Pouw Kraan et al. 2002; Hoshino et al. 2007).  
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In the transplant setting, IL-13 research is currently extremely limited.  Elevated IL-13 
levels have, however, been linked to chronic lung allograft rejection and the 
development of acute GVHD following HSCT (Jordan et al. 2004; Keane et al. 2007).  
In the latter study patients who developed severe acute GVHD (grades III-IV) had 
extremely high pre-transplant IL-13 production by their donor T cells; whereas those 
developing little or no acute GVHD had donors that produced no IL-13 prior to 
transplantation (Jordan et al. 2004).  Several SNPs have been identified within IL13, 
although the +2044 G/A polymorphism in exon 4 is the most common and has been 
linked with inflammatory and allergy phenotypes (Heinzmann et al. 2000; Liu et al. 
2000; Arima et al. 2002; Tsunemi et al. 2002; He et al. 2003; Heinzmann et al. 2003; 
Vladich et al. 2005; Zitnik et al. 2009).  To date, however, no studies have been 
published associating this polymorphism with HSCT outcomes.  The role of the IL13 
+2044 G/A polymorphism in both HLA-matched sibling and unrelated donor 
transplantation will therefore be examined in this current study. 
 
1.6.2 Innate Immunity Genes 
 
Other, non-cytokine genes associated with innate immunity have been assessed for their 
impact on HSCT outcome.  There are a number of key molecules that allow mammals 
to sense pathogens, such as pattern recognition receptors (PRRs), which in turn activate 
the immune response via both the innate and adaptive pathways. These molecules 
obviously play a very important role in post-transplant complications, especially 
infectious episodes.  Among these PRRs are a group of transmembrane receptors, Toll-
like receptors (TLRs), which have a potent ability to activate APCs (Kaisho and Akira 
2003; Kaisho and Akira 2004; Xu et al. 2004).  APCs have ligands for different TLRs 
that are differentially expressed.  TLR4 is a major receptor for LPS and has been 
implicated in the pathogenesis of GVHD.   Polymorphisms in the TLR4 gene have been 
associated with hyporesponsiveness to lipopolysaccharides.  This leads to a reduced risk 
of acute GVHD, but consequently results in an increased risk of gram-negative 
bacteraemia.  There is no hyporesponsiveness however in patients given prophylaxis for 
infection or GVHD (Lorenz et al. 2001).  Polymorphisms in the TLR1 and TLR6 genes 
have been investigated in patients with invasive aspergillosis following HSCT, with 
patient genotype being associated with an increased risk of infection (Kesh et al. 2005). 
These results suggest that the impact of patient genotype is influenced by the period of 
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immunosuppression pre- and post-transplant before donor immune reconstitution 
occurs.  
 
Intracellular PRRs, such as NOD-like receptors, which are associated with 
inflammatory bowel disease, are important molecules for study in HSCT because the 
gastrointestinal tract is damaged by conditioning regimens and is a target organ for 
GVHD.  There are three SNPs in NOD2/CARD15 (nucleotide-binding oligomerisation 
domains containing 2/caspase recruitment domain family number 15), SNP8, SNP12 
and SNP13, which are involved in defective NF-B responses.  Possession of two or 
more of the NOD2/CARD15 variants is associated with more severe GVHD and 
increased TRM in both HLA-matched siblings and unrelated donor transplants (Holler 
et al. 2004).  In a second cohort of HLA-matched siblings (Holler et al. 2006), the 
genetic risk could be modulated through different types of gastrointestinal 
decontamination prior to transplantation.  In T cell depleted transplants, possession of 
NOD2/CARD15 SNPs is associated with lower disease free survival (Granell et al. 
2007). These results illustrate that the altered immune response associated with NOD 
gene variants post-transplant is dependent on the type of immunomodulation (bacterial 
decontamination) and immunosuppression (T-cell depletion) administered. 
 
The incidence of severe infections post transplant has been investigated by a number of 
groups.  Severe bacterial infectious episodes are associated with the gene encoding 
myeloperoxidase (MPO), an enzyme released from neutrophils during inflammation.  
The A,G or A,A donor genotype of the MPO -463 G/A SNP rather than the wild-type 
G,G genotype have been associated the most severe infections.  Mannose-binding lectin 
(MBL) binds a range of pathogens and opsonises them for phagocytosis.  Human MBL 
is encoded by MBL2 on chromosome 10. SNPs in the promoter region affect serum 
MBL levels, with low MBL levels giving an elevated risk of infection in 
immunocompromised individuals.  In an Australian HLA-matched sibling HSCT 
cohort, MBL2 mutations in the patient and/or donor genotype were associated with a 
risk of major infection following allogeneic transplant (Mullighan et al. 2002).  
However, this association was not observed in an independent study (Rocha et al. 
2002). 
 
FcγRIIa receptors provide a crucial link between cellular and humoral components of 
the immune response and are expressed in Langerhan cells, DCs, endothelial cells and 
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leukaemic cells.  These receptors are genetically polymorphic. The FcγRIIa-R 131 
genotype in the HSCT patients has been associated with an increased incidence of 
severe infection, and time to neutrophil recovery is delayed when the donor genotype is 
FcRIIIb HNA-1a/HNA-1b (Rocha et al. 2002).  In a more recent study (van der Straaten 
et al. 2005), 73 acute monocytic leukaemia patients were analysed for FcγRIIa 
polymorphisms as candidates for acute GVHD.  A mismatch between donor and patient 
FcγRIIa-R/R 131, FcγRIIa-H/H131 and FcγRIIa-R/H 131 genotypes were associated 
with an increased probability of GVHD.  The presence of FcγRIIa allo-types on DCs, 
Langerhan cells and endothelial cells suggests that they may be candidate mHags due to 
recognition by donor T cells.  This type of mismatching and potential relevance in 
GVHD of candidate mHags was also shown for the CD31 adhesion molecule 
(PECAM1) (Cavanagh et al. 2005), where the Val/Asn/Gly haplotype in the transplant 
donor significantly associated with the incidence of GVHD and donor heterozygosity at 
codon 125 or 563 associated with worse overall survival.  Several other HLA-matched 
sibling studies have examined associations between PECAM1 polymorphisms and 
HSCT outcome with inconsistent results (Behar et al. 1996; Nichols et al. 1996; Grumet 
et al. 2001; Cavanagh et al. 2005).  
 
1.6.3 Steroid Hormone Receptor Genes 
 
Steroid hormone receptors are implicated in the development of the immune system; 
consequently, these genes could have an impact on the reconstitution of the HSCT graft.  
 
Vitamin D receptor (VDR) is the nuclear receptor of the steroid hormone vitamin D.  Its 
gene has been mapped to chromosome 12q12-q14 and several polymorphisms have 
been reported to exist at this gene locus.  The most common polymorphisms within the 
VDR gene are restriction fragment length polymorphisms (RFLPs).  The Apa1 A/C 
RFLP is found within intron 8 and has been associated with the incidence and severity 
of diseases of immune function, such as common variable immune deficiency.  In terms 
of complications following HSCT, Apa1 A has been found to correlate with both acute 
GVHD and lower overall survival following HLA-matched sibling transplantation 
(Middleton et al. 2002; Bogunia-Kubik et al. 2008).   
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Another steroid hormone receptor of interest in HSCT is oestrogen receptor.  This 
receptor mediates the cellular response to oestrogens and related compounds and 
promotes a wide range of effects on haemopoiesis.  The oestrogen receptor gene (ESR1) 
is located on chromosome 6q24 and within intron I two RFLPs, PvuII C/T and XbaI 
A/G exist.  Both of these polymorphisms have been shown to associate with increased 
bone mineral density and the likelihood of developing Alzheimer’s disease in Japanese 
individuals.  In the context of HSCT, the C-T haplotype has been found to 
independently associate with both acute GVHD and lower overall survival following 
HLA-matched sibling transplantation (Middleton et al. 2003).   
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Chapter 2. Study Aims 
 
 
The overall aim of this study was to investigate the genetic and functional impact of 
non-HLA polymorphisms on HSCT outcomes, including acute and chronic GVHD, 
overall survival, relapse incidence and TRM. 
 
Polymorphisms in the genes of IL-2 (-330 T/G), IL-4 (-590 C/T), IL-6 (-174 G/C), IL-
10 (-592 A/C, -1082 G/A), IL-1Ra (intron 2 VNTR), TNFα (intron 3 (GA)n), TNFRII (-
196 M/R), IFNγ (intron 1 (CA)n), vitamin D receptor (intron 8 A/C, exon 9 T/C) and 
oestrogen receptor (intron 1 A/G, intron 1 C/T), that have been studied extensively in 
HLA-matched sibling transplantation were correlated with HSCT outcomes in an 
unrelated donor transplant population.  The aim was to identify genetic markers that can 
be used pre-transplant to predict GVHD, overall survival, disease relapse and TRM in 
this setting.   
 
The study also examined a polymorphism in the gene encoding IL-13, an 
immunoregulatory cytokine that has been implicated in the pathogenesis of GVHD.  
The IL13 +2044 G/A polymorphism has been widely studied for disease associations; 
however its role in HSCT is currently unknown.  To determine if IL13 +2044 G/A is a 
predictive marker for HSCT outcomes, correlations between this polymorphism and 
GVHD, overall survival, disease relapse and TRM were investigated in both HLA-
matched sibling and unrelated donor transplants.  The in vitro human skin explant 
model of GVHD and peri-transplant serum samples were utilised to study IL-13 
expression in acute and chronic GVHD and the functional significance of IL13 +2044 
G/A was examined using supernatant samples collected from phytohaemagglutinin 
(PHA) stimulated patient and donor peripheral blood mononuclear cells (PBMCs).  In 
addition, correlations between pre-transplant IL-13 serum levels and GVHD, survival, 
disease relapse and TRM were investigated to determine the role they may have in the 
prediction of HSCT outcomes.   
 
The specific aims for each part of this study are described in the relevant chapters.  
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Chapter 3. Materials and Methods 
 
 
Only the company name of the supplier is included in the materials and methods section 
for reagents and materials utilised.  For a detailed list of the supplying companies see 
Appendix A.   
 
3.1 HSCT Patient and Control Populations 
 
3.1.1 HSCT Patients and Donors 
 
Investigations within this study, including non-HLA polymorphism analyses, acute 
GVHD model studies and the collection of clinical skin biopsies and serum samples 
from patients and donors (where applicable), were undertaken with informed consent as 
approved by the Joint Local Ethics Committee (JLEC) for the Newcastle upon Tyne 
Hospitals Trust (JLEC approval letters; Appendix B).  The exact characteristics of each 
of the populations studied are documented in the relevant results chapters in which that 
particular cohort was employed. 
 
3.1.2 Volunteer Blood Donors 
 
Approval for the collection of peripheral blood samples from volunteer blood donors 
(control population for genetic studies) was granted under the remit of NHS Blood and 
Transplant (NHSBT), Holland Drive, Newcastle upon Tyne, UK and covered by ethics 
established by the NHSBT for an existing project.  Individual blood donor consent 
however, was not necessary as the volume of blood collected from each individual was 
less than 10mls and the accrued data were anonymised. 
 
3.1.3 Laboratory Staff Volunteers 
 
Peripheral blood samples from laboratory staff volunteers were also utilised (control 
population for functional studies).  All samples were taken with informed consent as 
approved by the JLEC. 
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3.1.4 Definition of Outcome Measures 
 
The primary end points for the clinical aspects of this study were the development of 
acute or chronic GVHD.  Acute GVHD was graded by consensus conference criteria 
(Przepiorka et al. 1995) and chronic GVHD was graded using the system proposed by 
Atkinson et al. (Atkinson et al. 1989).  Although these grading systems, particularly that 
employed for chronic GVHD, were not the most up to date (section 1.3.2); they were 
the most relevant in terms of this study, as a large proportion of the clinical data utilised 
were obtained from transplants performed in the 1980s.  Patients were considered 
assessable for acute GVHD if they survived ≥30 days post-transplant or died before day 
30 with clinical acute GVHD (grades II-IV) and patients were deemed assessable for 
chronic GVHD if they survived ≥100 days.  Overall survival was measured from the 
date of transplantation to the date of death or most recent clinic appointment.  Relapse 
was classified as disease recurrence and TRM was defined as death from all causes 
other than relapse.  Clinical data were available for all patients included in this study for 
at least 1 year following HSCT. 
 
3.1.5 HLA Typing 
 
The 776 patients/donors pairs recruited to our HSCT populations (HLA-matched 
sibling, n=347; unrelated donor, n=429) were transplanted at five different clinical 
centres across Europe (Austria, England, France, Germany and Spain).  In order to 
ensure continuity of data, all transplant pairs underwent HLA typing prior to the 
performance of this study.  As HLA-matching has significant implications in HSCT, 
particularly in unrelated donor transplantation, it was of great importance that as much 
HLA typing data as possible was obtained.  Consequently, high resolution DNA-based 
typing (PCR with sequence specific oligonucleotide probes, PCR-SSOP) of the HLA-A, 
-B, -C, -DRB1 and –DQB1 genes was performed.  HLA-DPB1 typing was not carried 
out, as at the time, the importance of this gene in HSCT had not yet been established 
(Shaw et al. 2007).  HLA class I typing was performed by Dr G Fischer, Medical 
University of Vienna, Vienna, Austria and class II typing was performed by Dr M 
Uhrberg, University Clinic Düsseldorf, Düsseldorf, Germany.  Of the original 776 
patient/donor pairs, 55 unrelated donor transplant pairs were excluded from the study 
following typing, as incomplete HLA data was obtained.  Of the remaining 721 
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patient/donor pairs, complete matching at all 5 loci (10/10 match) was observed in 78% 
(n=603).        
 
3.2 Peripheral Blood Mononuclear Cell Preparation 
 
Peripheral blood samples were collected from transplant patients and donors (40-60ml) 
prior to allogeneic HSCT and from volunteer blood donors and laboratory staff (10ml).   
The heparinized blood samples were diluted 1:1 with Earle’s Balanced Salt Solution 
(EBSS, Gibco), layered onto lymphoprep (~5ml, Axis-Shield), and then separated by 
density gradient centrifugation (Jouan CR422, Fisher Scientific) at 800g (20
o
C) for 15 
minutes.  The PBMCs at the plasma:lymphoprep interface were collected and washed 
twice in EBSS by centrifugation (MSE Centaur, VWR) at 380g for 5 minutes.  The 
isolated cells were then re-suspended in cell culture medium for immediate use or in 
freezing solution for long term storage at –140oC.  Cell counting was performed using 
an Improved Neubauer haemocytometer (SLS) and viability was assessed using the 
trypan blue (Gibco) exclusion method. 
 
3.3 Freezing Solution and Cryopreservation 
 
Cells for cryopreservation were either pelleted and frozen at -80
○
C or stored as viable 
cells in freezing solution.  The freezing solution employed consisted of 70% Rosewell 
Park Memorial Institute 1640 culture medium (RPMI 1640, Lonza), 20% heat 
inactivated foetal calf serum (FCS, Gibco) and 10% dimethyl sulfoxide (DMSO, NBS 
Biologicals).  All components of the freezing solution were filter sterilised through a 
0.2m filter (Gelman Sciences).  Viable cells were pelleted, re-suspended in cold 
freezing solution at a concentration of 1x10
7
cells/ml and transferred to 1.5ml cryovials 
(Nunc).  Each vial was wrapped in bubble plastic and cryopreserved at –80oC for 24 
hours before being transferred to –140oC for long term storage.  When the 
cryopreserved cells were required for use they were thawed at 37
o
C and rapidly diluted 
using warm cell culture medium. 
 
 
45 
 
3.4 Cell Culture Medium and Culture Conditions 
 
Cell culture medium consisted of RPMI 1640 containing 100 IU/ml penicillin (Lonza), 
100g/ml streptomycin (Lonza), 2mM L-glutamine (Gibco) and either 20% heat-
inactivated human autologous serum (RPMI-AS), 10% heat-inactivated human AB 
serum (RPMI-AB, PAA) or 10% FCS (RPMI-FCS).  All cell cultures were incubated at 
37
o
C in a 95% air, 5% CO2 humidified incubator (Galaxy B, SLS). 
 
3.5 Genomic DNA Preparation  
 
DNA was extracted from frozen PBMC pellets prepared using the methods described in 
sections 3.2 and 3.3.  The cell pellets were thawed at room temperature (RT) and re-
suspended thoroughly in 0.9ml Tris Sodium Ethylenediaminetetraactic acid (EDTA) 
buffer (TNE buffer).  The re-suspended cells were lysed by the addition of 0.01ml 20% 
sodium dodecyl sulphate (SDS, Sigma) and nuclear proteins associated with DNA were 
digested by the addition of 0.01ml 10mg/ml proteinase K (Roche).  After gentle 
inversion, complete lysis and digestion was ensured by incubation at 37˚C overnight. 
 
After overnight incubation 0.9ml buffered phenol (Rathburn Chemicals) was added, the 
samples were mixed gently for 5 minutes to create an emulsion and then centrifuged at 
500g for 1 minute (MSE Centaur 2, VWR).  The phenol used in this extraction method 
acted as a solvent for nuclear proteins released by proteinase K and sank to the bottom 
of the tube.  The supernatant was carefully removed to a clean 1.5 ml cryovial and 
0.9ml chloroform:isoamyl alcohol was added.  The samples were then mixed by 
vigorous inversions for 5 minutes.  Following centrifugation at 500g for 1 minute, the 
supernatant was removed to a clean 15ml tube (Greiner).  0.5ml 7.5M ammonium 
acetate (BDH/Merck) was added to the supernatant.  Samples were mixed by gentle 
inversion then incubated for 20 minutes at RT to allow the DNA to precipitate.  3ml 
ethanol (BDH/Merck) was added and the samples were mixed by inversion.  
Precipitated DNA at the acetate/ethanol interface was spooled onto a clean glass rod, 
aired dried for 5 minutes to allow alcohol evaporation and unwound into 0.5ml Tris 
EDTA (TE) buffer.  The prepared DNA samples were left to re-suspend at RT for 48 
hours. 
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Reagents 
a) 1M Tris Stock Solution (pH 7.5):  60.55g Tris (2-amino-2-(hydroxymethyl) 
1,3-propanediol) (BDH/Merck) made up to 500ml with deionised water 
b) 0.5M EDTA Stock Solution (pH 8.0):  93.06g EDTA (BDH/Merck) made up    
to 500ml with deionised water.  Titrate pH to 8.0 using sodium hydroxide pellets 
(BDH/Merck) 
c) TNE Buffer:  4.39g sodium chloride (BDH/Merck), 5ml 1M Tris stock solution 
and 10ml 0.5M EDTA stock solution made up to 500ml with deionised water 
d) Chloroform:Isoamyl Alcohol:  240ml chloroform (BDH/Merck) and 10ml 
isoamyl alcohol (Fisher Scientific) 
e) TE Buffer:  10ml 1M Tris stock solution and 1ml 0.5M EDTA stock solution 
made up to 1L with deionised water  
 
3.6 Genotyping Methods 
 
Prior to the performance of any polymorphism genotyping, power calculations were 
carried out (performed by Dr H Bickeböller, University of Göttingen, Göttingen, 
Germany) to determine whether the transplant cohorts being employed in this study 
were large enough for all existing associations with HSCT outcome to be observed.  
Although there are no formal standards for power, a sample size with a calculated 
power >80% is regarded as adequate.  Power calculations in this study were performed 
on all transplant cohorts undergoing genotyping analyses (1: unrelated donor cohort; 2: 
a mixed unrelated donor and HLA-matched sibling cohort) and used the minor allele 
frequency (MAF) of each of the non-HLA polymorphisms (IL2 -330 T/G, IL4 -590 C/T, 
IL6 -174 G/C, IL10 -592 A/C, IL10 -1082 G/A, IL13 +2044 G/A, IL1RN  intron 2 
VNTR, TNFA intron 3 (GA)n, TNFRSF1B -196 M/R, IFNG  intron 1 (CA)n, VDR 
intron 8 A/C, VDR exon 9 T/C, ESR1 intron 1 A/G and ESR1 intron 1 C/T) being tested 
and the relative risk for each of the HSCT outcomes (GVHD, overall survival, disease 
relapse and TRM) being examined to determine the minimum sample size required.  
The calculated sample sizes ranged from 180-250 patients, with the largest populations 
being necessary for the IL4 -590 C/T, IL13 +2044 G/A and TNFRSF1B -196 M/R 
polymorphisms.  The unrelated donor (n=374) and mixed HSCT (n=721) populations 
employed in this study were substantially larger than these minimum values, 
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consequently, both cohorts had calculated powers >80% and therefore reached 
adequacy.  
 
Power calculations were also performed to determine whether any of the single-disease 
subgroups (acute lymphoblastic leukaemia, acute myeloid leukaemia, chronic 
lymphocytic leukaemia, chronic myeloid leukaemia, Hodgkin disease, non-Hodgkin 
lymphoma, myeloproliferative disorders, plasma cell neoplasm and aplastic anaemia) 
within the unrelated donor and mixed HSCT cohorts were large enough to permit non-
HLA polymorphism analysis.  Calculated minimum sample sizes ranged from 198-210 
patients, with the smallest population being required for the IL6 -174 G/C 
polymorphism.  The largest single-disease subgroup (acute myeloid leukaemia) in the 
unrelated donor and mixed HSCT cohorts contained only 132 and 196 patients 
respectively; consequently, none of the subgroups reached the minimum values required 
for adequacy (calculated powers of <80%) and were therefore not analysed as separate 
populations.       
 
3.6.1 Polymerase Chain Reaction 
 
The polymerase chain reaction (PCR) is a widely employed cell-free method designed 
to generate large amounts of a desired DNA sequence and can be used on fragments of 
DNA that are initially present in extremely small quantities.  The DNA region of 
interest is isolated by the use of primer sequences that are complementary to the 
sections of DNA flanking the target.  A heat-stable form of the DNA polymerase 
enzyme, typically Taq polymerase, is then employed to synthesize complementary 
strands of the target DNA via enzymatic replication (Mullis et al. 1987). 
 
There are three steps in the PCR reaction: 
 
Denaturation: The DNA to be amplified is denatured by heating to 94˚C.  This causes 
the double stranded DNA to dissociate into single strands.  All enzymatic reactions are 
inhibited in this step in order to prevent the continuous extension of DNA strands 
already generated. 
Annealing: During this step, primers hybridize to the complementary regions of DNA 
that flank the sequence being amplified.  The temperature required for annealing is 
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dependent upon the primer length and sequence, but is typically 55-65˚C.  Higher 
temperatures lead to increased PCR specificity.            
Extension: Taq polymerase creates new DNA strands by extending the primers in the 
5’ to 3’ direction using deoxynucleotide triphosphates (dNTPs: dATP, dCTP, dGTP, 
dTTP) that are present in excess.  This step of the reaction is carried out at 72˚C, as this 
is the ideal working temperature for the Taq polymerase enzyme. 
 
Each set of three steps is referred to as a cycle.  Repetition of this cycle (typically 25-35 
times) results in an exponential increase in the number of copies of the desired DNA 
sequence (Strachan and Read 2000).  The amplification of a particular DNA region in 
this way opens that area up for further investigations, such as DNA sequencing or 
polymorphism analysis as performed in this study. 
 
DNA samples from our HSCT and control populations were analysed for 
polymorphisms in cytokine, cytokine receptor and steroid hormone receptor genes.  
PCR amplification was performed using the same basic method, however, primer 
sequences, reagent concentrations and thermal cycling conditions varied (Table 3.1).  
Briefly, PCR products were amplified from target DNA in a 10x potassium chloride 
(KCl) based buffer (Bioline), with dNTPs (Roche) at 200μM.  Forward and reverse 
primers (MWG) at a final concentration of 1µM and 0.5 Units of Taq polymerase 
(Bioline) were used per 100µl of reaction mix.  All reagents were combined in a master 
mix and 23µl were added to each genomic DNA sample (2µl (50ng)).  Amplifications 
were performed using an ABI 2720 thermal cycler (AB).  PCR products were then 
subjected to a polymorphism analysis method or separated directly using 
electrophoresis. 
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Table 3.1 Primer sequences, PCR conditions and analysis methods employed for polymorphism genotyping.  
For each polymorphism, the location, nucleotide/amino acid change (where appropriate) and primer sequences are indicated.  The PCR conditions and analysis methods 
employed are also recorded.  PCR, polymerase chain reaction; VNTR, variable number tandem repeat; KCl, potassium chloride; dNTP, deoxynucleotide triphosphate; 
SSCP, single stranded conformational polymorphism; IHG, induced heteroduplex generator; RFLP, restriction fragment length polymorphism; MgCl2 , magnesium 
chloride 
 
 
Gene and 
Polymorphism 
Primers PCR Reaction Mix  PCR Conditions 
(35-40 cycles) 
Analysis Method References 
IL1RN 
Intron 2 VNTR 
5’-CTCAGCAACACTCCTAT-3’ 
5’-TCCTGGTCTGCAGGTAA-3’ 
10 x KCl Buffer 
dNTP (200µM) 
Forward Primer (1µM) 
Reverse Primer (1µM) 
Taq Polymerase (0.5U) 
Deionised Water 
94°C  30seconds 
60°C  1 minute 
72°C  1 minute 
 
2% agarose gel 
Ethidium Bromide 
(Hurme and Sattila 
1998) 
IL2 
-330 T/G 
rs2069762 
5’-ACCACAATATGCTATTCACATGTTCA-3’ 
5’-TGATAGCTCTAATTCATGCAATTAACG-3’ 
10X KCl Buffer 
dNTP (200µM) 
Forward Primer (1µM) 
Reverse Primer (1µM) 
Taq Polymerase (0.5U) 
Deionised Water 
94°C  30 seconds 
60°C  1 minute 
72°C  1 minute 
SSCP 
15°C electrophoresis 
12% acrylamide gel 
Siver Stain 
(Hdud, 2005) 
Unpublished -
Personal 
Communication 
IL4  
-590 C/T 
rs2243250 
5’-ACTAGGCCTCACCTCACCTGATAGC-3’ 
5’-GTTGTAATGCAGTCCTCCTG-3’ 
10 x KCl Buffer 
dNTP (200µM) 
Forward Primer (1µM) 
Reverse Primer (1µM) 
Taq Polymerase (0.5U) 
Deionised Water 
94°C  30 seconds  
57°C  30 seconds 
72°C  30 seconds 
SSCP 
10% acrylamide gel 
Silver Stain 
(Walley and Cookson 
1996) 
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IL6 
-174 G/C 
rs1800795 
5’-TGACGACCTAAGCTGCACTTTTC-3’ 
5’-GGGCTGATTGGAAACCTTATTAAGA-3’ 
1x TaqMan Universal Master 
Mix 
1x Assay Mix 
Deionised Water 
Initial Hold: 
95°C  10 minutes 
Cycle: 
92°C  15 seconds 
60°C  1 minute 
TaqMan 
 
AB 
Assay by-Design 
P/N: 4331349 
IL10 
-592 A/C 
rs1800872 
5’-GAAATCGGGGTAAAGGAGCC-3’ 
5’-AGTTCCCAAGCAGCCCTTCC-3’ 
10 x KCl Buffer 
dNTP (200µM) 
Forward Primer (1µM) 
Reverse Primer (1µM) 
Taq Polymerase (0.5U) 
Deionised Water 
94°C  30 seconds 
62°C  1 minute 
72°C  1 minute 
IHG 
15% acrylamide gel 
Silver Stain 
(Morse et al. 1999) 
IL10 
-1082 G/A 
rs1800896 
5’-AATCCAAGACAACACTACTAAGGC-3’ 
5’-CTGGATAGGAGGTCCCTTAC-3’ 
10 x KCl Buffer 
dNTP (200µM) 
Forward Primer (1µM) 
Reverse Primer (1µM) 
Taq Polymerase (0.5U) 
Deionised Water 
94°C  30 seconds 
57°C  1 minute 
72°C  1 minute 
IHG 
15% acrylamide gel 
Silver Stain 
(Morse et al. 1999) 
IL13 
+2044 G/A 
rs20541 
5’-CTTCCGTGAGGACTGAATGAGACGGTC-3’ 
5’-GCAAATAATGAGCTTTCAAGTTTCAGTGGA-3’ 
10 x KCl Buffer 
dNTP (200µM) 
Forward Primer (1µM) 
Reverse Primer (1µM) 
Taq Polymerase (0.5U) 
Deionised Water 
94°C  30 seconds 
56°C  1 minute 
72°C  1 minute 
PCR-RFLP 
NlaIV Digestion 
11% acrylamide gel 
Silver Stain 
(Graves et al. 2000) 
Modified 
IFNG 
Intron 1 (CA)n 
Microsatellite 
5’-GCTGTCATAATAATATTCAGAC-3’ 
5’-CGAGCTTTAAAAGATAGTTCC-3’ 
10 x KCl Buffer 
dNTP (200µM) 
Forward Primer (1µM) 
Reverse Primer (1µM) 
Taq Polymerase (0.5U) 
Deionised Water 
94°C  30 seconds 
60°C  1 minute 
72°C  1 minute 
8% acrylamide gel 
Silver Stain 
(Pravica et al. 2000) 
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TNFA 
Intron 3 LST1 
(GA)n 
Microsatellite 
5’-AGATCCTTCCCTGTGAGTTCTGCT-3’ 
5’-CATAGTGGGACTCTGTCTCCAAAG-3’ 
10 x KCl Buffer 
dNTP (200µM) 
Forward Primer (1µM) 
Reverse Primer (1µM) 
Taq Polymerase (0.5U) 
Deionised Water 
94°C  30 seconds 
60°C  1 minute 
72°C  1 minute 
8% acrylamide gel 
Silver Stain 
(Udalova et al. 1993) 
TNFRSF1B 
-196 M/R 
rs1061622 
5’-ACTCTCCTATCCTGCCTGCT-3’ 
5’-TTCTGGAGTTGGCTGCGTGT-3’ 
10 x KCl Buffer 
dNTP (400µM) 
Forward Primer (1µM) 
Reverse Primer (1µM) 
Taq Polymerase (0.5U) 
Deionised Water 
94°C  30 seconds 
57°C  1 minute 
72°C  1 minute 
SSCP 
12% acrylamide gel 
Silver Stain 
(Komata et al. 1999; 
Stark et al. 2003) 
VDR  
Intron 8 A/C 
Exon 9 T/C  
rs7975232 
rs731236 
5’-CAGAGCATGGACAGGGAGCAA-3’ 
5’-GGATGTACGTCTGCAGTGTG-3’ 
10 x KCl Buffer 
dNTP (200µM) 
Forward Primer (1µM) 
Reverse Primer (1µM) 
Taq Polymerase (0.5U) 
Deionised Water 
94°C  30 seconds 
63°C  1 minute 
72°C  1.5 minutes 
PCR-RFLP 
ApaI Digestion 
TaqI Digestion 
2% agarose gel 
Ethidium Bromide 
(Hennig et al. 1999; 
Middleton et al. 
2002) 
ESRI  
Intron 1 A/G 
Intron 1 C/T 
rs9340799 
rs2234693 
5'CTGCCACCCTATCTGTATCTTTTCCTATTCTCC3' 
5'TCTTTCTCTGCCACCCTGGCGTCGATTATCTGA3' 
10 x KCl Buffer 
dNTP (200µM) 
Forward Primer (1µM) 
Reverse Primer (1µM) 
MgCl2 (1.5mM) 
Taq Polymerase (0.5U) 
Deionised Water 
94°C  30 seconds 
58°C  1 minute 
72°C  1 minute 
PCR-RFLP 
XbaI Digestion 
PvuII Digestion 
1% agarose gel 
Ethidium Bromide 
(Middleton et al. 
2003) 
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3.6.2 Restriction Fragment Length Polymorphism Analysis 
 
Polymorphisms that lie within the recognition sequence for a specific restriction enzyme 
can be investigated using restriction fragment length polymorphism (PCR-RFLP) 
analysis.  Polymorphic allele identification by this method is dependent on the creation 
or destruction of a restriction enzyme cutting site.  If such a site is present in one allele 
of a polymorphism and absent in the other, then digestion with the appropriate 
restriction enzyme will produce DNA fragments of differing lengths and electrophoretic 
mobilities; that can be distinguished by gel electrophoresis (Strachan and Read 2000).  
This type of analysis was employed to identify the allelic variants of polymorphisms 
within the VDR (Intron 8 A/C and Exon 9 T/C), ESRI (Intron 1 A/G and C/T) and IL13 
(+2044 G/A) genes.  The VDR and ESRI polymorphisms were genotyped using 
established PCR-RFLP methods (Table 3.1), whilst the allelic variants of the IL13 
+2044 G/A polymorphism were identified using a method developed during the course 
of this study (section 3.6.3). 
 
Digest mixtures were prepared by combining 5μl of PCR products with 2.5μl of 
deionised water, 1μl of 10x bovine serum albumin (BSA, Promega), 0.5μl of restriction 
enzyme and 1μl of the corresponding restriction enzyme buffer.  After gentle mixing the 
digest samples were incubated at the appropriate temperature and then separated by gel 
electrophoresis (Figure 3.1).  All restriction digests were performed with a 5-fold excess 
of enzyme to avoid partial digestion of the products and thus erroneous allele detection.  
The restriction enzyme employed and specific digestion conditions utilised for each 
PCR-RFLP are displayed in Table 3.2. 
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Figure 3.1 A representative 2% agarose gel showing polymorphism analysis of VDR Intron 8 A/C 
using the PCR-RFLP method.  Alleles are identified according to the presence (C) or 
absence (A) of an ApaI restriction site.  All three possible genotype combinations are 
shown: AA (lane 2), AC (lane 1) and CC (lane 3).  M, DNA size markers (100bp Low 
Ladder, Sigma); bp, base pairs     
 
 
 
 
Gene Polymorphism Restriction Enzyme Conditions Reference 
VDR Intron 8 
A/C 
ApaI 
(Promega) 
2 hours at 25◦C 
2% agarose gel 
(Hennig et al. 1999) 
VDR Exon 9 
T/C 
TaqI 
(Promega) 
1 hour at 65◦C 
2% agarose gel 
(Hennig et al. 1999) 
ESRI Intron 1 
A/G 
XbaI 
(Promega) 
1.5 hours at 37◦C 
1% agarose gel 
(Middleton et al. 2003) 
ESRI Intron 1 
C/T 
PvuII 
(Roche) 
1.5 hours at 37
◦
C 
1% agarose gel 
(Middleton et al. 2003) 
IL13 Exon 4  
G/A 
NlaIV 
(NEB) 
2 hours at 37◦C 
11% acrylamide gel 
(Graves et al. 2000) 
         Modified 
 
Table 3.2 Restriction enzymes and digestion conditions employed for PCR-RFLP analysis.   
VDR, vitamin D receptor; ESRI, oestrogen receptor; IL13, interleukin-13 
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3.6.3 Method Development for IL13 +2044 G/A Determination 
 
Study Population: Newcastle Control Cohort 
 
A total of 100 Newcastle volunteer blood donors were recruited to act as the control 
cohort for the genotyping aspects of this current study.  The group comprised 53 males 
and 47 females, with a median age of 37 years (range 19-56).  DNA samples were 
obtained using the methods described in sections 3.2, 3.3 and 3.5.       
 
Controls were typed for the IL13 +2044 G/A polymorphism using the method 
developed.  In order to confirm that a reliable genotyping protocol had been established, 
allele and genotype frequencies were calculated and compared to those published in the 
literature. 
 
PCR Amplification 
 
PCR Conditions 
 
The primer sequences used to amplify the 236bp fragment containing the IL13 +2044 
G/A polymorphism were as follows:  
 
Forward Primer 5'-CTTCCGTGAGGACTGAATGAGACGGTC-3' 
Reverse Primer 5'- GCAAATAATGAGCTTTCGAAGTTTCAGTGGA -3' 
 
These primers were identical to those used in the previously published method by 
Graves et al (Graves et al. 2000).  Each PCR employed a 25μl reaction mix containing 
2μl of genomic DNA (50ng), 10x KCl buffer, dNTPs at 200μM, forward and reverse 
primers at 1μM and 0.5 Units of Taq polymerase.  Samples were thermal cycled for 35 
cycles of 94
o
C for 30 seconds, 56
o
C for 60 seconds and 72
o
C for 60 seconds. 
 
PCR Development 
 
The specificity of the amplification was assessed by electrophoresis of the PCR 
products on a 1% agarose gel.  The main problem encountered during method 
development was the presence of numerous high molecular weight products, suggesting 
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a lack of specificity in the PCR.  A variety of reaction conditions were tested in an 
attempt to address this problem.  The tested conditions were: variation in annealing 
temperature (55-60ºC), variation in primer concentration (0.5-1.5μM) and variation in 
dNTP concentration (100-500μM).  The optimal reaction conditions found were those 
described overleaf. 
 
Allele Discrimination 
 
IL13 +2044 G/A allele discrimination was achieved using PCR-RFLP analysis (section 
3.6.2).  The restriction enzyme NlaIV digests the PCR product 26bp from the 5’end in 
all cases (internal control) and then a further 32bp from the 3’ end for the more common 
G allele (Figure 3.2).  The presence of this allele leads to the creation of the NlaIV 
recognition sequence; GGNNCC (where N indicates any base and the IL13 +2044 G/A 
location is at G one).  The restriction enzyme then digests the sequence in the middle, 
leaving a 178bp fragment (Graves et al. 2000; Chmiel et al. 2005).    
 
Digested products were initially separated using 1% agarose gels.  Successful digestion 
was confirmed, but adequate separation of the products was not achieved.  In an attempt 
to improve the resolution, higher concentrations of agarose were utilised (2% and 3%).  
However, separation was still insufficient for accurate allele discrimination.  
Consequently, acrylamide gel electrophoresis was employed.  As acrylamide has a 
smaller gel matrix in comparison to agarose, it was hoped that this method would permit 
greater separation of the digested products.  In order to identify the optimal conditions 
for IL13 +2044 G/A discrimination a variety of reaction conditions were examined.  
The tested conditions were: variation in the percentage of acrylamide (10-15%), 
variation in voltage (200-400V) and variation in electrophoresis temperature (15-30 ºC).  
The cleanest product separation was achieved using 11% acrylamide gels run overnight 
at a constant voltage of 200V and a constant temperature of 25 ºC. 
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Figure 3.2 A representative 11% acrylamide gel showing polymorphism analysis of IL13+2044 
G/A using the PCR-RFLP method.  The two allelic variants (G or A) are identifiable 
and all three possible genotype combinations are shown: GG (lanes 1 and 3), GA (lanes 
4, 5 and 6) and AA (lanes 2).  bp, base pairs 
 
 
 
Allele and Genotype Frequencies 
 
The allele and genotype frequencies calculated for the Newcastle control cohort were 
very similar to those reported in the literature (P=0.860 and 0.910 respectively; Table 
3.3) (Heinzmann et al. 2003; Maier et al. 2006).  Thus, an accurate genotyping protocol 
for the IL13 +2044 G/A polymorphism had been successfully established. 
 
 
 
 Newcastle Control  
Cohort (n=100) 
Published Control 
Cohort 
   
Alleles   
G 0.81 0.79 
A 0.19 0.21 
Genotypes   
GG 0.66 0.68 
GA 0.30 0.29 
AA 0.04 0.03 
 
Table 3.3 IL13 +2044 G/A allele and genotype frequencies for the Newcastle control cohort. 
 
178bp G
210bp A
1         2          3          4           5          6
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In order to assess the reproducibility of the method, 25% of the control cohort was re-
genotyped.  No differences were observed between the two sets of data (P=1.000; Table 
3.4). 
 
 
 
 Newcastle Control Cohort (n=25) 
 Genotype 1 Genotype 2 
 
IL13 +2044 G/A 
  
GG 15 15 
GA 9 9 
AA 1 1 
 
Table 3.4 Reproducibility assessment of the IL13 +2044 G/A genotyping method in 25% of the 
Newcastle control cohort.  IL13, interleukin-13 
 
 
The method developed for IL13 +2044 G/A determination was therefore accurate and 
reproducible enough to be utilised in the remainder of this study for genotyping of our 
HSCT cohort. 
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3.6.4 Single Stranded Conformational Polymorphism Analysis 
 
Single stranded conformational polymorphism (SSCP) analysis is a highly sensitive 
single tube assay employed for mutation detection (Orita et al. 1989; Nataraj et al. 
1999).  The method works on the principle that single-stranded DNA fragments adopt 
specific tertiary conformations that are dependent upon their nucleotide sequence.  
Thus, the presence of a polymorphism within DNA fragments results in the generation 
of products with different shapes and electrophoretic mobilities that can be 
distinguished by acrylamide electrophoresis.  In this study SSCP analysis was employed 
to identify the allelic variants of polymorphisms within IL2 (-330 T/G), IL4 (-590 C/T) 
and TNFRSF1B (-196 M/R).  
 
SSCP mixtures were prepared by combining PCR products and formamide load in a 1:1 
ratio (5μl of each).  Samples were denatured to single-stranded DNA at 98˚C for 5 
minutes and then snap cooled on ice for 5 minutes to prevent re-annealing.  After 
cooling, 4μl of products were loaded onto an acrylamide gel and separated by 
electrophoresis overnight at 400V (Figure 3.3). 
 
 
 
 
 
Figure 3.3 A representative 12% acrylamide gel showing polymorphism analysis of TNFRSF1B -
196 M/R using the SSCP method.  The two allelic variants (M or R) are identifiable and 
all three possible genotype combinations are shown: MM (lanes 2, 3, 4 and 7), MR 
(lanes 1 and 5) and RR (lanes 6)   
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3.6.5 Induced Heteroduplex Generator Analysis 
 
Induced heteroduplex generator (IHG) analysis is a mutation detection method that uses 
synthetic DNA fragments (heteroduplex generators) to identify polymorphic alleles.  
Polymorphisms within PCR products are identified by the induction of conformational 
changes in the target DNA following inter-strand hybridization with heteroduplex 
generators.  The conformational changes produced are specific for each of the allelic 
variants and due to differences in their electrophoretic mobility can be visualised 
following electrophoresis (Morse et al. 1999; Wood et al. 2001).  IHG analysis was 
employed in this study to identify the allelic variants of two polymorphisms within the 
IL10 promoter region (IL10 -592 A/C and IL10 -1082 G/A).   
 
IHG mixtures were prepared by combining PCR products, heteroduplex generators 
(supplied by Dr L Keen, Department of Pathology and Microbiology, University of 
Bristol, Bristol, UK) and formamide load in a 1:1:1 ratio (5μl of each).  Samples were 
then heated to 94°C for 4 minutes and ramp cooled to 37°C over 30 minutes (Morse et 
al. 1999).  These conditions facilitated the production of allele specific heteroduplexes 
between the PCR products and generators; that were separated by acrylamide 
electrophoresis (Figure 3.4).   
 
The heteroduplex generators employed contained poly-adenine (A) identifiers inserted 
immediately downstream of the IL10 polymorphisms (Figure 3.5).  These identifiers 
introduce a degree of mismatch between the PCR products and the generators, which 
varies depending on the nucleotide sequence of the products.  The variation in the 
degree of mismatching between the strands alters the conformation and electrophoretic 
behaviour of the PCR products and consequently permits the identification of the IL10 
allelic variants.       
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Figure 3.4 A representative 15% acrylamide gel showing polymorphism analysis of IL10 -1082 
G/A using the IHG method.  The two allelic variants (G or A) are identifiable and all 
three possible genotype combinations are shown: GG (lanes 2 and 3), GA (lane 4) and 
AA (lane 1)  
 
 
 
 
 
 
 
Figure 3.5 Nucleotide sequences of IL10 promoter polymorphism alleles and heteroduplex 
generators. Polymorphism positions and heteroduplex generator identifiers (poly-
adenine (A) inserts) are denoted using asterisks (Morse et al. 1999).  IL-10, interleukin-
10; HG, heteroduplex generators  
 
 
 
 
 
G
A
1 2 3 4
 
 
* 
* 
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3.6.6 TaqMan Analysis 
 
TaqMan is a fluorescence-based PCR assay used for gene expression quantification and 
genetic polymorphism detection (Watson and Li 2005).  Polymorphism identification 
using this method is achieved by including fluorescently labelled probes in the PCR.  In 
order to differentiate between the allelic variants, each probe contains a different 
fluorescent dye (VIC or FAM).   
 
Two probes are used in TaqMan analysis, each one specific for one of the polymorphic 
alleles.  The probes consist of an oligonucleotide with a 5’-fluorescent reporter dye and 
a 3’-quencher dye.  When a probe is intact, the proximity of the reporter dye to the 
quencher results in suppression of the fluorescent signal.  During PCR, primers bind to 
specific sequences flanking the DNA to be amplified and the probe hybridises to a 
specific sequence within the amplified DNA.  Taq polymerase extends the primers in 
the 5’ to 3’ direction and cleaves any bound probe with its 5’-3’ nuclease activity.  The 
reporter dye and quencher dye become separated during cleavage and a fluorescent 
signal, unique to each dye is produced (Figure 3.6).  This process occurs in every PCR 
cycle, consequently, repetition of the cycle results in an exponential accumulation of 
PCR product and fluorescence (Watson and Li 2005). 
 
 
 
Figure 3.6 A schematic diagram of a single PCR cycle in TaqMan analysis.  Taq polymerase 
extends the primers bound to the target DNA in the 5’→3’ direction and cleaves any 
probe hybridised to the target.  Cleavage separates the reporter dye from the quencher 
dye, which results in a fluorescent signal (Lyamichev et al. 1993). 
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TaqMan analysis of the IL6 -174 G/C polymorphism was carried out using a custom 
TaqMan genotyping assay supplied by AB (P/N: 4331349).  Primer and probe 
sequences employed are shown in Tables 3.1 and 3.5 respectively.  PCR products were 
amplified from target DNA using 1x TaqMan universal PCR master mix (buffer, 
dNTPs, MgCl2 and Taq polymerase) and 1x assay mix (TaqMan primers and VIC/FAM 
labelled probes).  The reagents were combined in a master mix and 13µl were added to 
each genomic DNA sample (12µl).  All DNA samples were diluted to 10ng in deionised 
water.  PCR amplification was then performed using the ABI 7500 Real-time PCR (RT-
PCR) system (AB).  After an initial hold at 95
o
C for 10 minutes, the samples were 
cycled for 40 cycles of 92ºC for 15 seconds and 60ºC for 1 minute.  Following thermal 
cycling, fluorescence measurements were recorded and genotyping data was obtained 
after analysis with Sequence Detection System (SDS) software (AB, Figure 3.7).  
 
 
 
 Probe Sequence Reporter Dye 
 
 
 
IL6 -174 G/C 
 
5’-TCTTGCGATGCTAA-3’ 
5’-TCTTGCCATGCTAAA-3’ 
 
VIC 
FAM 
 
Table 3.5 Probe sequences employed for IL6 -174 G/C TaqMan analysis. 
  FAM, 6-carboxyfluorescein 
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Figure 3.7 A representative plot showing allelic discrimination of IL6 -174 G/C using a custom 
TaqMan genotyping assay (AB).  Alleles are identified by the detection of VIC and/or 
FAM fluorescence.  All three possible genotype combinations are show: GG, GC and 
CC.  NTC, no-template control; ?, sample fail     
 
 
3.6.7 Sequencing of PCR Products 
 
To confirm that the PCR products generated by each genotyping method contained the 
appropriate polymorphism, control DNA samples were amplified and sequenced by the 
Molecular Biology Unit, Newcastle University, Newcastle upon Tyne, UK.  The DNA 
sequences obtained were compared to the full sequence of the corresponding gene using 
MacVector software; direct alignment and polymorphism detection was achieved for all 
the samples analysed.  The sequenced samples were then employed in all future PCR 
analyses as positive controls (homozygous and heterozygous).  
 
 
Reagents 
a) dNTP:  0.0125ml each dNTP stock (dATP, dCTP, dGTP, dTTP) in 0.95ml 
deionised water  
b) Formamide Loading Buffer:  9ml formamide (Sigma), 0.5ml glycerol 
(BDH/Merck), 0.2ml 0.5M EDTA stock solution, 25mg bromophenol blue 
(Sigma) and 0.3ml distilled water 
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3.7 Gel Preparation 
 
3.7.1 Agarose Gels 
 
1%, 2% and 3% agarose gels were prepared by dissolving Microsieve Low Melt GTG 
agarose (0.64g, 1.28g and 1.92g respectively, Flowgen) and SeaKem LE agarose 
(0.16g, 0.32g and 0.48g respectively, Flowgen) in 80ml Tris Acetate EDTA (TAE) 
buffer using a heated magnetic stirrer (Fisher Scientific).  Any volume lost during the 
heating process was replaced with deionised water.  The agarose solution was then 
cooled under cold water, poured into a casting tray (Bio-Rad) around a plastic well 
forming comb (Bio-Rad) and left to set at RT for approximately 1 hour.     
 
3.7.2 Acrylamide Gels 
 
Glass casting plates (Bio-Rad) were cleaned with distilled water and chloroform; then 
coated in Sigmacote (Sigma) to allow gel removal after electrophoresis.  The gel rig 
(Sequi-gel, Bio-Rad) was then assembled, ensuring the correct alignment of the plates, 
spacers and clamps to avoid leakage.  Gel solutions of 8%, 10%, 11%, 12% and 15% 
were prepared using 30ml, 39ml, 43ml, 46ml and 49ml respectively of acrylamide stock 
solution (30% w/v acrylamide : 0.8% w/v bisacrylamide, Flowgen or 40% 
acrylamide/bis solution 19:1, Bio-Rad) and 15ml Tris Borate EDTA (TBE) buffer.  All 
gel solutions were made up to 150ml with deionised water and degassed for 5 minutes.  
0.1ml N-tetramethylethylenediamine solution (BDH/Merck) and 0.2ml 50% ammonium 
persulphate (BDH/Merck) solution were added to allow matrix formation and after 
gentle mixing the gels were cast between the glass plates.  A plastic well forming comb 
was inserted and the gels were left to set at RT for approximately 1 hour.  
 
Reagents 
a) TAE Buffer:  4.84g Tris, 1.1ml glacial acetic acid (BDH/Merck) and 2ml 0.5M 
EDTA stock solution made up to 1L with deionised water 
b) TBE Buffer:  10.8g Tris, 5.5g orthoboric acid (Sigma) and 0.58g EDTA made 
up to 1L with deionised water 
c) 50% Ammonium Persulphate:  0.5g ammonium persulphate in 1ml of 
deionised water 
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3.8 Staining Techniques 
 
3.8.1 Ethidium Bromide 
 
PCR products separated by agarose gel electrophoresis were stained with ethidium 
bromide (Sigma).  0.02ml 2mg/ml ethidium bromide was included in all molten agarose 
before casting and 0.01ml was also added to the electrophoresis buffer (TAE) prior to 
separation.  Stained products were visualised using UV transillumination (AlphaImager, 
Alpha Innotech).   
 
3.8.2 Silver Staining 
 
Silver staining was employed to visualise PCR products separated by acrylamide gel 
electrophoresis.  Gels were removed from the glass plates of the gel rig, washed twice in 
a fixing solution (10% ethanol; 0.5% acetic acid) for 3 minutes and then soaked in a 
silver nitrate solution (0.1% silver nitrate) for 15 minutes.  During this 15 minute period 
the gel and staining solution were gently agitated to allow the positive charged silver 
ions to bind to the negatively charged DNA.  Colour was developed using a solution of 
1.5% sodium hydroxide and 0.15% formaldehyde.  After agitation in developing 
solution for 20 minutes the gels were rinsed in tap water and sealed in plastic before 
visualisation on a light box. 
 
Reagents 
a) Fixing Solution:  100ml ethanol and 1ml glacial acetic acid made up to 1L 
with deionised water 
b) Staining Solution:  0.5g silver nitrate (BDH/Merck) in 500ml deionised water 
c) Developing Solution:  6g sodium hydroxide pellets and 0.6ml formaldehyde 
(Fisher Scientific) made up to 500ml with deionised water 
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3.9 Mixed Lymphocyte Cultures  
 
The mixed lymphocyte culture (MLC) was the first widely used functional test of allo-
reactivity in HSCT and provided the platform for the development of other cellular-
based assays (Mickelson et al. 1993).  Traditionally, MLCs were employed prior to 
HSCT to predict the incidence and severity of acute GVHD by determining the degree 
of allo-reactivity between the donor and patient in a transplant pair.  Irradiated patient 
cells and non-irradiated donor cells are combined in culture and allo-reactivity is 
quantified by the incorporation of 
3
H-thymidine into proliferating donor cells.  Since the 
first application of the MLC, studies have demonstrated that the allo-reaction produced 
is not sensitive enough to accurately predict acute GVHD in either HLA-matched 
sibling (Lim et al. 1988; DeGast et al. 1992) or unrelated donor (Mickelson et al. 1993) 
HSCT; consequently, this technique is no longer widely used in the clinical setting.  The 
MLC is still however an extremely useful tool in the research setting.  A modified 
version of the assay was employed in this study to mimic the allo-response following 
HSCT.  
 
MLCs were set up primarily between a HSCT patient and donor in the graft-versus-host 
(GVH) direction (allogeneic MLC); patient (host) PBMCs were irradiated and acted as 
stimulator cells for the unirradiated donor (graft) responder cells.  As controls, 
autologous MLCs were set up using patient cells as both stimulator and responder. 
 
As previously described (section 3.2), patient and donor PBMCs were separated from 
heparinized whole blood samples by density gradient centrifugation.  1x10
7
 stimulator 
cells (patient) were irradiated (20 Gy) and co-cultured with 1x10
7
 responder cells 
(donor) in 10ml 10% RPMI-AB in 25cm
3
 tissue culture flasks (Greiner).  Each MLC 
was incubated at 37
o
C with 5% CO2 for 7 days. 
 
After 7 days the culture was harvested for cells and supernatant by centrifugation at 
380g for 5 minutes.  The supernatant was removed and frozen in aliquots at –80oC for 
IL-13 analysis by ELISA.  The viable cells were counted by the trypan blue exclusion 
method and either used immediately in the in vitro human skin explant assay or 
cryopreserved for use at a later date. 
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3.10 In Vitro Human Skin Explant Assay 
 
The human skin explants assay is an in vitro model that has been used over the years for 
the prediction of acute GVHD prior to transplantation (Vogelsang et al. 1985; 
Dickinson et al 1988; Sviland et al 1990; Dickinson et al. 1998; Dickinson et al. 1999).  
Prediction is based on the degree of damage observed when allo-reactive donor cells 
(previously stimulated in the MLC) and a pre-transplant patient-derived skin biopsy are 
combined in culture.  The skin damage produced is a consequence of donor-derived 
allo-reactive cytotoxic T cells recognising specific allo-antigens present in the patient-
derived skin as foreign (graft-versus-host reaction, GVHR).  The resultant skin damaged 
is graded from I-IV using the classification of GVHD histopathology described by 
Lerner et al. (1974). 
 
In addition to its use in the prediction of acute GVHD, the human skin explants assay 
has also developed into a useful research tool to investigate potential mechanisms in the 
pathogenesis of the disease.  In this current study, the assay was performed prior to 
transplantation and was employed to examine the possible roles of IL-13 in acute 
GVHD. 
 
Two 4mm punch biopsies of skin were taken from a patient’s upper arm and placed in 
EBSS (1-2 hours) prior to their use in the assay.  The skin biopsies were dissected using 
sterile instruments, removing the sub-dermal adipose tissue and leaving a portion of the 
dermis under the epithelium.  The biopsies were then divided into a total of six pieces of 
approximately equal size. 
 
Cells harvested from the previously described allogeneic and autologous MLCs (section 
3.9) were diluted to 2x10
6
 cells and pelleted by centrifugation at 380g for 5 minutes.  
The pelleted cells were then re-suspended in 0.4ml 20% RPMI-AS.  
 
The six skin sections prepared from the two punch biopsies were cultured in duplicate 
in a 96 well U-bottomed microtitre plate (Greiner) under three conditions; with 
allogeneic MLC cells, autologous MLC cells and 20% RPMI-AS.  0.2ml of each cell 
suspension or medium solution was added to the appropriate well.  A skin section was 
then added to the bottom of each well.  Full submersion of the sections ensured there 
was maximum contact between the skin and the MLC cells.  To avoid any 
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contamination between the wells, forceps were sterilised by immersion in 70% ethanol 
and washed twice in EBSS before contact with any skin.  Once prepared, each human 
skin explant assay was incubated at 37
o
C with 5% CO2 for 3 days. 
 
After 3 days the skin sections were removed with sterile forceps and submerged in 10% 
buffered formalin (supplied by the Department of Pathology, Royal Victoria Infirmary, 
Newcastle upon Tyne, UK).  The biopsies were paraffin-embedded, sectioned and 
stained with haematoxylin and eosin (H&E) in the Department of Pathology.  The H&E 
stained sections were then graded for GVHR by Professor A.M. Dickinson and Dr X.N. 
Wang, and verified by Dr L Sviland (Figure 3.8).  All explants were graded 
independently and whilst blinded to culture conditions and clinical outcome.   
 
 
 
 
 
Figure 3.8 Grading system for the human skin explant assay.  GVHR, graft-versus-host reaction 
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3.11 Mitogen Stimulation Assay 
 
Mitogen stimulation allowed cytokine production responses by activated cells to be 
examined in vitro.  Two mitogens were employed in these assays, lipopolysaccharide 
(LPS) and phytohaemagglutinin (PHA).  LPS is a constituent of the cell wall of gram-
negative bacteria that activates granulocytes and PHA is a plant-derived polysaccharide 
that activates lymphocytes, particularly T cells (Goldsby et al. 2003).  PBMCs were 
cultured with LPS and PHA for 24 and 72 hours respectively.  Unstimulated PMCS in 
10% RPMI-FCS were also cultured for 24 and 72 hours (spontaneous cytokine release).  
These time points were chosen for optimal mitogenic responses and followed a method 
previously established by our research group (unpublished data). 
 
Pre-transplant patient and donor PBMCs were obtained from heparinised blood using 
the previously described method (section 3.2) and re-suspended in 10% RPMI-FCS at a 
concentration of 1x10
6
 cells/ml.  0.1ml of the PBMC suspension was added to 60 wells 
of a 96 well U-bottomed microtitre plate.  0.1ml 10% RPMI-FCS was then added to 30 
of the wells, 0.1ml 10% RPMI-FCS containing 200ng/ml LPS was added to 15 wells 
and 0.1ml 10% RPMI-FCS containing 10μg/ml PHA was added to the remaining 15 
wells (Figure 3.9).  The plate was then incubated at 37C with 5% CO2 for 24 hours. 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 3.9 Plate layout for mitogen stimulation assay.  PBMC, peripheral blood mononuclear 
cells; FCS, foetal calf serum; LPS, lipopolysaccharide; PHA, phytohaemagglutinin 
24hr PBMC + RPMI-FCS 24hr PBMC + RPMI-LPS   
72hr PBMC + RPMI-FCS 72hr PBMC + RPMI-PHA
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After 24 hours the supernatants from 15 of the wells containing PBMCs and 10% 
RPMI-FCS were pooled, centrifuged at 380g for 5 minutes, aliquoted and frozen.  This 
procedure was then repeated for the 15 wells containing PBMCs and 10% RPMI with 
LPS.  The plate was incubated for a further 48 hours.  After this time, the supernatant 
for the remaining two conditions (10% RPMI-FCS and 10% RPMI with PHA) were 
processed as above.  All the samples were stored at -80C for IL-13 analysis by ELISA. 
 
Reagents 
a) 200ng/ml LPS:  17.5μl LPS stock solution (40μg/ml, Sigma) and 3.5ml 
10% RPMI-FCS 
b) 10μg/ml PHA:  35μl PHA stock solution (1mg/ml, Inverness Medical) and 
3.5ml 10% RPMI-FCS 
 
3.12 Serial Serum Sample Collection and Preparation 
 
Serum samples were obtained from blood collected from patients at eight time points 
across the transplant period (day -7 (pre-HSCT), day 0, day 7, day 14, day 28, 3 months, 
6 months and 12 months) and from laboratory volunteers at eight time points (day -7, 
day 0, day 7, day 14, day 28, 3 months, 6 months and 12 months).  The blood (6ml) was 
collected into an anticoagulant free vacutainer tube (BD) and allowed to clot at RT for 
15-20 minutes and then at 4
o
C for 2-4 hours.  The serum was separated by 
centrifugation at 380g for 5 minutes, aliquoted and frozen at -80
o
C for IL-13 analysis by 
ELISA. 
  
3.13 Interleukin-13 Quantification by Enzyme-Linked ImmunoSorbent Assay 
 
Enzyme-linked immunosorbent assay (ELISA) is an immunoassay used to detect and 
quantify the amount of an analyte (antigen or antibody) in a variety of biological 
samples.  Several different ELISA techniques exist however, they all rely on the same 
basic principle; an analyte is immobilised on a surface, either directly or via a capture 
antibody (sandwich ELISA) and an enzyme-labelled antibody is used to detect its 
presence.  The detection antibody may bind directly (primary antibody) or indirectly via 
an unlabelled intermediary (secondary antibody) and on addition of an enzymatic 
substrate a visible signal is produced.  The application of appropriate standards of 
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known concentrations permits the quantification of the analyte in the experimental 
system (Goldsby et al. 2003). 
 
IL-13 expression was quantified in MLC supernatants, PHA stimulated supernatants 
and serum samples using two ELISA kits; Human IL-13 ELISA Development Kit (39-
10,000pg/ml, PeproTech) and Human IL-13 Low Level ELISA Kit (0-40pg/ml, 
RayBiotech).  All supernatants were initially tested neat using the PeproTech supplied 
ELISA kit.  Samples with IL-13 measurements above the upper limits of this kit were 
diluted 1:10 with assay diluent and re-tested.  Any sample producing IL-13 
measurements below the kits lowest limits were re-assayed using the low level IL-13 
ELISA kit supplied by RayBiotech.  All serum samples were tested neat using the low 
level IL-13 kit.  All samples were tested in duplicate and the mean absorbance for each 
set was used for quantification.        
 
Assays were performed and all reagents prepared according to the manufacturer’s 
instructions.  Before commencing the ELISAs, reagents, microtitre plates, standards and 
samples were allowed to equilibrate to RT; temperature-dependent inter-well variation 
was therefore minimised. 
 
Human IL-13 Development Kit (PeproTech) 
 
A 96 well microtitre plate (Maxisorb, Nunc) was coated by incubating 0.1ml of anti-
human IL-13 capture antibody (1μg/ml) in each well at RT overnight.  After this 
incubation period, the plate was washed 4 times with a Tween-based wash buffer 
(Wellwash 4 Mk2, ThermoLabsystems).  In order to minimise non-specific binding, 
0.3ml blocking buffer (1% BSA) was introduced into each well and the plate was 
incubated at RT for 1 hour.  After a further 4 washes, 0.1ml standards and samples in 
duplicate were added to the plate.  Using assay diluent, a dilution series of the standard 
stock solution (1μg/ml)) was prepared.  Solutions containing the following 
concentrations of IL-13 were used: 10,000, 5000, 2500, 1250, 625, 312.5, 156.25, 
78.125, 39.06 (pg/ml).  Neat assay diluent was employed as a negative control (blank, 
0pg/ml).  The plate was incubated for 2 hours at RT and then washed 4 times.  0.1ml of 
biotinylated detection antibody (0.25μg/ml) was pipetted into each well and the plate 
was incubated for a further 2 hours at RT.  The plate was washed 4 times and 0.1ml 
avidin-horseradish peroxidise (HRP) conjugate was added.  After 30 minutes incubation 
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at RT, the plate was washed a further 4 times and 0.1ml 2,2-azino-bis-3-
ethylbenzthiazoline-6-sulfonic acid (ABTS) liquid substrate (Sigma) was added to each 
well.  The plate was then incubated at RT for colour development. 
 
After 20 minutes incubation, the absorbance of each well was measured 
spectrophotometrically at 405nm (A405) with a correction for absorbance at 650nm 
(A650).  Absorbances were measured using a Multiskan Acsent plate reader in 
combination with Acsent software (ThermoLabsystems).  Readings were considered 
acceptable when optical density (OD) measurements less than 0.2 units for the negative 
control and 1.2 units for the highest standard concentration were obtained.   Mean 
values for A405 and A650 were calculated for each duplicate set, including all standards 
and controls and the appropriate negative control measurements were subtracted from 
these means (blank subtraction).  Corrected A405 values for the standards and samples 
were then calculated (mean A405 – mean A650).  A standard calibration curve (Figure 
3.10) was plotted and the IL-13 concentration of each sample was derived from the 
curve.  Any dilution factor was taken into account at this point. 
 
 
 
Figure 3.10 A typical standard curve generated using the Human IL-13 ELISA Development 
kit (PeproTech).  Corrected OD at 405nm accounts for the subtraction of the OD 
at 650nm from the OD at 405nm.  OD, optical density; IL-13, interleukin-13  
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Reagents 
a) 10x Phosphate Buffered Saline (PBS):  96g of PBS (Gibco) dissolved in 1L  
deionised water 
b) 1x PBS:  100ml 10x PBS made up to 1L with deionised water 
c) Wash Buffer:  0.5ml Tween-20 (Sigma) and 1L 1x PBS 
d) Blocking Buffer:  1g bovine serum albumin (BSA (fraction 5), Sigma) 
dissolved in 100ml 1x PBS 
e) Assay Diluent:  10ml blocking buffer, 90ml 1x PBS and 0.05ml Tween-20 
f) Anti-Human IL-13 Capture Antibody (1μg/ml):  0.1ml reconstituted capture 
antibody (lyophilised antibody in 1ml sterile deionised water, 100μg/ml) in 
9.9ml 1x PBS 
g) Standard Dilution Series:  0.1ml reconstituted recombinant human IL-13 
(lyophilised standard in 1ml sterile deionised water, 1μg/ml) in 9.9ml assay 
diluent (10,000pg/ml, top standard).  Remaining 8 standards were prepared   
using a doubling dilution series (0.5ml previous standard + 0.5ml assay diluent) 
h) Human IL-13 Detection Antibody (0.25μg/ml):  0.025ml reconstituted 
detection antibody (lyophilised antibody in 0.25ml sterile deionised water, 
100μg/ml) in 10ml assay diluent 
i) Avidin-HRP Conjugate:  5.5μl avidin-HRP conjugate in 11ml assay diluent 
 
 
Human IL-13 Low Level Kit (RayBiotech) 
 
A dilution series of the standard stock solution (20ng/ml) was prepared using assay 
diluent.   Solutions containing the following concentrations of IL-13 were employed: 
40, 16, 6.4, 2.56, 1.03, 0.41, 0.16 (pg/ml).  Assay diluent alone was used as a negative 
control (blank, 0pg/ml).  0.1ml of all standards and samples in duplicate were added to 
the pre-coated (anti-human IL-13 capture antibody) microtitre plate.  The plate was 
incubated at RT for 2.5 hours then washed 4 times using the wash buffer provided.  
0.1ml biotinylated anti-human detection antibody was added to each well and the plate 
was incubated for a further 1 hour at RT.  Following 4 more washes, 0.1ml HRP-
streptavidin was added and the plate was incubated for 45 minutes at RT.   After a 
further 5 washes, 0.1ml 3,3’,5,5’-tetramethylbenzidine (TMB) substrate solution was 
added to each well and the plate was incubated (RT)  in the dark for 30 minutes to allow 
colour development.   
74 
 
The colour reaction was stopped by adding 0.05ml sulfuric acid (2M) to each well. The 
plate was gently agitated to ensure an even distribution of colour and the absorbances 
were measured at 450nm (A450).  Readings were considered acceptable when OD 
measurements of less than 0.03 for the negative control were obtained.  The mean 
absorbance for each set of duplicate standards and samples was calculated and the mean 
A450 for the negative control was then subtracted from these values.  A standard 
calibration curve (Figure 3.11) was plotted and IL-13 concentrations were derived.  Any 
dilution factor was taken into account at this point. 
 
 
Figure 3.11 A typical standard curve generated using the Human IL-13 Low Level ELISA kit 
(RayBiotech Inc).  OD, optical density; IL-13, interleukin-13 
 
 
Reagents 
a) Wash Buffer:  20ml wash buffer (20x) concentrate in 380ml deionised water 
b) Assay Diluent:  15ml assay diluent (5x) concentrate in 60ml deionised water 
c) Standard Dilution Series:  0.002ml reconstituted recombinant human IL-13 
(lyophilised standard in 166μl assay diluent, 20ng/ml) in 0.998ml assay diluent 
(40pg/ml, top standard).  Remaining 6 standards were prepared using a 2.5 
dilution series (0.2ml of previous standard + 0.3ml assay diluent)  
d) Human IL-13 Detection Antibody:  0.2ml reconstituted detection antibody 
(lyophilised antibody in 0.2ml assay diluent) in 15.8ml assay diluent   
e) HRP-Streptavidin:  0.002ml HRP-streptavidin concentrate in 12ml assay 
diluent 
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3.14 Cytometric Bead Array 
 
A cytometric bead array (CBA) is an immunoassay with the ability to detect and 
quantify multiple analytes in a single sample.  The assay employs a series of beads with 
discrete fluorescent intensities to detect soluble analytes.  Each bead population utilised 
provides a capture surface (coated with a capture antibody) for a specific analyte and is 
analogous to an individually coated well in an ELISA.  Analyte detection is achieved by 
addition of a fluorescent dye and measurement of fluorescence-based emission using 
flow cytometry.  The application of appropriate standards of known concentrations 
permits the quantification of the analytes in the experimental system.        
 
The quantification of IL-2, IL-4, IL-5, IL-10, IL-13, IFNγ and TNFα in supernatants 
collected from harvested allogeneic MLCs (section 3.9) was carried out using a Human 
Soluble Protein CBA kit (20-10,000pg/ml, BD).  The supernatants were tested neat and 
a standard dilution series for each cytokine was included in all assays.  Due to the high 
reproducibility and expensive nature of the CBA kit, standards and samples were not 
tested in duplicate.  10% of the sample cohort was however re-assayed and no 
significant differences were observed between the values.  IL-13 levels obtained using 
this method and standard ELISA (section 3.13.1) were also compared and again no 
significant differences were observed between the values; thus, the two methods 
employed for IL-13 quantification were comparable.           
 
Assays were performed and reagents prepared according to the manufacturer’s 
instructions.  Before commencing, all reagents, standards, samples and tubes (BD) were 
allowed to equilibrate to RT. 
 
A dilution series of the standard stock solution (5000pg/ml) was prepared using assay 
diluent.  Solutions containing the following IL-2, IL-4, IL-5, IL-10, IL-13, IFNγ and 
TNFα concentrations were employed: 5000, 2500, 1250, 625, 312.5, 156, 80, 40, 20 
(pg/ml).  Assay diluent alone was used as a negative control (blank, 0pg/ml).  0.05ml of 
each standard and supernatant sample was combined with 0.05ml of capture beads and 
the tubes were incubated at RT for 1 hour.  0.05ml of phycoerythrin (PE) detection 
reagent was added and the tubes were incubated at RT for further 2 hours.  1ml of wash 
buffer was introduced and the tubes were centrifuged (MSE Centaur) at 200g for 5 
minutes.  The supernatant from each tube was then aspirated and discarded.  0.3ml of 
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wash buffer was added and the tubes were vortexed (Vortex-Genie 2, SLS) briefly to 
resuspend the beads.  The fluorescent intensity of the standards and samples were 
measured using flow cytometry (FACSCalibur, BD) and IL-2, IL-4, IL-5, IL-10, IL-13, 
IFNγ and TNFα concentrations were calculated using standard curves (Figure 3.11) 
constructed following data analysis with FCAP Array software (BD). 
 
 
 
 
Figure 3.12 A typical set of standard curves generated using the Human Soluble Protein CBA kit 
(BD).  IL-2, interleukin-2; IL-4, interleukin-4; IL-5, interleukin-5; IL-10, interleukin-
10; IFNG, interferon gamma; IL-13, interleukin-13; TNFa, tumour necrosis factor 
alpha; I, intensity; CC, calculated concentration   
 
 
Reagents 
a) Capture Beads:  0.1ml each cytokine capture bead (IL-2, IL-4, IL-5, IL-10, 
IL13, IFNγ and TNFα) in 4.3ml capture bead diluent 
b) Standard Dilution Series:  Lyophilised standards (IL-2, IL-4, IL-5, IL-10, 
IL13, IFNγ and TNFα) in 2ml assay diluent (5000pg/ml, top standard).  
Remaining 8 standards were prepared using a doubling dilution series (0.5ml 
previous standard + 0.5ml assay diluent) 
c) PE Detection Reagent:  0.1ml each cytokine PE detection (IL-2, IL-4, IL-5, IL-
10, IL13, IFNγ and TNFα) in 4.3ml detection diluent 
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3.15 Statistical Analysis 
 
Statistical analyses carried out throughout this study employed the computer software 
packages Graphpad Prism 5.0, SPSS 15.0 and NCSS 97 (supplied by Newcastle 
University).   
 
HSCT allele and genotype frequencies were compared to control frequencies using the 
chi-square (2) test and Fisher’s exact test where appropriate.  All genotypic data were 
analysed for associations with acute and chronic GVHD, overall survival, relapse 
incidence and TRM.  GVHD analyses were carried out using the chi-square (2) test and 
forward stepwise logistic regression, whilst Kaplan-Meier curves, the Log-Rank test 
and Cox regression were utilised for survival analyses.  Relapse incidence and TRM 
were analysed using competing risks methods (cumulative incidence curves and the 
Log-Rank test).  For all genotypic analyses that examined two or more genetic factors in 
a given population, multiple comparison corrections (Bonferroni adjustment) were 
performed (sections 4.3.3).   
 
The Kolmogorov-Smirnov test was used to determine whether functional data was 
normally distributed – a Gaussian distribution.  All normally distributed data was 
analysed using a parametric statistical test (paired/unpaired Student’s t-test or One-way 
ANOVA), whilst any data that was not normally distributed was analysed by a non-
parametric method (Wilcoxon Signed-Rank test, Mann-Whitney U test or Kruskal-
Wallis test).  Correlation calculations were performed using the Pearson’s or 
Spearman’s Rank Correlation tests. 
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Chapter 4. Non-HLA Polymorphisms in Unrelated Donor HSCT 
 
 
While the influence of non-HLA polymorphisms on HSCT outcome has been studied 
extensively in HLA-matched sibling transplantation (see section 1.4), relatively little is 
still known about these polymorphisms in unrelated donor HSCT (Ishikawa et al. 2002; 
MacMillan et al. 2003a; MacMillan et al. 2003b; Remberger et al. 2003; Kean et al. 
2004; Bettens et al. 2006).  Since an HLA-matched sibling is available to fewer than 
30% of patients (de Lima and Champlin 2001), unrelated donor HSCT constitutes a 
large proportion of the transplants performed each year, thus investigations into the 
impact of non-HLA polymorphisms in this setting are also important.  Considering that 
the risk of GVHD and post-transplant mortality is substantially increased following 
unrelated donor HSCT (Anasetti et al. 1995), the identification of genetic markers that 
can predict these outcomes would be extremely beneficial.    
 
Polymorphisms within the genes of IL-2 (-330 T/G), IL-4 (-590 C/T), IL-6 (-174 G/C), 
IL-10 (-592 A/C, -1082 G/A), IL-1Ra (intron 2 VNTR), TNFα (d intron 3 (GA)n), 
TNFRII (-196 M/R), IFNγ (intron 1 (CA)n), vitamin D receptor (intron 8 A/C, exon 9 
T/C) and oestrogen receptor (intron 1 A/G, intron 1 C/T) have been demonstrated by 
our research group and numerous others worldwide to significantly associate with both 
GVHD and survival following HLA-matched sibling HSCT (Middleton et al. 1998; 
Cavet et al. 1999; Cavet et al. 2001; Cullup H 2001; Socie et al. 2001; Middleton et al. 
2002; Rocha V 2002; Lin et al. 2003; Middleton et al. 2003; Stark et al. 2003; 
Mlynarczewska et al. 2004; Bogunia-Kubik et al. 2005b; Karabon et al. 2005; Rocha et 
al. 2009).  Considering this, the aim of the current study was therefore to determine the 
role, if any that these polymorphisms play in the unrelated donor transplant setting.          
 
4.1 Study Aims 
 
i) To establish and compare the allele and genotype frequencies of the IL2 -330 T/G, 
IL4 -590 C/T, IL6 -174 G/C, IL10 -592 A/C, IL10 -1082 G/A, IL1RN intron 2 
VNTR, TNFAd intron 3 (GA)n, TNFRSF1B -196 M/R, IFNG intron 1 (CA)n, 
VDR intron 8 A/C, VDR exon 9 T/C, ESR1 intron 1 A/G and ESR1 intron 1 C/T 
polymorphisms in a Newcastle control population with an unrelated donor HSCT 
cohort. 
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ii) To correlate transplant outcome, in terms of acute GVHD incidence and severity, 
chronic GVHD incidence, overall survival, relapse incidence and TRM with the 
IL2 -330 T/G, IL4 -590 C/T, IL6 -174 G/C, IL10 -592 A/C, IL10 -1082 G/A, 
IL1RN intron 2 VNTR, TNFAd intron 3 (GA)n, TNFRSF1B -196 M/R, IFNG 
intron 1 (CA)n, VDR intron 8 A/C, VDR exon 9 T/C, ESR1 intron 1 A/G and 
ESR1 intron 1 C/T polymorphisms by univariate and multivariate statistical 
analyses. 
 
4.2 Statistical Analysis 
 
Polymorphic allele and genotype frequencies calculated for the unrelated donor HSCT 
cohort were compared to those of Newcastle controls using the chi-square (2) and 
Fisher’s exact test where appropriate.  Expected and observed genotype frequencies for 
the Newcastle controls, HSCT patients and unrelated donors were assessed for Hardy-
Weinberg equilibrium using the chi-square (2) test.  Non-HLA polymorphisms were 
correlated with acute and chronic GVHD using the chi-square (2) test and forward 
stepwise logistic regression.  Overall survival was analysed using Kaplan-Meier curves 
and the Log-Rank test, followed by Cox regression.  The incidence of relapse and TRM 
were analysed using cumulative incidence curves and the Log-Rank test (competing risk 
analysis). 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
4.3 Experimental Design 
 
4.3.1 Inclusion and Exclusion Criteria 
 
All patients and their donors recruited as part of a European Commission FP5 
biotechnology project (Eurobank QLRI-CT-2000-00010, PI Professor A M Dickinson), 
that received an unrelated donor HSCT between November 1983 and December 2006 
and had DNA and 1 year’s clinical follow-up available were included in the analyses.  
The study was given JLEC approval (Appendix B) and informed consent was obtained 
from all patients and donors.  Exclusion criteria were as follows:  
 
i) HLA-matched sibling HSCT  
ii) Transplantation not performed 
iii) Incomplete HSCT outcome data 
iv) Incomplete HLA typing data  
v) Below the age of 16 at the time of transplant    
vi) Transplantation for an immunological disease  
vii) Transplantation with a source other than PBSC or bone marrow 
viii) Two or more transplants performed 
 
Once the inclusion and exclusion criteria had been taken into account, the unrelated 
donor HSCT cohort employed had been reduced from 374 patient/donor pairs to 362. 
 
4.3.2 Control Measures 
 
For all samples, successful PCR amplification was confirmed by agarose gel 
electrophoresis prior to the performance of any PCR-RFLP, SSCP or IHG analyses 
(section 3.6.1, 3.6.2, 3.6.3 and 3.6.4).  Accurate ascertainment of polymorphic alleles 
was ensured by the inclusion of both homozygous and heterozygous control samples of 
known genotype (positive controls) in all PCR reactions, polymorphism analysis 
methods (PCR-RFLP, SSCP and IHG) and electrophoresis gels (section 3.6.6).  
Genotypes were determined with reference to these known samples and verified by an 
independent observer.  In equivocal cases, samples were re-analysed (less than 5% of 
the cohort).  All genotypes were determined whilst blinded to clinical outcome.  Correct 
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allele determination was also ensured by the inclusion of negative controls, appropriate 
DNA size markers and by re-typing 25% of each cohort tested. 
 
4.3.3 Method of Analysis    
 
Prior to any correlation with clinical outcome, the accuracy of IL2 -330 T/G, IL4 -590 
C/T, IL6 -174 G/C, IL10 -592 A/C, IL10 -1082 G/A, IL1RN intron 2 VNTR, TNFAd 
intron 3 (GA)n, TNFRSF1B -196 M/R, IFNG intron 1 (CA)n, VDR intron 8 A/C, VDR 
exon 9 T/C, ESR1 intron 1 A/G and ESR1 intron 1 C/T genotyping in our unrelated 
donor HSCT cohort was assessed by the comparison of calculated allele and genotype 
frequencies with those of a Newcastle control group and previously published data.  
Only the major allele and genotype frequencies were calculated for the microsatellite 
(TNFAd intron 3 (GA)n, IFNG intron 1 (CA)n) and VNTR (IL1RN intron 2) 
polymorphisms examined in this study.  In order to rule out selection bias and genotype 
deviation, patient, donor and control genotype frequencies were also tested for Hardy-
Weinberg equilibrium. 
 
For each of the non-HLA polymorphisms examined, the alleles and/or genotypes 
previously identified as significant factors in the HLA-matched sibling HSCT setting 
were individually correlated with the incidence and severity of acute GVHD, incidence 
of chronic GVHD and overall survival using univariate analysis methods (chi-square 
test (2), Kaplan-Meier curves and Log-Rank test).  Alleles/genotypes with P values 
≤0.1 were then tested for independence against identified confounding clinical factors 
using multivariate analysis methods (forward stepwise logistic and Cox regression).  In 
order to retain adequate power only the strongest factors, up to a maximum of 5, were 
entered into all multivariate analyses.  P values <0.05 were considered statistically 
significant and values between 0.05 and 0.1 were considered indicative of a trend.  
 
As thirteen non-HLA polymorphisms were examined in our unrelated donor HSCT 
cohort and the replication of any associations observed in a second independent cohort 
was not possible, multiple comparison corrections were performed in order to reduce 
the chance of type I errors (false positive results).  These corrections were achieved 
using Bonferroni adjustment.  This method reduces the chance of spurious results by 
lowering the level of statistical significance (typically 0.05) according to the number of 
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tests i.e. corrected values are achieved by dividing the P value obtained by the number 
of factors analysed; 13 in the case of the current study.  Although Bonferroni adjustment 
is highly conservative and prone to over-correction, it can be applied simply to any 
multiple testing situation, has a high power in large populations such as ours and other 
than replication, is the most appropriate methods for ruling out associations by chance 
(Aickin and Gensler 1996; Perneger 1998). 
 
Non-HLA polymorphism alleles/genotypes were also correlated with relapse incidence 
and TRM.  As both of these outcomes are affected by other clinical events, competing 
risk analysis methods were required.  These methods allow all possible associations to 
be observed by excluding the relevant competing event (relapse or TRM).  Due to the 
extreme complexity of multivariate analyses for competing risks and the requirement 
for specialised statistical software, univariate analysis (cumulative incidence curves and 
Log-Rank test) alone was performed in this study.  Again, P values <0.05 were 
considered statistically significant and values between 0.05 and 0.1 were considered 
indicative of a trend. 
 
HLA disparity is a substantial risk factor in HSCT, particularly in the unrelated donor 
transplant setting; where the risk of GVHD and post-transplant mortality increases 
significantly with single mismatches at HLA-A, -B, -C, -DRB1 or –DPB1 (Sasazuki T 
1998; Flomberg et al. 2004; Chalandon et al. 2006; Lee et al. 2007; Shaw et al. 2007).  
As a result, it was extremely likely that this factor would have a considerable impact on 
HSCT outcome in this study.  Thus, prior to any analyses with the non-HLA 
polymorphisms, HLA disparity was tested for associations with GVHD.  In our 
unrelated donor HSCT cohort HLA-mismatched transplants were found to correlate 
with a higher incidence of both acute and chronic GVHD (P=0.015 and P=0.042 
respectively).  The most accurate and reliable means of accounting for such associations 
involves stratification of the cohort into HLA-matched and HLA-mismatched transplant 
groups.  However, this was not possible in the current study, as the mismatched group 
would be too small to analyse (n=114).  Instead, associations with HSCT outcome were 
tested for in the whole unrelated donor cohort with HLA-mismatch entered into all 
multivariate analyses as a confounding factor.  Due to the heterogeneity of the unrelated 
donor HSCT cohort employed, stratification should also be considered for clinical 
factors such as underlying disease, disease stage (early/advanced), conditioning regimen 
(low intensity/myeloablative), prophylaxis intensity (low/high) and graft manipulation 
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(T cell replete/T cell deplete).  However, due to number constraints and as these factors 
had no impact on HSCT outcome in this study, stratification was not performed (section 
4.6). 
 
In recent years, there has been concern around the proliferation of genetic association 
studies, especially those in which results have not been replicated (Colhoun et al. 2003).  
In an attempt to address this problem, any significant correlation observed in this study 
was verified in a smaller second cohort (n=248).  This cohort was a subset of the 
original unrelated donor transplant population and comprised the 10/10 HLA-matched 
patient/donor pairs only.  This cohort was not independent and therefore not ideal; 
however, it was the most appropriate means of verification available.  Time constraints 
did not permit the formation of a completely independent population of adequate size 
(power).  Sample collection for the creation of a large independent verification cohort is 
currently being undertaken.    
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4.4 Study Populations 
 
4.4.1 Newcastle Control Cohort 
 
A total of 100 Newcastle volunteer blood donors were recruited to act as a control 
cohort for this study.  The group comprised 53 males and 47 females, with a median age 
of 37 years (range 19-56).   
 
4.4.2 Unrelated Donor HSCT Cohort 
 
Genomic DNA was obtained from allogeneic HSCT patients and their unrelated donors 
for IL2 -330 T/G, IL4 -590 C/T, IL6 -174 G/C, IL10 -592 A/C, IL10 -1082 G/A, IL1RN 
intron 2 VNTR, TNFAd intron 3 (GA)n, TNFRSF1B -196 M/R, IFNG intron 1 (CA)n, 
VDR intron 8 A/C, VDR exon 9 T/C, ESR1 intron 1 A/G and ESR1 intron 1 C/T 
polymorphism genotyping.  This was an adult cohort (≥16 at the time of transplant) 
comprising 362 unrelated donor transplants.  HLA matching between patients and 
donors was performed by high resolution DNA-based typing for HLA-A, B, C, DRB1 
and DQB1.  Complete matching at all 5 loci was observed in 248 (69%) transplant 
pairs. 
 
Cohort characteristics: 
The 362 HSCT patients included in this cohort were transplanted between November 
1983 and December 2006 at clinical centres in Austria, England, France, Germany and 
Spain.  All patients and donors were recruited and consented as part of the previously 
described ‘Eurobank Project’ (section 4.3.1).  
 
Acute GVHD was deemed assessable in those alive ≥30 days post-transplant and 
developed in 237 patients.  125 patients had no acute GVHD (grade 0), 67 grade I, 102 
grade II, 41 grade III and 27 had grade IV.  Acute GVHD grades III and IV were 
considered severe.  Chronic GVHD was assessable from 100 days post-transplant in 286 
patients.  145 of these patients developed the condition.  All transplant patients were 
prepared for HSCT with low intensity (n=138) or myeloablative conditioning (n=234) 
regimens and 61% (n=221) were transplanted with T cell depleted stem cell grafts.  275 
patients were given high intensity GVHD prophylaxis (CsA plus MTX or MM), whilst 
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87 received CsA monotherapy.  The overall survival rate for this cohort was 49% 
(n=179) and causes of death included disease relapse, infection and GVHD.  Table 4.1 
shows the demographic characteristics of the unrelated donor HSCT cohort examined in 
this study. 
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Table 4.1 Characteristics of the unrelated donor HSCT cohort (n=362). 
CMV, cytomegalovirus; CsA, cyclosporine A; MTX, methotrexate; MM, 
mycophenolate mofetil; TCD, T cell depletion 
 
 
TRANSPLANT PATIENTS 
Median Age      41 years (range 16-67) 
      Number in each group 
Gender 
 Male      202 
 Female      160 
 Female to Male HSCT      52 
 
CMV Status 
 Positive      178 
 Negative      184 
 
Underlying Disease 
 Acute Lymphoblastic Leukaemia     46 
 Acute Myeloid Leukaemia    132 
 Chronic Lymphocytic Leukaemia       7 
 Chronic Myeloid Leukaemia      83 
 Hodgkin disease         7 
 Non-Hodgkin Lymphoma      24 
 Myeloproliferative Disorders      22 
  Plasma Cell Neoplasm       33 
  Aplastic Anaemia         8 
Conditioning Therapy 
   Low intensity       138 
   Myeloablative       234 
 
GVHD Prophylaxis 
   CsA          87 
   CsA and MTX       185 
   CsA and MM         90 
 
  TCD        221 
 
 
TRANSPLANT DONORS 
 
Median Age      36 years (range 19-64)   
       Number in each group 
Gender  
   Male         235 
   Female         127 
 
CMV Status 
   Positive        153 
   Negative        209 
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4.5 Allele and Genotype Frequencies 
 
Allele and genotype frequencies for the IL2 -330 T/G, IL4 -590 C/T, IL6 -174 G/C, 
IL10 -592 A/C, IL10 -1082 G/A, IL1RN intron 2 VNTR, TNFAd intron 3 (GA)n, 
TNFRSF1B -196 M/R, IFNG intron 1 (CA)n, VDR intron 8 A/C, VDR exon 9 T/C, 
ESR1 intron 1 A/G and ESR1 intron 1 C/T polymorphisms were determined in the 
Newcastle control cohort, HSCT patients and unrelated donors.  The allele frequencies 
calculated for the three groups are shown in Table 4.2.  The frequencies determined 
were comparable and did not differ significantly to those published in the literature 
(Walley and Cookson 1996; Middleton et al. 1998; Cavet et al. 1999; Cavet et al. 2001; 
Cullup et al. 2001; Middleton et al. 2002; MacMillan et al. 2003b; Middleton et al. 
2003; Stark et al. 2003).  Thus, the non-HLA polymorphisms examined in this study are 
not a consequence of disease, but occur naturally within all populations 
 
All possible genotype combinations for each of the non-HLA polymorphisms examined 
were observed in the patient and donor groups and the genotype frequencies determined 
were similar to those calculated for the Newcastle control cohort (Table 4.3).  Potential 
deviation from Hardy-Weinberg equilibrium was examined for using the chi-square (2) 
test.  No significant differences were demonstrated between the observed and calculated 
expected values for the patients, donors or controls (Table 4.4, P values only).  Thus, 
the genotype frequencies observed in all three groups were in Hardy-Weinberg 
equilibrium; there was no selection bias and genotype deviation was absent.  
Furthermore, the observed genotype frequencies were comparable to those published in 
the literature (Walley and Cookson 1996; Middleton et al. 1998; Cavet et al. 1999; 
Cavet et al. 2001; Cullup H 2001; Middleton et al. 2002; MacMillan et al. 2003b; 
Middleton et al. 2003; Stark et al. 2003). 
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 Newcastle Controls 
n=100 
HSCT Patients 
n=362 
HSCT Donors 
n=362 
 
Polymorphic Alleles 
 
   
IL2 -330 T/G 
T 
G 
 
0.73 
0.27 
 
0.71 
0.29 
 
0.72 
0.28 
IL4 -590 C/T 
C 
T 
 
0.84 
0.16 
 
0.84 
0.16 
 
0.82 
0.18 
IL6 -174 G/C 
G 
C 
 
0.39 
0.61 
 
0.41 
0.59 
 
0.41 
0.59 
IL10 -592 A/C 
A 
C 
 
0.25 
0.75 
 
0.27 
0.73 
 
0.25 
0.75 
IL10 -1082 G/A 
G 
A 
 
0.47 
0.53 
 
0.47 
0.53 
 
0.47 
0.53 
IL1RN intron 2 VNTR 
1 
2 
 
0.75 
0.20 
 
0.75 
0.22 
 
0.73 
0.21 
TNFAd intron 3 (GA)n 
d3 
d4 
 
0.57 
0.29 
 
0.58 
0.27 
 
0.58 
0.27 
TNFSRF1B -196 M/R 
M 
R 
 
0.72 
0.28 
 
0.72 
0.28 
 
0.72 
0.28 
IFNG intron 1 (CA)n 
2 
3 
 
0.44 
0.25 
 
0.43 
0.25 
 
0.44 
0.24 
VDR intron 8 A/C 
A 
C 
 
0.50 
0.50 
 
0.52 
0.48 
 
0.50 
0.50 
VDR exon 9 T/C 
T 
C 
 
0.60 
0.40 
 
0.58 
0.42 
 
0.58 
0.42 
ESR1 intron 1 A/G 
A 
G 
 
0.65 
0.35 
 
0.65 
0.35 
 
0.66 
0.34 
ESR1 intron 1 C/T 
C 
T 
 
0.47 
0.53 
 
0.47 
0.53 
 
0.48 
0.52 
    
 
 
Table 4.2 Non-HLA polymorphism allele frequencies for the Newcastle control cohort, HSCT 
patients and unrelated donors.  IL2, interleukin-2; IL4, interleukin-4; IL6, interleukin-6; 
IL10, interleukin-10; IL1RN, interleukin-1 receptor antagonist; TNFA, tumour necrosis 
factor α; IFNG, interferon γ; VDR, vitamin D receptor; ESR1, oestrogen receptor  
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 Newcastle Controls 
n=100 
HSCT Patients 
n=362 
HSCT Donors 
n=362 
 
Polymorphic Genotypes 
 
   
IL2 -330 T/G 
TT 
TG 
GG 
 
0.50 
0.45 
0.05 
 
0.49 
0.45 
0.06 
 
0.50 
0.43 
0.07 
IL4 -590 C/T 
CC 
CT 
TT 
 
0.71 
0.26 
0.03 
 
0.71 
0.26 
0.03 
 
0.69 
0.27 
0.04 
IL6 -174 G/C 
GG 
GC 
CC 
 
0.14 
0.49 
0.37 
 
0.13 
0.48 
0.39 
 
0.13 
0.48 
0.39 
IL10 -592 A/C 
AA 
AC 
CC 
 
0.07 
0.35 
0.58 
 
0.07 
0.37 
0.56 
 
0.06 
0.34 
0.60 
IL10 -1082 G/A 
GG 
GA 
AA 
 
0.22 
0.49 
0.29 
 
0.22 
0.49 
0.29 
 
0.24 
0.46 
0.30 
IL1RN intron 2 VNTR 
11 
12 
22 
 
0.24 
0.18 
0.07 
 
0.23 
0.16 
0.08 
 
0.22 
0.19 
0.07 
TNFAd intron 3 (GA)n 
d3d3 
d3d4 
d4d4 
 
0.32 
0.17 
0.07 
 
0.32 
0.19 
0.06 
 
0.32 
0.19 
0.06 
TNFSRF1B -196 M/R 
MM 
MR 
RR 
 
0.54 
0.36 
0.10 
 
0.54 
0.37 
0.09 
 
0.54 
0.37 
0.09 
IFNG intron 1 (CA)n 
22 
23 
33 
 
0.18 
0.44 
0.22 
 
0.18 
0.42 
0.24 
 
0.17 
0.47 
0.21 
VDR intron 8 A/C 
AA 
AC 
CC 
 
0.24 
0.52 
0.24 
 
0.26 
0.51 
0.23 
 
0.25 
0.50 
0.25 
VDR exon 9 T/C 
TT 
TC 
CC 
 
0.33 
0.53 
0.14 
 
0.35 
0.52 
0.13 
 
0.35 
0.52 
0.13 
ESR1 intron 1 A/G 
AA 
AG 
GG 
 
0.42 
0.45 
0.13 
 
0.45 
0.45 
0.10 
 
0.43 
0.45 
0.12 
ESR1 intron 1 C/T 
CC 
CT 
TT 
 
0.22 
0.49 
0.29 
 
0.23 
0.49 
0.28 
 
0.22 
0.51 
0.27 
 
Table 4.3 Non-HLA polymorphism genotype frequencies for the Newcastle control cohort, HSCT 
patients and unrelated donors.  IL2, interleukin-2; IL4, interleukin-4; IL6, interleukin-6; 
IL10, interleukin-10; IL1RN, interleukin-1 receptor antagonist; TNFA, tumour necrosis 
factor α; IFNG, interferon γ; VDR, vitamin D receptor; ESR1, oestrogen receptor 
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 Newcastle Controls 
P Value 
HSCT Patients 
P Value 
HSCT Donors 
P Value 
    
IL2 -330 T/G 0.892 0.911 0.879 
IL4 -590 C/T 0.901 0.735 0.824 
IL6 -174 G/C 1.000 0.978 0.945 
IL10 -592 A/C 0.945 1.000 1.000 
IL10 -1082 G/A 1.000 0.967 1.000 
IL1RN intron 2, VNTR 0.752 0.721 0.697 
TNFAd intron 3 (GA)n 0.853 0.978 0.901 
TNFRSF1B -196 M/R 0.741 0.847 0.867 
IFNG intron 1 (CA)n 0.752 0.641 0.689 
VDR intron 8 A/C 0.861 0.895 0.887 
VDR exon 9 T/C 0.978 0.894 0.732 
ESR1 intron 1 A/G 0.881 0.971 1.000 
ESR1 intron 1 C/T 
 
0.811 1.000 0.955 
 
 
 
Table 4.4 P values for Hardy-Weinberg equilibrium analysis of the non-HLA polymorphism 
genotype frequencies in the Newcastle control population (n=100), HSCT patients 
(n=362) and unrelated donors (n=362).  No significant difference was demonstrated 
between the observed and calculated expected frequencies (data not shown).  IL2, 
interleukin-2; IL4, interleukin-4; IL6, interleukin-6; IL10, interleukin-10; IL1RN, 
interleukin-1 receptor antagonist; TNFA, tumour necrosis factor α; IFNG, interferon γ; 
VDR, vitamin D receptor; ESR1, oestrogen receptor  
 
 
 
4.6 Correlation of Clinical Factors with Acute and Chronic GVHD 
 
It is well established that certain clinical factors have a considerable impact on HSCT 
outcome, particularly GVHD (section 1.3.4) (Beatty et al. 1985; Atkinson et al. 1990; 
Gratwohl et al. 1998; Nichols et al. 2002; Hahn et al. 2008).  These factors are therefore 
potential confounding variables that need to be accounted for when genetic association 
studies are performed in the HSCT setting.  As a result of this, the effects of clinical 
factors on the development of acute and chronic GVHD in our unrelated donor HSCT 
cohort were assessed prior to polymorphism analysis.     
 
Eight clinical factors were tested for associations with acute and chronic GVHD.  These 
were patient and donor age at HSCT (over 40 years), gender mismatch transplantation 
(female to male), CMV status (patient and/or donor positivity), HLA matching, 
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conditioning regimen (low intensity/myeloablative), prophylaxis intensity (low/high) 
and graft manipulation (T cell replete/T cell deplete).  The results of the univariate 
analyses are shown in Table 4.5.  No significant associations were demonstrated with 
patient or donor age over 40 years, myeloablative conditioning, low intensity 
prophylaxis and T cell depletion.  Thus, these factors had no impact on HSCT outcome 
in this study and as a result were not included in any further analyses.  Significant 
correlations were however; demonstrated between GVHD and female to male 
transplantation, CMV positivity and HLA-mismatch.  These three clinical factors were 
therefore identified as confounding variables and needed to be accounted for when 
associations between the non-HLA polymorphisms and HSCT outcome were examined 
using multivariate analysis.     
 
 
 
 Acute GVHD Chronic GVHD 
 P OR P OR 
     
Clinical Factors     
Patient age >40 years 0.146 0.657 0.233 0.542 
Donor age >40 years 0.389 0.250 0.367 0.384 
Female/male transplantation 0.017 5.698 0.035 4.072 
CMV positivity 0.047 3.614 0.050 3.680 
HLA-mismatch 0.015 5.786 0.042 3.937 
Myeloablative conditioning 0.359 0.868 0.623 0.103 
Low intensity prophylaxis 0.481 0.091 0.353 0.442 
T cell depletion 0.172 0.535 0.100 0.710 
     
 
 
Table 4.5 Univariate analysis demonstrating the associations between clinical factors and acute 
and chronic GVHD.  P values showing a significant association (≤0.1) are shown in 
bold.  CMV, cytomegalovirus; HLA, human leukocyte antigen; GVHD, graft-versus-
host disease; P, P value; OR, odds ratio    
 
 
 
4.7 Correlation of Non-HLA Polymorphisms with Acute and Chronic GVHD 
 
Associations between the IL2 -330 T/G, IL4 -590 C/T, IL6 -174 G/C, IL10 -592 A/C, 
IL10 -1082 G/A, IL1RN intron 2 VNTR, TNFAd intron 3 (GA)n, TNFRSF1B -196 M/R, 
IFNG intron 1 (CA)n, VDR intron 8 A/C, VDR exon 9 T/C, ESR1 intron 1 A/G and 
ESR1 intron 1 C/T polymorphisms and the incidence and severity of acute GVHD were 
examined in the entire cohort of 362 unrelated donor HSCT patients.  Associations 
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between these polymorphisms and the incidence of chronic GVHD were analysed in 
286 patients alive greater than 100 days post-HSCT.  The results of the univariate 
analyses are shown in Tables 4.6.  No associations could be demonstrated between the 
non-HLA polymorphisms examined and the overall incidence of acute GVHD (grades 
I-IV) or the incidence of clinical acute GVHD (grades II-IV).  A strong correlation was 
however; demonstrated between the VDR intron 8 A/C polymorphism and the 
development of severe acute GVHD (grades III-IV).  HSCT patients possessing the 
VDR intron 8 A,A genotype were more susceptible to the higher grades of acute GVHD 
than patients with the A,C or C,C genotypes (41% versus 16% respectively, P=0.015 
OR=5.786).  A similar association was also demonstrated for the IFNG intron 1 (CA)n 
polymorphism.  HSCT patients possessing the IFNG intron 1 (CA)n 3,3 genotype were 
more susceptible to the higher grades of acute GVHD than patients without the 
genotype (48% versus 27% respectively, P=0.037 OR=4.071).  In terms of chronic 
GVHD, patients possessing the IL6 -174 G,G genotype were more at risk of developing 
the condition than patients with the G,C or C,C genotypes (80% versus 56% 
respectively, P=0.010 OR=5.634).                 
 
The associations identified by univariate analyses were then tested for independence 
against confounding clinical factors using multivariate analysis.  The clinical factors 
entered into the analyses where those shown in section 4.6 to have a significant impact 
on the development of GVHD in this cohort.  The factors included were: female to male 
transplantation, CMV positivity and HLA-mismatch.  Acute GVHD grades I-IV and 
PBSC transplants were also included in the multivariate analysis for chronic GVHD, as 
both are considerable risk factors for the development of the condition (Atkinson et al. 
1990; Bensinger et al. 2001).  The results of the multivariate analyses are shown in 
Table 4.7.   
 
Following multivariate analyses, the previously demonstrated associations between 
patient VDR intron 8 A,A and IFNG intron 1 3,3 genotypes and severe acute GVHD 
(grades III-IV) and patient IL6 -174 G,G genotype and chronic GVHD retained their 
significance (P=0.005 OR=7.991, P=0.007 OR=5.507 and P=0.007 OR=6.562 
respectively).  Thus, the observed associations are independent of established clinical 
risk factors for HSCT outcome.  As thirteen genetic factors were examined in our 
unrelated donor HSCT cohort and an adequately sized independent second cohort does 
not currently exist to validate these findings, multiple comparisons corrections 
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(Bonferroni adjustment) were performed in an attempt to rule out spurious positive 
results.  After correction, the associations demonstrated for the VDR intron 8 A,A, 
IFNG intron 1 (CA)n 3,3 and IL6 -174 G,G genotypes remained, however, their 
significance had been substantially reduced (corrected P values; P=0.065, P=0.091 and 
P=0.091 respectively (trends)). 
 
 
 
 Acute GVHD Grade   
 I-IV II-IV III-IV Chronic GVHD 
 P OR P OR P OR P OR 
         
Patient         
IL2 -330 G  0.455 0.199 0.440 0.125 0.253 0.860 0.243 0.801 
IL4 -590 T  0.254  0.784 0.143 0.722 0.216   0.524 0.359 0.868 
IL6 -174 G,G  0.525 
34 
0.034 0.379 0.319 0.413 0.255 0.010 5.634 
IL10 -592 A  0.587 0.002 0.236 0.988 0.476 0.191 0.677 0.001 
IL10 -1082 G  0.577 0.002 0.371 0.801 0.414 0.231 0.356 0.388 
IL1RN VNTR 2  0.535 0.026 0.490 0.053 0.373 0.347 0.481 0.091 
TNFAd (GA)n 3,3  0.124 0.667 0.354 0.450 0.197 0.941 0.600 0.003 
TNFRSF1B -196 R,R  0.509 0.043 0.413 0.182 0.407 0.225 0.311 0.580 
IFNG (CA)n 3,3  0.601 0.003 0.470 0.103 0.037 4.071 0.226 0.698 
VDR intron 1 A,A  0.239 0.504 0.100 0.991 0.015 5.786 0.556 0.020 
VDR exon 9 T/C  0.288 0.676 0.267 0.694 0.331 0.479 0.423 0.223 
ESR1 intron 1 G  0.526 0.990 0.364 0.397 0.234 0.928 0.259 0.995 
ESR1 intron 1 C 
 
 
 
 
 C/T 
 
 0.222 0.721 0.567 0.002 0.213   0.677 0.414 0.255 
         
Donor         
IL2 -330 G  0.193  0.957 0.573 0.001  0.287 0.650  0.564 0.013 
IL4 -590 T  0.353 0.398 0.490 0.055  0.210   0.579  0.467 0.122 
IL6 -174 G,G  0.443 0.201 0.530 0.028  0.250 0.859  0.353 0.442 
IL10 -592 A  0.606 0.001 0.188 0.813  0.203 0.601  0.564 0.013 
IL10 -1082 G  0.563 0.004 0.290 0.713  0.250 0.859  0.242 0.511 
IL1RN VNTR 2  0.249 0.813 0.522 0.022  0.531 0.023  0.467 0.139 
TNFAd (GA)n 3,3  0.245 0.852 0.273 0.756  0.198 0.681  0.402 0.263 
TNFRSF1B -196 R,R  0.419 0.190 0.568 0.002  0.303 0.867  0.623 0.103 
IFNG (CA)n 3,3  0.292 0.594 0.113 0.920  0.391 0.260  0.264 0.960 
VDR intron 8 A,A  0.148 0.603 0.300 0.058  0.499 0.069  0.469 0.126 
VDR exon 9 C  0.447 0.161 0.616 0.006  0.575 0.003  0.452 0.261 
ESR1 intron 1 G  0.491 0.069 0.371 0.801  0.544 0.019  0.527 0.057 
ESR1 intron 1 C 
 
 0.500 0.060 0.530 0.028  0.213 0.511  0.580 0.016 
 
 
 
 
 
 
        
 
Table 4.6 Univariate analysis for acute and chronic GVHD in the unrelated donor HSCT cohort 
(n=362).  Significant associations (P≤0.01) are shown in bold.  GVHD, graft-versus-
host disease; P, P value; OR, odds ratio; IL2, interleukin-2; IL4, interleukin-4; IL6, 
interleukin-6; IL10, interleukin-10; IL1RN, interleukin-1 receptor antagonist; TNFA, 
tumour necrosis factor α; IFNG, interferon γ; VDR, vitamin D receptor; ESR1, 
oestrogen receptor 
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Table 4.7 Multivariate analysis for severe acute (grades III-IV) and chronic GVHD in the 
unrelated donor HSCT cohort (n=362).  Significant associations (P<0.05) are shown in 
bold.  GVHD, graft-versus-host disease; CMV, cytomegalovirus; HLA, human 
leukocyte antigen; VDR, vitamin D receptor; IFNG, interferon γ; PBSC, peripheral 
blood stem cell; IL6, interleukin-6 
 
 
 
Several clinical factors were also shown to be significantly associated with GVHD 
following multivariate analyses.  Female to male transplantation and HLA-mismatch 
correlated with acute GVHD (P=0.047 OR=3.614 and P=0.032 OR=3.832 respectively), 
whilst HLA-mismatch, PBSC transplantation and acute GVHD grades I-IV were linked 
to chronic GVHD (P=0.020 OR=5.393, P=0.005 OR=8.137 and P=0.001 OR=15.798 
respectively).  These findings acted as a further control in this study, by validating the 
cohort analysed.  As all five factors are well recognised clinical risks in HSCT 
(Atkinson et al. 1990; Gratwohl et al. 1998; Bensinger et al. 2001), demonstrated 
associations with GVHD would be expected in an unbiased cohort.  
 
In an attempt to verify the genetic associations demonstrated, the VDR intron 8 A,A, 
IFNG intron 1 3,3 and IL6 -174 G,G genotypes were correlated with GVHD in a second 
cohort.  This population was a subset of the original unrelated donor transplant cohort 
that comprised the 10/10 HLA-matched HSCT patient/donor pairs only (n=248).  
 P Value Odds Ratio 
   
Acute GVHD III-IV   
Female/male transplantation 0.047 3.614 
CMV positivity 0.242 0.997 
HLA-mismatch 0.032 3.832 
Patient VDR intron 8 A,A 0.005 7.991 
Patient IFNG intron 1 3,3 0.007 5.507 
   Chronic GVHD   
Female/male transplant 0.137 0.847 
HLA-mismatch 0.020 5.393 
PBSC Transplants 0.005 8.137 
Acute GVHD I-IV 0.001 15.798 
Patient IL6 -174 G,G 0.007 6.562 
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Again, patient VDR intron 8 A,A and IFNG intron 1 3,3 genotypes were significantly 
linked with the development of severe acute GVHD (grades III-IV, P=0.008 OR=6.979 
and P=0.011 OR=5.801 respectively) and patient IL6 -174 G,G genotype correlated 
with chronic GVHD (P=0.018 OR=5.799).  Although significance was reduced 
considerably following multiple comparison corrections, confirmation of the results in 
this cohort seems to suggest that the associations demonstrated are real.  Replication of 
the results in an independent cohort is however necessary to completely rule out 
associations by chance.  
 
4.8 Correlation of Non-HLA Polymorphisms with Overall Survival 
 
Overall survival was defined as the total amount of time (in months) each patient 
survived post-HSCT and was measured from the date of transplantation to the date of 
death or most recent clinic appointment.  The relationship between the IL2 -330 T/G, 
IL4 -590 C/T, IL6 -174 G/C, IL10 -592 A/C, IL10 -1082 G/A, IL1RN intron 2 VNTR, 
TNFAd intron 3 (GA)n, TNFRSF1B -196 M/R, IFNG intron 1 (CA)n, VDR intron 8 
A/C, VDR exon 9 T/C, ESR1 intron 1 A/G and ESR1 intron 1 C/T polymorphisms and 
this outcome was examined in the entire cohort of 362 unrelated donor HSCT patients.  
Following univariate analysis, a significant association was demonstrated with the IL6 -
174 G/C polymorphism.  Patients with the IL6 -174 G,G genotype were found to have a 
lower overall survival than those with the G,C or C,C genotype (P=0.096 OR=2.174).  
No correlations could be demonstrated for the remaining non-HLA polymorphisms 
examined (Table 4.8).  
 
The association observed for the IL6 -174 G,G genotype was then tested for 
independence against confounding clinical factors using multivariate analysis.  The 
factors included were female to male transplantation, CMV positivity and HLA-
mismatch (section 4.6).  Severe Acute GVHD (grades III-IV) was also included in the 
multivariate analysis, as this is a major cause of death following HSCT (Vogelsang et 
al. 1988).  The results of the multivariate analyses are shown in Table 4.9.  
  
Following multivariate analysis, only acute GVHD demonstrated an association; HSCT 
patients with a severe form of the condition (grades III-IV) had a significantly lower 
overall survival than those with minimal or no acute GVHD (P<0.0001 OR=32.734; 
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Figure 4.1).  Patient carriage of the IL6 -174 G,G genotype was again found to associate 
with lower overall survival compared to patient carriage of the G,C or C,C genotype, 
however, significance was not retained (P=0.101 OR=0.979).  It therefore seems 
unlikely that the IL6 -174 G/C polymorphism is an independent risk factor for overall 
survival.  Although, testing of this variable in a larger cohort may strengthen this 
association and allow it to be retained following multivariate analysis. 
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 Overall Survival (months) 
 P value Odds Ratio 
   
Patient    
IL2 -330 G 0.248 0.895 
IL4 -590 T 0.201 0.589 
IL6 -174 G,G 0.096 2.174 
IL10 -592 A 0.479 0.066 
IL10 -1082 G 0.278 0.651 
IL1RN intron 2, VNTR 2 0.328 0.425 
TNFAd intron 3 (GA)n 3,3 0.399 0.212 
TNFRSF1B -196 R,R 0.272 0.833 
IFNG intron 1 (CA)n 3,3 0.241 0.822 
VDR intron 8 AA 0.434 0.168 
VDR exon 9 C 0.520 0.033 
ESR1 intron 1 G 0.455 0.105 
ESR1 intron 1 C 
 
0.256 0.829 
Donor   
IL2 -330 G 0.312      0.495 
IL4 -590 T 0.515 0.044 
IL6 -174 G,G 0.398 0.413 
IL10 -592 A 0.569 0.188 
IL10 -1082 G 0.285 0.625 
IL1RN intron 2, VNTR 2 0.284 0.598 
TNFAd intron 3 (GA)n 3,3 0.324 0.427 
TNFRSF1B -196 R,R 0.445 0.128 
IFNG intron 1 (CA)n 3,3 0.293 0.558 
VDR intron 8 AA 0.487 0.056 
VDR exon 9 C 0.595 0.054 
ESR1 intron 1 G 0.257 0.731 
ESR1 intron 1 C 
 
0.305 0.515 
 
 
Table 4.8 Univariate analysis for overall survival in the unrelated donor HSCT cohort (n=362 
patient/donor pairs).  Significant associations (P≤0.01) are shown in bold.  IL2, 
interleukin-2; IL4, interleukin-4; IL6, interleukin-6; IL10, interleukin-10; IL1RN, 
interleukin-1 receptor antagonist; TNFA, tumour necrosis factor α; IFNG, interferon γ; 
VDR, vitamin D receptor; ESR1, oestrogen receptor  
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Table 4.9 Multivariate analysis for overall survival.  Significant associations (P<0.05) are shown 
in bold.  CMV, cytomegalovirus; HLA, human leukocyte antigen; GVHD, graft-versus-
host disease; IL6, interleukin-6  
 
 
 
 
 
Figure 4.1 Overall Survival analysis using Kaplan-Meier curves and the Log-Rank test. A 
significant correlation was demonstrated between severe acute GVHD (grades III-IV) 
and decreased overall survival.  P, P value; GVHD, graft-versus-host disease 
 
 
 
 
 P Value Odds Ratio 
   
Overall Survival   
Female/male transplantation 0.297 0.475 
CMV positivity 0.453 0.217 
HLA-mismatch 0.211 0.543 
Acute GVHD III-IV <0.0001 32.734 
Patient IL6 -174 G,G 0.101 0.979 
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4.9  Correlation of Non-HLA Polymorphisms with Relapse Incidence 
 
Relapse was defined as the reoccurrence of an original disease following a period of 
treatment.  As aplastic anaemia is a non-malignant disease, patients transplanted for this 
were not included in any analyses correlating non-HLA polymorphisms with relapse.  
Consequently, 8 patient/donor transplant pairs were excluded from this analysis and 
associations between the IL2 -330 T/G, IL4 -590 C/T, IL6 -174 G/C, IL10 -592 A/C, 
IL10 -1082 G/A, IL1RN intron 2 VNTR, TNFAd intron 3 (GA)n, TNFRSF1B -196 M/R, 
IFNG intron 1 (CA)n, VDR intron 8 A/C, VDR exon 9 T/C, ESR1 intron 1 A/G and 
ESR1 intron 1 C/T polymorphisms and relapse incidence were examined in 105 
unrelated donor HSCT patients.  Following univariate analysis, no correlations were 
demonstrated in either of the patient or donor groups (Table 4.10).  
 
To determine whether the absence of any significant associations was related to the 
unrelated donor HSCT cohort employed, established clinical risk factors for disease 
relapse were analysed.  Both animal and human studies have demonstrated that acute 
and chronic GVHD lower the incidence of relapse via the GVL effect (Weiden et al. 
1979; Weiden et al. 1981; Horowitz et al. 1990), as a result the absence of these 
conditions constitute considerable risk factors.  Consequently, acute and chronic GVHD 
was examined in our cohort.  The absence of both factors was found to be significantly 
associated with an increased risk of relapse (no acute GVHD P=0.002, no chronic 
GVHD P=0.010).  Thus, the unrelated donor HSCT cohort employed in this study was 
not responsible for the lack of associations between the non-HLA polymorphisms 
examined and the incidence of relapse. 
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 Relapse Incidence 
 P value Odds Ratio 
   
Patient    
IL2 -330 G 0.146 0.674 
IL4 -590 T 0.389 0.250 
IL6 -174 G,G 0.367 0.348 
IL10 -592 A 0.233 1.004 
IL10 -1082 G 0.370 0.308 
IL1RN intron 2, VNTR 2 0.295 0.624 
TNFAd intron 3 (GA)n 3,3 0.173 0.931 
TNFRSF1B -196 R,R 0.455 0.199 
IFNG intron 1 (CA)n 3,3 0.580 0.031 
VDR intron 8 A,A 0.383 0.512 
VDR exon 9 C 0.240 0.933 
ESR1 intron 1 G 0.201 0.985 
ESR1 intron 1 C 
 
0.134 0.724 
Donor   
IL2 -330 G 0.401 0.202 
IL4 -590 T 0.296 0.605 
IL6 -174 G,G 0.571 0.008 
IL10 -592 A 0.528 0.160 
IL10 -1082 G 0.548 0.008 
IL1RN intron 2, VNTR 2 0.371 0.283 
TNFAd intron 3 (GA)n 3,3 0.585 0.001 
TNFRSF1B -196 R,R 0.267 0.694 
IFNG intron 1 (CA)n 3,3 0.401 0.202 
VDR intron 8 A,A 0.431 0.196 
VDR exon 9 C 0.441 0.158 
ESR1 intron 1 G 0.616 0.006 
ESR1 intron 1 C 
 
0.620 0.005 
 
 
Table 4.10 Univariate analysis for relapse incidence in the unrelated donor HSCT cohort (n=105 
patient/donor pairs).  No significant associations were demonstrated in either the patient 
or the donor group.  IL2, interleukin-2; IL4, interleukin-4; IL6, interleukin-6; IL10, 
interleukin-10; IL1RN, interleukin-1 receptor antagonist; TNFA, tumour necrosis factor 
α; IFNG, interferon γ; VDR, vitamin D receptor; ESR1, oestrogen receptor 
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4.10 Correlation of Non-HLA Polymorphisms with TRM 
 
TRM was defined as death following transplantation, from all causes other than disease 
relapse.  The relationship between this outcome and the IL2 -330 T/G, IL4 -590 C/T, 
IL6 -174 G/C, IL10 -592 A/C, IL10 -1082 G/A, IL1RN intron 2 VNTR, TNFAd intron 3 
(GA)n, TNFRSF1B -196 M/R, IFNG intron 1 (CA)n, VDR intron 8 A/C, VDR exon 9 
T/C, ESR1 intron 1 A/G and ESR1 intron 1 C/T polymorphisms was examined in 249 
unrelated donor HSCT patients.  Following univariate analysis, no correlations were 
demonstrated in either of the patient or donor groups (Table 4.11). 
 
As with relapse incidence, a clinical risk factor for TRM was analysed in order to 
confirm that the absence of any associations was not related to our unrelated donor 
HSCT cohort.  Gender mismatched transplantation is a well recognised risk, with TRM 
being significantly increased in male recipients of female donor stem cells (Zwaan et al. 
1989; Gratwohl et al. 2001).  Consequently, female to male transplantation was 
examined in this study.  A significant link with TRM was observed (P=0.001).  Thus, 
our inability to demonstrate any associations between the non-HLA polymorphisms 
examined and TRM in this study was not cohort related.  
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 TRM 
 P value Odds Ratio 
   
Patient    
IL2 -330 G 0.531 0.023 
IL4 -590 T 0.175 0.563 
IL6 -174 G,G 0.250 0.859 
IL10 -592 A 0.156 0.647 
IL10 -1082 G 0.100 0.691 
IL1RN intron 2, VNTR 2 0.253 0.860 
TNFAd intron 3 (GA)n 3,3 0.147 0.734 
TNFRSF1B -196 R,R 0.531 0.023 
IFNG intron 1 (CA)n 3,3 0.476 0.191 
VDR intron 8 A,A 0.414 0.231 
VDR exon 9 C 0.373 0.347 
ESR1 intron 1 G 0.216 0.829 
ESR1 intron 1 C 
 
0.346 0.575 
Donor   
IL2 -330 G 0.546 0.022 
IL4 -590 T 0.567 0.019 
IL6 -174 G,G 0.583 0.010 
IL10 -592 A 0.243 0.716 
IL10 -1082 G 0.359 0.868 
IL1RN intron 2, VNTR 2 0.654 0.002 
TNFAd intron 3 (GA)n 3,3 0.115 0.973 
TNFRSF1B -196 R,R 0.141 0.685 
IFNG intron 1 (CA)n 3,3 0.335 0.989 
VDR intron 8 A,A 0.564 0.013 
VDR exon 9 C 0.530 0.738 
ESR1 intron 1 G 0.489 0.086 
ESR1 intron 1 C 
 
0.309 0.516 
 
 
Table 4.11 Univariate analysis for TRM in the unrelated donor HSCT cohort (n=249 patient/donor 
pairs).  No significant associations were demonstrated in either the patient or the donor 
group.  IL2, interleukin-2; IL4, interleukin-4; IL6, interleukin-6; IL10, interleukin-10; 
IL1RN, interleukin-1 receptor antagonist; TNFA, tumour necrosis factor α; IFNG, 
interferon γ; VDR, vitamin D receptor; ESR1, oestrogen receptor 
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4.11 Discussion 
 
Polymorphisms in the genes of IL-2 (-330 T/G), IL-4 (-590 C/T), IL-6 (-174 G/C), IL-
10 (-592 A/C, -1082 G/A), IL-1Ra (intron 2 VNTR), TNFα (d intron 3 (GA)n), TNFRII 
(-196 M/R), IFNγ (intron 1 (CA)n), vitamin D receptor (intron 8 A/C, exon 9 T/C) and 
oestrogen receptor (intron 1 A/G, intron 1 C/T) have been shown to have a substantial 
influence on HSCT outcome, associating with both GVHD and survival after HLA-
matched sibling HSCT (Middleton et al. 1998; Cavet et al. 1999; Cavet et al. 2001; 
Cullup H 2001; Socie et al. 2001; Middleton et al. 2002; Rocha V 2002; Lin et al. 2003; 
Middleton et al. 2003; Stark et al. 2003; Mlynarczewska et al. 2004; Bogunia-Kubik et 
al. 2005b; Karabon et al. 2005; Rocha et al. 2009).  Consequently, these non-HLA 
polymorphisms were correlated with HSCT outcome in our unrelated donor transplant 
cohort.  While no associations were observed with overall survival, relapse incidence 
and TRM, significant correlations were demonstrated with the development of acute and 
chronic GVHD.     
 
Polymorphism analysis demonstrated significant associations between VDR intron 8 
A/C and IFNG intron 1 (CA)n and acute GVHD in this study.  Transplant patients 
possessing the VDR intron 8 A,A or the IFNG intron 1 (CA)n 3,3 genotypes were found 
to be much more susceptible to the development of severe acute GVHD (grades III-IV) 
than those without these genotypes.  These associations were observed in the whole 
HSCT cohort (n=362, P=0.015 OR=5.786 and P=0.037 OR=4.071 respectively), a 
smaller validation cohort that consisted of the 10/10 HLA-matched unrelated donor 
HSCT patient/donor pairs (n=248, P=0.008 OR=6.979 and P=0.011 OR=5.801 
respectively) and when established clinical risk factors for acute GVHD were entered 
into the analysis (P=0.005 OR=7.991 and P=0.007 OR=5.507 respectively).  Although 
somewhat reduced, these associations also retained their significance (trend) following 
multiple comparison corrections (Bonferroni adjustment: P=0.065 and P=0.091 
respectively).  It therefore seems likely that the VDR intron 8 A/C and IFNG intron 1 
(CA)n polymorphisms are independent risk factor for severe acute GVHD (grades III-
IV) following unrelated donor HSCT.  
 
The observed association with the IFNG intron 1 (CA)n 3,3 genotype has also been 
demonstrated by our research group in a cohort of HLA-matched sibling transplants 
(Cavet et al. 2001).  As the 3,3 genotype has previously been linked to lower in vitro 
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IFN production following mitogen stimulation (Pravica et al. 1999), an association 
with GVHD was unexpected.  However, it may be explained if IFN had a negative 
feedback regulatory role, as seen in some mouse models of GVHD.  Weekly injections 
of IFN in a subacute murine model of GVHD prevents the condition and increases 
survival, whereas mice receiving stem cells from IFN knockout donors have been 
shown to develop accelerated lethal GVHD (Brok et al. 1997).  An alternative 
explanation is that in vivo stimulation by HSCT conditioning regimens may have a 
different relationship to the IFNG intron 1 (CA)n polymorphism than in vitro 
stimulation by mitogens, as the network of cytokine interactions initiating acute GVHD 
is much more complex than direct in vitro T-cell activation (Cavet et al. 2001).  A more 
recent study correlating the IFNG inton 1 (CA)n 3,3 genotype with an increased 
susceptibility to viral reactivation following HSCT may offer another explanation for 
the association with acute GVHD (Bogunia-Kubik et al. 2005a).  As IFN plays a key 
role in anti-microbial and anti-viral immunity, the low IFN expression associated with 
IFNG intron 1 (CA)n 3,3 genotype may result in a decreased ability to fight and abolish 
infections and an increased susceptibility to pathogens, particularly viruses.  It is 
therefore possible that the immune response produced against such infections could 
exacerbate GVHD (Bogunia-Kubik et al. 2005a).  The correlation of skin and bowel 
manifestation of GVHD with herpes virus (CMV) reactivation seems to supports this 
theory (Yoshikawa et al. 2001; Holler 2002). 
 
Patient carriage of the VDR intron 8 A,A genotype was also shown to associate with an 
increased susceptibility to severe acute GVHD (grades III-IV) in this study.  The 
finding conflicts with that of Middleton et al (2002) and Bogunia-Kubik et al. (2008), 
who have reported an inverse association between the VDR intron 8 A,A genotype and 
the development of severe acute GVHD (grades III-IV).  The reason for the conflicting 
data is currently unknown, but may reflect differences in cohort size; the current study 
examined the VDR intron 8 A/C polymorphism in 362 HSCT patients and donors, 
whereas Middleton et al (2002) and Bogunia-Kubik et al. (2008) employed cohorts of 
only 80 and 123 respectively.  However, as the findings of the latter studies were 
demonstrated in HLA-matched sibling HSCT cohorts, it is also possible that the 
conflicting data reflects fundamental differences between HLA-matched sibling and 
unrelated donor transplantation.  This is further supported by the observation that very 
few of the associations previously reported in the HLA-matched sibling setting have 
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been demonstrated in this study.  In comparison to HLA-matched sibling HSCT, 
unrelated donor transplantation is associated with a greater degree of HLA disparity, has 
an increased risk of GVHD and other complications and is typically treated with higher 
intensity conditioning regimens and prophylaxis strategies (de Lima and Champlin 
2001; Petersdorf et al. 2001); consequently there is a substantial difference in transplant 
biology between the two HSCT types.  As a result, it is extremely unlikely that all 
genetic associations will exist in both transplant settings.  In terms of future studies, it 
would therefore be sensible to analyse non-HLA polymorphisms in independent HLA-
matched sibling and unrelated donor HSCT cohorts.  Differences in transplant biology 
does not however explain the inability of this study to replicate the associations 
previously reported for the IL2 -330 T/G, ILRN intron 2, IL10 -592 A/C, IL10 -1082 
G/A, TNFAd intron 3 (GA)n and TNFRSF1B -196 M/R polymorphisms in the unrelated 
donor HSCT setting (Ishikawa et al. 2002; MacMillan et al. 2003a; MacMillan et al. 
2003b; Kean et al. 2004; Bettens et al. 2006).  Differences in the size, degree of 
heterogeneity and the ethnicity of the populations examined may be possible 
explanations.    
 
Patient treatment could be another explanation for conflicting data, as the type of 
conditioning and prophylaxis used depends greatly on the transplant type, the age and 
condition of the patient and the stage of the disease at the time of HSCT (Morris and 
Hill 2007), consequently protocols employed differ from study to study.  Due to the 
immunosuppressive rather than damaging nature of low intensity regimens, patients 
conditioned with these milder strategies are likely to produce completely different non-
HLA polymorphism data, particularly in terms of GVHD, to those conditioned by 
myeloablation.  The therapeutic effects of transplant drugs may also have a substantial 
impact on the results of genetic association studies.  In this current study 61% of the 
transplant patients received stem cell grafts that had been treated with ATG or 
Campath-1H.  Both of these drugs reduce the incidence of post-transplant GVHD by 
depleting T cells (Chakrabarti et al. 2004; Van Lint et al. 2006).  The loss of this cell 
type is likely to have had a considerable affect on cytokine production during 
transplantation and subsequently on the genetic associations observed.  The 
administration of steroids such as methylprednisone and prednisolone may also have a 
considerable effect on genetic association studies, as the anti-inflammatory actions of 
these drugs reduce the severity and even abolish GVHD.    
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The non-HLA polymorphism analysis performed in this study also demonstrated a 
significant association between IL6 -174 G/C and chronic GVHD.  Transplant patients 
possessing the IL6 -174 G,G genotype were more at risk of developing the condition 
than those with the G,C or C,C genotypes.  This association was again observed in the 
whole HSCT cohort (n=362, P=0.010 OR=5.634), the smaller validation cohort that 
consisted of the 10/10 HLA-matched unrelated donor HSCT patient/donor pairs (n=248, 
P=0.018 OR=5.799) and when established clinical risk factors for chronic GVHD were 
entered into the analysis (P=0.007 OR=6.562).  Although substantially reduced, this 
association also retained its significance (trend) following multiple comparison 
corrections (Bonferroni adjustment, P=0.091).  It therefore seems likely that the IL6 -
174 G/C polymorphism is an independent risk factor for chronic GVHD following 
unrelated donor HSCT.  
 
Several studies have been undertaken to assess the role of IL-6 in chronic GVHD and 
the evidence appears to be consistent.  IL-6 serum levels have been shown to be higher 
post-transplant in patients with chronic GVHD than in those without the condition 
(Imamura et al. 1994) (Barak et al. 1995) and the onset of extensive chronic GVHD has 
been shown to coincide with an increase in IL-6 mRNA expression (Tanaka et al. 
1996).  The involvement of this cytokine in chronic GVHD is also supported by 
polymorphism data.  In HLA-matched sibling studies the relative risk for the condition 
has been shown to be significantly higher for patients with the IL6 -174 G,G genotype 
(Cavet et al. 2001; Socie et al. 2001).  The association demonstrated for IL6 -174 G,G 
in this study therefore agrees with the previously published results and provides further 
support for the role of IL-6 in chronic GVHD.  Although only a trend, the link between 
IL6 -174 G,G and decreased overall survival demonstrated following univariate analysis 
in this study, also seems to substantiate the association between the IL6 -174 G,G 
genotype and chronic GVHD; as the condition is still the major cause of late mortality 
following HSCT (Horwitz and Sullivan 2006).           
 
In unrelated donor HSCT the HLA system is of great importance, as complete matching 
between patients and their unrelated donors is extremely low and the risk of GVHD and 
post-transplant mortality increases dramatically with single mismatches at HLA-A, -B, -
C, -DRB1 or -DPB1 (Sasazuki T 1998; Flomberg et al. 2004; Chalandon et al. 2006; 
Lee et al. 2007; Shaw et al. 2007).  It is therefore essential that HLA disparity is 
accounted for in genetic association studies performed in this setting.  As no standard 
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method currently exists, previously published studies have employed different 
approaches, Ishikawa et al (2002) examined the TNFA and TNFRSF1B polymorphisms 
in HLA-A, -B and –DRB1 matched cases only, whilst Bettens et al (2006) analysed the 
TNFA and IL10 polymorphisms initially in a cohort containing matched and 
mismatched transplants and then in a 10/10 HLA-matched sub-group.  Other studies, 
however, have not accounted for HLA disparity at all (MacMillan et al. 2003a; 
MacMillan et al. 2003b; Remberger et al. 2003; Kean et al. 2004).  These differences in 
methodology may therefore be another explanation for conflicting data.  HLA disparity 
was accounted for in this study using a similar approach to that of Bettens et al (2006).  
As the associations demonstrated between the VDR intron 8 A/C, IFNG intron 1 (CA)n 
and IL6 -174 G/C polymorphisms and GVHD were observed in the whole unrelated 
donor HSCT cohort and the 10/10 HLA-matched subset and were demonstrated to be 
independent of HLA-mismatching in all multivariate analyses, it is likely that the 
method employed adequately accounted for the effects of HLA disparity and the 
associations demonstrated in this study are real.   
 
Although the data presented implicates the VDR intron 8 A/C, IFNG intron 1 (CA)n and 
IL6 -174 G/C polymorphisms as independent risk factor for the development of GVHD, 
the unrelated donor HSCT cohort employed in this study was heterogeneous and due to 
number constraints all potential confounding variable could not be accounted for.  It 
would therefore be of interest to examine the non-HLA polymorphisms in a larger 
independent cohort, as this would provide evidence of reproducibility, which is often 
lacking in disease association studies (Colhoun et al. 2003), and would allow the 
heterogeneous nature of HSCT populations to be addressed more effectively.  Larger 
cohorts would permit the inclusion of a wider range of transplant parameters, such as 
stem cell source, underlying disease and stage of disease and would allow the thorough 
investigation of non-HLA polymorphisms in more homogeneous disease, treatment and 
transplant specific groups.  Genetic factors identified and confirmed in large studies 
have implications for the inclusion, alongside clinical risk factors in a prognostic index 
for the prediction of GVHD prior to transplantation.  Successful prediction would allow 
the identification of at risk patients, improve donor selection and allow post-transplant 
therapies to be tailored to an individual.  Such an analysis would be extremely 
advantageous; particularly in the unrelated donor HSCT setting, were the risk of GVHD 
is greatly increased and several potential donors are often identified (Anasetti et al. 
1995). 
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Chapter 5. The Role of IL-13 in GVHD: Genotyping and Functional 
Studies 
 
 
IL-13 is a 10 KDa immunoregulatory cytokine that was first described in 1989 as P600, 
a protein cloned from a murine Th-2 cell-line (Brown et al. 1989).  It is an 
unglycosylated protein product of 132 amino acids that is secreted predominantly by 
activated Th2 CD4
+
 T cells (Brown et al. 1989; de Vries 1996).  However, B cells, mast 
cells, basophils, NK cells and DCs also produce this cytokine (Burd et al. 1995; Gibbs 
et al. 1996; Li et al. 1996; de Saint-Vis et al. 1998; Hoshino et al. 1999).  IL-13 
mediates its effects through the type II IL-4 receptor that is expressed on a broad range 
of haematopoietic and non-haematopoietic cells types; except for T cells (Zurawski and 
de Vries 1994; Bochner et al. 1995; Murata et al. 1998; Li et al. 1999; Wills-Karp 
2001).  This receptor is composed of an IL-4 receptor chain (IL-4Rα) and an IL-13 
receptor chain (IL-13Rα1) and can bind both of these cytokines (Aman et al. 1996; 
Hilton et al. 1996).  Accordingly, IL-13 has biological activities very similar to those of 
IL-4. 
 
The IL13 gene has been mapped to chromosome 5q31-33 within the ‘Th2-cytokine 
cluster’.  It is located 12kb upstream of the gene encoding IL4 and in close proximity to 
the IL3, IL5, IL9 and CSF2 genes (McKenzie et al. 1993).  The 3950bp IL13 gene is 
comprised of 4 exons and 3 introns and has been demonstrated to be highly 
polymorphic.  31 SNPs have been identified to date  (Tarazona-Santos and Tishkoff 
2005).  An arginine (G)→glutamine (A) transition in exon 4 at position +2044 is 
however the most common, occurring in approximately 25% of the population.  It is the 
only non-synonymous polymorphism within the IL13 gene and results in the 
replacement of an arginine residue with a glutamine at position 130 (Heinzmann et al. 
2000; Vladich et al. 2005).  Mutational and nuclear magnetic resonance studies have 
shown IL13 +2044 G/A to be located in the C-terminus of the IL-13 molecule, an area 
which has been implicated in interaction with the IL-13 receptor chain (Horie et al. 
1997; Lentsch et al. 1997; Madhankumar et al. 2002).  Thus, this polymorphism maps 
to a region which is potentially critical for the functional properties of the cytokine 
(Vercelli 2002).  IL13 +2044 G/A has been widely studied for disease associations, with 
the A allele being correlated with inflammatory and allergy phenotypes, including 
asthma (Heinzmann et al. 2000; Arima et al. 2002; Heinzmann et al. 2003; Vladich et 
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al. 2005), atopy (He et al. 2003), atopic dermatitis (Liu et al. 2000; Tsunemi et al. 
2002) and food sensitization (Zitnik et al. 2009). 
 
To date no studies examining the IL13 +2044 G/A polymorphism in the HSCT setting 
have been published.  However, IL-13 expression has been correlated with transplant 
outcome.  Elevated IL-13 production by allo-reactive donor T cells has been 
demonstrated to associate with acute GVHD in humans (Jordan et al. 2004), whilst high 
IL-13 expression has been shown to attenuate the condition in murine models 
(Hildebrandt et al. 2007).  In order to establish if IL-13 plays a role in the pathogenesis 
of GVHD, the IL13 +2044 G/A polymorphism and in vitro and in vivo IL-13 expression 
will be examined in a HSCT cohort.  
 
5.1 Study Aims 
 
i) To establish and compare the allele and genotype frequencies of the IL13 +2044 
G/A polymorphism in a Newcastle control population with a HSCT cohort. 
  
ii) To correlate HSCT outcome, in terms of acute GVHD incidence and severity, 
chronic GVHD incidence, overall survival, relapse incidence and TRM with the 
IL13 +2044 G/A polymorphism by univariate and multivariate statistical analyses. 
 
iii) To examine the role of in vitro and in vivo IL-13 expression in acute and chronic 
GVHD in a cohort of Newcastle HSCT patients. 
 
iv) To determine whether IL-13 expression varies with the IL13 +2044 G/A 
polymorphism in a cohort of Newcastle HSCT patients and donors. 
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5.2 Statistical Analysis 
 
IL13 +2044 allele and genotype frequencies calculated for the HSCT cohort were 
compared to those of Newcastle controls using the chi-square (2) and Fisher’s exact 
test where appropriate. Expected and observed IL13 +2044 genotype frequencies for 
both cohorts were assessed for Hardy-Weinberg equilibrium using the chi-square (2) 
test.  The IL13 +2044 G/A polymorphism was correlated with acute and chronic GVHD 
using the chi-square (2) test and forward stepwise logistic regression.  Overall survival 
was analysed using Kaplan-Meier curves and the Log-Rank test, followed by Cox 
regression.  The incidence of relapse and TRM were analysed using cumulative 
incidence curves and the Log-Rank test (competing risk analysis). 
 
The distribution of IL-13 levels in MLC supernatants and mitogen stimulated 
supernatants were tested for normality using the Kolmogorov-Smirnov test.  IL-13 
expression in these sample cohorts did not fulfil the criteria for a Gaussian (normal) 
distribution.  Consequently, the data were analysed using non-parametric methods.  The 
Mann-Whitney U test was employed when comparing two groups and the Kruskal-
Wallis test was utilised when three or more groups were present.  Correlation 
calculations were performed using the Spearman’s Rank Correlation test.   
 
The sample sizes for all comparisons made with respect to IL-13 expression in serum 
samples were small (n=30), thus a normality test was not required and the data was 
assumed to have a non-Gaussian distribution.  The relationship between IL-13 
expression and acute or chronic GVHD was therefore examined using a non-parametric 
method; Mann-Whitney U test.    
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5.3 Experimental Design 
 
5.3.1 Inclusion and Exclusion Criteria 
 
IL13 Genotyping Study 
 
All patients and their donors recruited as part of a European Commission FP5 
biotechnology project (Eurobank QLRI-CT-2000-00010, PI Professor A M Dickinson), 
that were transplanted between November 1983 and December 2006 and had DNA and 
1 year’s clinical follow-up available, were included in the analyses.  The study was 
given JLEC approval (Appendix B) and informed consent was obtained from all 
patients and donors.  Exclusion criteria were as follows:  
 
i) Transplantation not performed 
ii) Incomplete HSCT outcome data 
iii) Incomplete HLA typing data   
iv) Below the age of 16 at the time of transplant  
v) Transplantation for an immunological disease  
vi) Transplantation with a source other than PBSC or bone marrow 
vii) Two or more transplants performed 
 
Once the inclusion and exclusion criteria had been taken into account, the HSCT cohort 
employed in the genotyping study had been reduced from 721 patient/donor pairs to 
600. 
 
IL-13 Functional Study 
 
All patients and their donors recruited as part of a European Commission FP5 
biotechnology project (Eurobank QLRI-CT-2000-00010, PI Professor A M Dickinson), 
that were transplanted between November 1983 and December 2006; with IL13 +2044 
G/A genotyping data plus MLC supernatants, GVHR grades and 1 year’s clinical 
follow-up available, were included in the analyses.  The study was given JLEC approval 
(Appendix B) and informed consent was obtained from all patients and donors.  
Exclusion criteria were the same as those employed for the genotyping study. 
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Once the inclusion and exclusion criteria had been taken into account, the cohort 
utilised in the functional study consisted of 93 Newcastle HSCT patient/donor pairs. 
 
5.3.2 Control Measures 
 
For all samples, successful IL13 PCR amplification was confirmed by agarose gel 
electrophoresis prior to PCR-RFLP analysis (section 3.6.2).  Accurate ascertainment of 
IL13 +2044 G/A alleles was ensured by the inclusion of both homozygous and 
heterozygous control samples of known genotype in all PCR reactions, PCR-RFLP 
analyses and electrophoresis gels (section 3.6.6).  Genotypes were determined with 
reference to these known samples and verified by an independent observer.  In 
equivocal cases, samples were re-analysed (less than 5% of the cohort).  All IL13 +2044 
G/A genotypes were determined whilst blinded to clinical outcome.  Correct allele 
determination was also ensured by the inclusion of negative controls, appropriate DNA 
size markers and by re-typing 25% of each cohort tested. 
 
In all MLC cultures and mitogen stimulations, IL-13 expression was determined in the 
experimental sample and its corresponding control.  The specific controls employed for 
each method are described in sections 3.9 and 3.11.  In order to demonstrate that any 
variation in in vivo IL-13 expression in HSCT patients was transplant or outcome 
related rather than a naturally occurring phenomenon, IL-13 serum levels in patients and 
controls were compared prior to any correlation with clinical outcome.  All ELISAs and 
CBAs performed (sections 3.13 and 3.14) included an appropriate standard dilution 
series and a negative control.  ELISA samples and standards were tested in duplicate 
and the mean value for each set was used for quantification.  Samples were re-assayed if 
the values for the two replicates varied by more than 15%.  All functional studies were 
performed whilst blinded to clinical outcome.   
 
5.3.3 Method of Analysis    
 
Prior to any correlation with clinical outcome, the accuracy of IL13 +2044 G/A 
determination in the HSCT cohort was assessed by the comparison of calculated allele 
and genotype frequencies with those of a Newcastle control group and previously 
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published data.  In order to rule out selection bias and genotype deviation, patient, donor 
and control genotype frequencies were also tested for Hardy-Weinberg equilibrium. 
 
HSCT patient and donor IL13 +2044 G/A alleles were then individually correlated with 
the incidence and severity of acute GVHD, incidence of chronic GVHD and overall 
survival using univariate analysis methods (chi-square test (2), Kaplan-Meier curves 
and Log-Rank test).  Alleles with P values ≤0.1 were each tested for independence 
against identified confounding clinical factors using multivariate analysis methods 
(forward stepwise logistic and Cox regression).  In order to retain adequate power, only 
the strongest factors, up to a maximum of 5, were entered into all multivariate analyses.  
P values <0.05 were considered statistically significant and values between 0.05 and 0.1 
were considered indicative of a trend.  
 
IL13 +2044 G/A alleles were also correlated with relapse incidence and TRM.  As both 
of these outcomes are affected by other clinical events, competing risk analysis methods 
were required.  These methods allow all possible associations to be observed by 
excluding the relevant competing event (relapse or TRM).  Univariate analysis 
(cumulative incidence curves and Log-Rank test) alone was performed in this study 
(section 4.3.3).  Again, P values <0.05 were considered statistically significant and 
values between 0.05 and 0.1 were considered indicative of a trend. 
 
HLA disparity and unrelated donor transplants are well established risk factors in 
HSCT, particularly for GVHD; where the risk of the condition increases in parallel with 
the number of mismatched HLA loci (Beatty et al. 1985; Petersdorf et al. 1998; 
Sasazuki T 1998).  As our cohort included both HLA-matched sibling and unrelated 
donor transplants, these factors could have had a substantial impact on outcome in this 
study.  Thus, prior to any analyses with the IL13 +2044 G/A polymorphism, HLA 
disparity and transplant type were tested for associations with GVHD.  Both HLA-
mismatched transplants and unrelated donor transplants were found to correlate with a 
higher incidence of acute and chronic GVHD in this study (acute GVHD P=0.073 and 
P=0.067 respectively; chronic GVHD P=0.098 and P=0.077 respectively).  The most 
accurate and reliable means of accounting for such associations involves stratification of 
the cohort.  However, this was not possible for HLA disparity, as the mismatched group 
would be too small to analyse (n=102).  Instead, HLA-mismatch was entered into all 
multivariate analyses as a confounding factor.  Cohort stratification was possible for 
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transplant type.  Consequently, IL13 +2044 G/A alleles were correlated with HSCT 
outcome in the whole cohort (n=600) and then in HLA-matched sibling (n=342) and 
unrelated donor transplant (n=258) sub-groups.  Due to the heterogeneity of the cohort, 
stratification should also be considered for clinical factors such as underlying disease, 
disease stage (early/advanced), conditioning regimen (low intensity/myeloablative), 
prophylaxis intensity (low/high) and graft manipulation (T cell replete/T cell deplete).  
However, due to number constraints and as these factors had no impact on HSCT 
outcome in this study, stratification according to these factors was not performed. 
 
In an attempt to address the concerns about the proliferation of genetic association 
studies, especially those in which results have not been replicated (Colhoun et al. 2003), 
any significant correlation observed in this study was verified in a smaller second cohort 
(n=300).  This cohort consisted of 50% of the original HSCT population selected using 
the random assignment function in SPSS 15.0.  This cohort was not independent and 
therefore not ideal; however, it was the most appropriate means of verification 
available.  Time constraints did not permit the formation of a completely independent 
population of adequate size (power).  Sample collection for the creation of such a 
verification cohort is currently being undertaken.    
 
The role of IL-13 in acute and chronic GVHD was further investigated via functional 
analysis of IL-13 expression.  In vitro expression was correlated with the incidence and 
severity of acute GVHD; in both the clinical setting and in an in vitro model, and with 
chronic GVHD.  While in vivo IL-13 expression was correlated with clinical acute and 
chronic GVHD alone.  The impact of the IL13 +2044 G/A polymorphism on IL-13 
expression was also examined.  Although the primary HSCT outcome investigated in 
this study was GVHD, IL-13 expression was also correlated with overall survival, 
disease relapse and TRM where possible.  In all analyses, P values <0.05 were 
considered statistically significant and values between 0.05 and 0.1 were considered 
indicative of a trend. 
 
The HSCT cohort employed in this functional study also contained HLA-matched 
sibling and unrelated donor transplants.  However, due to the small nature of the 
population (n=93), cohort stratification was not possible. Instead, the three HLA-
mismatched unrelated donor transplants in the original HSCT cohort were excluded 
from the study and IL-13 expression was examined in the remaining mixed population 
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(n=90; 62 HLA-matched sibling, 28 unrelated donor).  There was no significant 
difference in the incidence of acute or chronic GVHD between the HLA-matched 
sibling and the unrelated donor transplants in this cohort (P=0.927 and P=0.842 
respectively).  Sample size also prevented the stratification of this heterogeneous cohort 
according to underlying disease, disease stage (early/advanced), conditioning regimen 
(low intensity/myeloablative), prophylaxis intensity (low/high) and graft manipulation 
(T cell replete/T cell deplete). 
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5.4 Correlation of the IL13 +2044 G/A Polymorphism with HSCT Outcome 
 
5.4.1 Study Population 
 
HSCT Cohort 
 
Genomic DNA was obtained from 600 allogeneic HSCT patients and their donors for 
genotyping of the IL13 +2044 G/A polymorphism.  This was an adult cohort (≥16 at the 
time of transplant) comprising 342 HLA-matched sibling transplants and 258 unrelated 
donor transplants.  HLA matching between patients and donors was performed by high 
resolution DNA-based typing for HLA-A, B, C, DRB1 and DQB1.  Complete matching 
at all 5 loci was observed in 498 (83%) transplant pairs. 
 
Cohort characteristics: 
The 600 HSCT patients included in this cohort were transplanted between November 
1983 and December 2006 at clinical centres in Austria, England, France, Germany and 
Spain.  All patients and donors were recruited and consented as part of the previously 
described ‘Eurobank Project’ (section 5.3.1).  
 
Acute GVHD was deemed assessable in those alive ≥30 days post-transplant and 
developed in 392 patients.  208 patients had no acute GVHD (grade 0), 116 grade I, 165 
grade II, 67 grade III and 44 had grade IV.  Acute GVHD grades III and IV were 
considered severe.  Chronic GVHD was assessable from 100 days post-transplant in 463 
patients.  250 of these patients developed the condition.  All transplant patients were 
prepared for HSCT with low intensity (n=221) or myeloablative conditioning (n=370) 
regimens and 34% (n=202) were transplanted with T cell depleted stem cell grafts.  462 
patients were given high intensity GVHD prophylaxis (CsA plus MTX or MM), whilst 
138 received CsA monotherapy.  The survival rate for this cohort was 49% (n=297) and 
causes of death included disease relapse, infection and GVHD.  Table 5.1 shows the 
demographic characteristics of the HSCT cohort examined in this aspect of the study. 
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Table 5.1 Characteristics of the HSCT cohort (n=600). 
CMV, cytomegalovirus; CsA, cyclosporine A; MTX, methotrexate; MM, 
mycophenolate mofetil; TCD, T cell depletion 
 
 
TRANSPLANT PATIENTS 
Median Age      40 years (range 16-67) 
      Number in each group 
Gender 
 Male      359 
 Female      241 
 Female to Male HSCT    130 
 
CMV Status 
 Positive     309 
 Negative     291 
 
Underlying Disease 
 Acute Lymphoblastic Leukaemia     78 
 Acute Myeloid Leukaemia    196 
 Chronic Lymphocytic Leukaemia     11 
 Chronic Myeloid Leukaemia    129 
 Hodgkin disease       14 
 Non-Hodgkin Lymphoma      73 
 Myeloproliferative Disorders      44 
  Plasma Cell Neoplasm       39 
  Aplastic Anaemia       16 
Conditioning Therapy 
   Low intensity      221 
   Myeloablative      379 
 
GVHD Prophylaxis 
   CsA       138 
   CsA and MTX      298 
   CsA and MM      164 
 
  TCD       202 
 
 
TRANSPLANT DONORS 
 
Median Age      38 years (range 19-62)   
       Number in each group 
Gender  
   Male        345 
   Female        255 
 
CMV Status 
   Positive       281 
   Negative       319 
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5.4.2 Allele and Genotype Frequencies 
 
IL13 +2044 G/A allele and genotype frequencies were determined in the HSCT cohort 
for both patients and donors.  Allele frequencies were calculated as 0.80 and 0.20 for the 
G and A alleles respectively in the two groups.  These values did not differ significantly 
from those determined for the Newcastle control cohort (P=0.704; Table 3.3, section 
3.6.2) and European controls published in the literature (P=1.000; Table 3.3, section 
3.6.2) (Heinzmann et al. 2003).  This polymorphism is therefore not a consequence of 
disease, but occurs naturally within all populations 
 
All three possible IL13 +2044 G/A genotype combinations were observed in the patient 
and donor groups and the genotype frequencies determined were similar to those 
calculated for the control cohort (patient, P=0.965; donor, P=0.911).  Potential deviation 
from Hardy-Weinberg equilibrium was examined for using the chi-square (2) test.  No 
significant difference between the observed and calculated expected values was 
demonstrated for the patients, donors or controls (P=0.772, P=0.883 and P=1.000 
respectively; Table 5.2).  Thus, the genotype frequencies for all three groups were in 
Hardy-Weinberg equilibrium; there was no selection bias and genotype deviation was 
absent.  Furthermore, the genotype frequencies generated in this study were comparable 
to those published in the literature (Heinzmann et al. 2003; Maier et al. 2006; 
Sadeghnejad et al. 2008). 
 
 
 
 
 Newcastle Controls (n=100) HSCT Patients (n=600) HSCT Donors (n=600) 
 Observed Expected Observed Expected Observed Expected 
       
IL13 +2044       
GG 0.66 0.66 0.65 0.65 0.64 0.64 
GA 0.30 0.30 0.30 0.32 0.31 0.32 
AA 0.04 0.04 0.05 0.03 0.05 0.04 
       
 
 
Table 5.2 Hardy-Weinberg equilibrium analysis of IL13 +2044 G/A genotype frequencies in the 
Newcastle controls and the HSCT patients and donors.  HSCT, haematopoietic stem 
cell transplantation; IL13, interleukin-13 
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5.4.3 Correlation of Clinical Factors with Acute and Chronic GVHD 
 
It is well established that certain clinical factors have a considerable impact on HSCT 
outcome, particularly GVHD (section 1.3.4) (Beatty et al. 1985; Atkinson et al. 1990; 
Gratwohl et al. 1998; Nichols et al. 2002; Hahn et al. 2008).  These factors are therefore 
potential confounding variables that need to be accounted for when genetic association 
studies are performed in the HSCT setting.  As a result of this, the effects of clinical 
factors on the development of acute and chronic GVHD in our HSCT cohort were 
assessed prior to IL13 +2044 G/A polymorphism analysis.     
 
Eight clinical factors were tested for associations with acute and chronic GVHD.  These 
were patient and donor age at HSCT (over 40 years), gender mismatch transplantation 
(female to male), CMV status (patient and/or donor positivity), HLA matching, 
conditioning regimen (low intensity/myeloablative), prophylaxis intensity (low/high) 
and graft manipulation (T cell replete/T cell deplete).  The results of the univariate 
analyses are shown in Table 5.3.  No significant associations were demonstrated with 
donor age over 40 years, CMV positivity, myeloablative conditioning, low intensity 
prophylaxis and T cell depletion.  Thus, these factors had no impact on HSCT outcome 
in this study and as a result were not included in any further analyses.  Significant 
correlations were however demonstrated between GVHD and patient age over 40 years, 
female to male transplantation and HLA-mismatch.  These three clinical factors were 
therefore identified as confounding variables and needed to be accounted for when 
associations between the IL13 +2044 G/A polymorphism and HSCT outcome were 
examined using multivariate analysis.     
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 Acute GVHD Chronic GVHD 
 P OR P OR 
     
Clinical Factors     
Patient age >40 years 0.013 6.132 0.107 1.393 
Donor age >40 years 0.362 0.183 0.299 0.353 
Female/male transplantation <0.0001 10.536 0.001 7.560 
CMV positivity 0.108 1.311 0.112 1.151 
HLA-mismatch 0.073 1.992 0.098 1.713 
Myeloablative conditioning 0.452 0.114 0.446 0.135 
Low intensity prophylaxis 0.211 0.371 0.337 0.213 
T cell depletion 0.304 0.245 0.529 0.079 
     
 
 
Table 5.3 Univariate analysis demonstrating the associations between clinical factors and acute 
and chronic GVHD.  P values showing a significant association (≤0.1) are shown in 
bold.  CMV, cytomegalovirus; HLA, human leukocyte antigen; GVHD, graft-versus-
host disease; P, P value; OR, odds ratio    
 
 
 
5.4.4 Correlation of the IL13 +2044 G/A Polymorphism with Acute and Chronic 
GVHD 
 
In all published studies to date, the A allele of the IL13 +2044 G/A polymorphism has 
been linked with disease susceptibility.  Consequently, only the A allele was examined 
for associations with HSCT outcome in this study.  The very low frequency of the AA 
genotype in our HSCT cohort (0.05% in both patients and donors) prevented disease 
association analysis with this genotype. 
 
Associations between the IL13 +2044 A allele and the incidence and severity of acute 
GVHD were examined in the entire cohort of 600 HSCT patients.  Associations 
between this allele and the incidence of chronic GVHD were analysed in 463 patients 
alive >100 days post-HSCT.  The results of the univariate analyses are shown in Table 
5.4.  No associations were observed between the A allele and overall acute GVHD 
(grades I-IV) or clinical acute GVHD (grades II-IV).  A strong correlation was however 
demonstrated between the A allele and the development of severe acute GVHD (grades 
III-IV).  HSCT patients possessing the IL13 +2044 A allele were more susceptible to 
higher grades of acute GVHD than patients with the G allele (22% versus 16% 
respectively, P=0.028 OR=3.977).  A significant association was also demonstrated 
between the A allele and chronic GVHD.  Patients receiving stem cell transplants from 
121 
 
donors with the IL13 +2044 A were more at risk of developing chronic GVHD than 
patients with IL13 +2044 G donors (59% versus 48% respectively, P=0.010 OR=5.808).  
 
 
                 
 Acute GVHD Grade   
 I-IV II-IV III-IV Chronic GVHD 
 P OR P OR P OR P OR 
         
IL13 +2044 A         
Patient 0.171 0.900 0.362 0.183 0.028 3.977 0.498 0.008 
Donor 0.304 0.345 0.404 0.101 0.201 0.701 0.010 5.808 
         
 
Table 5.4 Univariate analysis demonstrating the associations between the IL13 +2044 A allele and 
acute and chronic GVHD.  P values demonstrating an association (≤0.1) are shown in 
bold.  IL13, interleukin-13; GVHD, graft-versus-host disease; P, P value; OR, odds 
ratio  
 
 
 
The associations identified between the IL13 +2044 A allele and acute (grades III-IV) 
and chronic GVHD were tested for independence against confounding clinical factors 
using multivariate analysis.  The clinical factors entered into the analyses where those 
shown in section 5.4.3 to have a significant impact on the development of GVHD in this 
cohort.  The factors included were: patient age over 40 years, female to male 
transplantation and HLA-mismatch.  Acute GVHD grades I-IV and PBSC transplants 
were also included in the multivariate analysis for chronic GVHD, as both are 
considerable risk factors for the development of the condition (Atkinson et al. 1990; 
Bensinger et al. 2001).  The results of the multivariate analyses are shown in Table 5.5.   
 
Following multivariate analyses, the previously demonstrated associations between 
patient IL13 +2044 A and severe acute GVHD (grades III-IV) and donor IL13 +2044 A 
and chronic GVHD retained their significance (P=0.023 OR=2.260 and P=0.013 
OR=6.848 respectively).  Thus, the observed associations are independent of established 
clinical risk factors for HSCT outcome.  
 
Several clinical factors were also shown to be significantly associated with GVHD 
following multivariate analyses.  Patient age over 40 years, female to male 
transplantation and HLA-mismatch correlated with acute GVHD III-IV (P=0.048 
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OR=1.225, P=0.045 OR=1.884 and P=0.047 OR=1.453 respectively), whilst female to 
male transplantation, patient age over 40 years, PBSC transplantation and acute GVHD 
grades I-IV were linked to chronic GVHD (P=0.014 OR=6.447, P=0.049 OR=3.375, 
P=0.002 OR=12.646 and P<0.0001 OR=36.202 respectively).  These findings acted as a 
further control in this study, by validating the cohort analysed.  As all five factors are 
well recognised clinical risks in HSCT (Atkinson et al. 1990; Gratwohl et al. 1998; 
Bensinger et al. 2001), demonstrated associations with GVHD would be expected in an 
unbiased cohort.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.5 Multivariate analysis for severe acute (grades III-IV) and chronic GVHD.  Significant 
associations (P<0.05) are shown in bold.  GVHD, graft-versus-host disease; HLA, 
human leukocyte antigen; IL13; interleukin-13; PBSC, peripheral blood stem cell 
 
 
 
In an attempt to replicate the genetic associations demonstrated, the IL13 +2044 A allele 
was correlated with acute (grades III-IV) and chronic GVHD in a second cohort.  This 
population consisted of a randomly selected subset of the original HSCT cohort 
(n=300).  The A allele was again significantly linked with the development of severe 
acute (grades III-IV, patient) and chronic GVHD (donor) (P=0.018 OR=6.762 and 
P=0.011 OR=10.107 respectively).  Consequently, it is extremely likely that these 
associations are real and not merely a result of chance. 
 P Value Odds Ratio 
   
Acute GVHD III-IV   
Patient age >40 0.048 1.225 
Female/male transplantation 0.045 1.884 
HLA-mismatch 0.047 1.453 
Patient IL13 +2044 A allele 0.023 2.260 
   
Chronic GVHD 
 
 
 
 
  
Patient age >40 0.049 3.375 
Female/male transplant 0.014 6.447 
PBSC Transplants 0.002 12.646 
Acute GVHD I-IV <0.0001 36.202 
Donor IL13 +2044 A allele 0.013 6.848 
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The relationship between the IL13 +2044 G/A alleles and GVHD was also examined in 
separate cohorts of HLA-matched sibling (n=342) and unrelated donor (n=258) 
transplants.  Following univariate analyses, the previously described associations 
between patient IL13 +2044 A and severe acute GVHD (III-IV) and donor IL13 +2044 
A and chronic GVHD were demonstrated in both transplant groups.  The observed 
associations for unrelated donor transplantation were, however, almost twice as strong 
as those for HLA-matched sibling HSCT (acute GVHD III-IV, P=0.024 OR=3.722 and 
P=0.042 OR=1.794 respectively; chronic GVHD, P=0.015 OR=9.851 and P=0.034 
OR=5.063 respectively). 
 
To determine the significance of transplant type, the demonstrated associations between 
IL13 +2044 A and acute and chronic GVHD in both the HLA-matched sibling and 
unrelated donor HSCT cohorts were then tested against each other using multivariate 
analysis.  The three strongest confounding clinical factors for each outcome (acute III-
IV or chronic GVHD) were also included.  The results of the multivariate analyses are 
shown in Table 5.6. 
 
Following multivariate analyses, the associations between patient IL13 +2044 A and 
severe acute GVHD (III-IV) and donor IL13 +2044 A and chronic GVHD were still 
observable for both transplant types.  In the unrelated donor cohort, significance was 
retained; in fact both associations had gained in strength (acute GVHD III-IV, P=0.020 
OR=5.451; chronic GVHD, P=0.011 OR=11.087).  In the HLA-matched sibling cohort, 
however, the significance for both associations had been substantially reduced (acute 
GVHD III-IV, P=0.091 OR=0.798; chronic GVHD, P=0.076 OR=0.703).  The data 
therefore seems to suggest that even though it has an impact on GVHD in both HLA-
matched sibling and unrelated donor HSCT, the IL13 +2044 G/A polymorphism is of 
greater importance in the latter setting.       
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Table 5.6 Multivariate analysis of the IL13 +2044 G/A polymorphism in HLA-matched sibling 
versus unrelated donor transplants.  Significant associations (P<0.05) are shown in 
bold.  GVHD, graft-versus-host disease; HLA, human leukocyte antigen; P, patient; 
IL13; interleukin-13; HSCT, haematopoietic stem cell transplantation; PBSC, 
peripheral blood stem cell; D, donor 
 
 
 
5.4.5 Correlation of the IL13 +2044 G/A Polymorphism with Overall Survival 
 
Overall survival was defined as the total amount of time (in months) each patient 
survived post-HSCT and was measured from the date of transplantation to the date of 
death or most recent clinic appointment.  The relationship between the IL13 +2044 A 
allele and this outcome was examined in the entire cohort of 600 HSCT patients.  
Following univariate analysis, no correlations were demonstrated in either of the patient 
or donor groups (P=0.743 and P=0.868 respectively, Figure 5.1 A and B respectively).  
Due to the lack of associations at this stage, no further analyses were performed.   
 
To determine whether the absence of any significant associations was related to the 
HSCT cohort employed, clinical factors with already established links to post-transplant 
mortality were analysed.  The factors included were severe acute GVHD (III-IV) and 
disease relapse.  Correlations with overall survival were demonstrated; both factors 
were found to be significantly linked to increased mortality in our cohort (P<0.0001 and 
P=0.001 respectively, Figure 5.1 C and D).  These findings agree with those already 
published in the literature (Vogelsang et al. 1988; Gratwohl et al. 1998; Doney et al. 
 P Value Odds Ratio 
   
Acute GVHD III-IV   
Patient age >40 0.107 0.572 
Female/male transplantation 0.015 7.899 
HLA-mismatch 0.049 1.210 
P IL13 +2044 A allele in sibling HSCT 0.091 0.798 
P IL13 +2044 A allele in unrelated HSCT 0.020 5.451 
   
Chronic GVHD 
 
 
 
 
  
Female/male transplant 0.069 0.854 
PBSC Transplants 0.047 1.131 
Acute GVHD I-IV 0.007 15.331 
D IL13 +2044 A allele in sibling HSCT 0.076 0.703 
D IL13 +2044 A allele in unrelated HSCT 0.011 11.087 
125 
 
2003).  Thus, our inability to demonstrate any associations with the IL13 +2044 A allele 
was not cohort related, but was an observation of the apparent lack of associations 
between this allele and overall survival in our study.  
 
 
 
 
 
Figure 5.1 Overall survival analysis using Kaplan-Meier curves and the Log-Rank test.  
Correlation with patient (A.) and donor (B.) IL13 +2044 G/A, acute GVHD grades III-
IV (C.) and relapse (D.). P, P value; IL13, interleukin-13; GVHD, graft-versus-host 
disease 
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5.4.6  Correlation of the IL13 +2044 G/A Polymorphism with Relapse Incidence 
and TRM 
 
Relapse was defined as the reoccurrence of an original disease following a period of 
treatment.  As aplastic anaemia is a non-malignant disease, patients transplanted for this 
were not included in any analyses correlating the IL13 +2044 G/A polymorphisms with 
relapse.  Consequently, 16 patient/donor transplant pairs were excluded from this 
analysis and associations between the IL13 +2044 A allele and relapse incidence were 
examined in 156 HSCT patients.  The incidence of relapse was calculated for the IL13 
+2044 G and A alleles at 12, 24, 36, 48 and 60 months post-transplant.  Our findings 
demonstrate that disease relapse was lower at all five time points for the patients and 
donors with the A allele than those with the G allele (Table 5.7).  However, the 
difference did not reach significance in either group (patient, P=0.336; donor, P=0.453).  
The small nature of the relapse population investigated (n=172) may have prevented 
these findings reaching significance.  Thus, the examination of IL13 +2044 G/A alleles 
in a larger cohort of relapsed patients would be beneficial. 
 
 
 
 Cumulative  Incidence (95% CL) 
IL13 +2044 12M 24M 36M 48M 60M 
      
Patient      
A Allele 0.205 
(0.167-0.250) 
0.253 
(0.212-0.301) 
0.278 
(0.235-0.328) 
0.283 
(0.239-0.333) 
0.290 
(0.240-0.340) 
G Allele 0.267 
(0.217-0.333) 
0.306 
(0.261-0.386) 
0.371 
(0.310-0.447) 
0.388 
(0.324-0.465) 
0.397 
(0.332-0.476) 
      
Donor      
A Allele 0.194 
(0.157-0.239) 
0.257 
(0.215-0.306) 
0.281 
(0.237-0.331) 
0.289 
(0.245-0.341) 
0.295 
(0.249-0.347) 
G Allele 0.234 
(0.183-0.299) 
0.279 
(0.225-0.345) 
0.312 
(0.253-0.384) 
0.319 
(0.260-0.391) 
0.332 
(0.282-0.411) 
      
 
Table 5.7 Competing risk analysis for the IL13 +2044 G/A polymorphism and relapse incidence. 
   IL13, interleukin-13; 95% CL, 95% confidence limits (lower-upper); M, months 
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TRM was defined as death following transplantation, from all causes other than disease 
relapse.  The relationship between this outcome and the IL13 +2044 A allele was 
examined in 179 HSCT patients.  No significant difference was observed in the 
incidence of TRM at 12, 24, 36, 48 and 60 months post-HSCT between the G and A 
alleles in either the patient or donor groups (P=0.993 and P=0.950 respectively, Table 
5.8).    
 
As with overall survival, a clinical risk factor for TRM was analysed in order to confirm 
that the absence of any associations was not cohort related.  Gender mismatched (female 
to male) transplantation is a well recognised risk for TRM (Zwaan et al. 1989; Gratwohl 
et al. 2001), consequently, this factor was examined for associations in this study.  A 
strong link with TRM was demonstrated (P<0.001), thus, our cohort was not responsible 
for the lack of associations with the IL13 +2044 A allele. 
 
 
 
 Cumulative Incidence (95% CL) 
IL13 +2044 12M 24M 36M 48M 60M 
      
Patient      
A Allele 0.246 
(0.193-0.314) 
0.269 
(0.213-0.338) 
0.275 
(0.219-0.345) 
0.284 
(0.226-0.357) 
0.295 
(0.237-0.368) 
G Allele 0.244 
(0.204-0.291) 
0.258 
(0.217-0.306) 
0.271 
(0.229-0.319) 
0.287 
(0.244-0.338) 
0.303 
(0.257-0.356) 
      
Donor      
A Allele 0.249 
(0.196-0.314) 
0.265 
(0.211-0.333) 
0.275 
(0.233-0.356) 
0.284 
(0.226-0.335) 
0.293 
(0.248-0.345) 
G Allele 0.233 
(0.182-0.298) 
0.250 
(0.209-0.298) 
0.268 
(0.226-0.317) 
0.286 
(0.238-0.339) 
0.290 
(0.232-0.351) 
      
 
Table 5.8 Competing risk analysis for the IL13 +2044 G/A polymorphism and TRM. 
   IL13, interleukin-13; 95% CL, 95% confidence limits (lower-upper); M, months 
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5.5 Examination of the Functional Effects of IL-13 in GVHD 
 
5.5.1 Study Populations 
 
HSCT Cohort 
 
The functional effects of IL-13 in GVHD were studied in a cohort of 90 allogeneic 
HSCT patients and their donors.  This was an adult cohort (≥16 at the time of 
transplant) comprising 62 HLA-matched sibling transplants and 28 unrelated donor 
transplants.  HLA matching between patients and donors was performed by high 
resolution DNA-based typing for HLA-A, B, C, DRB1 and DQB1.  Complete matching 
at the 5 loci was observed for all transplant pairs. 
 
Cohort characteristics:  
The 90 HSCT patients included in this cohort were transplanted between November 
1983 and December 2006 at the Royal Victoria Infirmary, Newcastle upon Tyne, UK.  
All patients and donors were recruited and consented as part of the previously described 
‘Eurobank Project’ (section 5.3.1). 
 
Acute GVHD was assessable in those alive ≥30 days post-transplant and developed in 
53 patients.  37 patients had no acute GVHD (grade 0), 17 grade I, 24 grade II, 8 grade 
III and 4 had grade IV.  Chronic GVHD was assessable from 100 days post-transplant 
in 71 patients.  41 of these patients developed the condition.  All transplant patients 
were prepared for HSCT with low intensity (n=49) or myeloablative conditioning 
(n=41) regimens and 56% (n=50) were transplanted with T cell depleted stem cell 
grafts.  46 patients were given high intensity GVHD prophylaxis (CsA plus MTX), 
whilst 44 received CsA monotherapy.  The survival rate for this cohort was 52% (n=47) 
and causes of death included relapse, infection and GVHD.  Table 5.9 shows the 
demographic characteristics of the HSCT cohort examined in this aspect of the study.           
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Table 5.9 Characteristics of the HSCT cohort (n=90). 
CMV, cytomegalovirus; CsA, cyclosporine A; MTX, methotrexate; TCD, T cell 
depletion 
 
 
TRANSPLANT PATIENTS 
Median Age      38 years (range 19-57) 
      Number in each group 
Gender 
 Male      55 
 Female      35 
 Female to Male HSCT    25 
 
CMV Status 
 Positive     42 
 Negative     48 
 
Underlying Disease 
 Acute Lymphoblastic Leukaemia  14 
 Acute Myeloid Leukaemia   28 
 Chronic Myeloid Leukaemia   15 
 Hodgkin disease      7 
 Non-Hodgkin Lymphoma   13 
  Plasma Cell Neoplasm      7 
  Aplastic Anaemia      2 
  Other        5 
Conditioning Therapy 
   Low intensity      49 
   Myeloablative      41 
 
GVHD Prophylaxis 
   CsA       44 
   CsA and MTX      46 
 
  TCD       50 
 
 
 
TRANSPLANT DONORS 
 
Median Age      37 years (range 16-58)   
       Number in each group 
Gender  
   Male        51 
   Female        39 
 
CMV Status 
   Positive       37 
   Negative       51 
   Unknown         2 
 
130 
 
Control Cohort 
 
18 Newcastle laboratory staff volunteers were employed as healthy controls when IL-13 
expression in vivo was examined.  The volunteer group comprised 5 males and 13 
females, with a median age of 39 years (range 27-52). 
 
5.5.2 IL-13 Expression in the In Vitro Human Skin Explant Model of Acute GVHD 
 
In this aspect of the study allogeneic MLCs were used to mimic the allo-response 
produced following HSCT and the human skin explant assay was utilised as an in vitro 
model of acute GVHD (sections 3.9 and 3.10).  IL-13 expression during these assays 
was examined in order to establish the roles, if any that IL-13 plays in the development 
of acute GVHD. 
 
The cohort employed comprised of 90 HSCT patients with MLC supernatants and 
GVHR grades.  The severity of GVHR ranged from I-IV; 17 human skin explants were 
found to give a histopathological grade of I, 12 grade II, 57 grade III and 4 human skin 
explants were found to give a grade IV.  IL-13 quantification was achieved using the 
Human IL-13 Development ELISA kit described in section 3.13.            
 
Comparison of IL-13 Expression in Autologous and Allogeneic MLC Supernatants 
 
To determine if IL-13 expression in allogeneic MLC supernatants was a consequence of 
an allo-response between donor and patient cells, IL-13 levels in autologous (patient 
cells only as stimulator and responder) and allogeneic MLC supernatants were 
compared.  IL-13 levels were found to be significantly higher in the latter samples.  In 
some cases, the IL-13 levels observed in the allogeneic supernatants were over 5 times 
greater than those in the autologous MLCs.  The mean (± standard error of the mean 
(SEM)) IL-13 level (pg/ml) in the allogeneic MLC supernatants was 101.89 ± 15.11 
compared to only 46.19 ± 2.94 in the autologous supernatants (P=0.040, Figure 5.2).  
Thus, the IL-13 expression observed in the allogeneic MLC supernatant samples was a 
consequence of allo-recognition between donor and patient cells.  
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Figure 5.2 Comparison of IL-13 expression (pg/ml) in autologous (n=90) and allogeneic (n=90) 
MLC supernatants.  The mean (± SEM) level of IL-13 was significantly higher in the 
supernatants from allogeneic MLCs (P=0.040).  IL-13, interleukin-13; P, P value; 
MLC, mixed lymphocyte culture 
 
 
The Relationship between IL-13 Expression in MLC Supernatants and GVHR 
Grade 
 
Comparison of IL-13 levels in allogeneic MLC supernatants with human skin explant 
GVHR grades demonstrated an increase in IL-13 expression with increasing GVHR 
severity (Figure 5.3).  The mean (± SEM) IL-13 level (pg/ml) for GVHR grades II-IV 
was 117.30 ± 18.45 compared to only 34.80 ± 19.26 for grade I (P=0.002, Figure 5.4A).  
Moreover, the mean (± SEM) IL-13 level for GVHR grades III-IV was 125.70 ± 21.59 
compared to only 53.44 ± 15.96 for grades I-II (P=0.008, Figure 5.4B).             
 
Figure 5.3 Relationship between GVHR grade in the human skin explant model and IL-13 
expression (pg/ml) in allogeneic MLC supernatants.  IL-13 expression increases with 
increasing severity of GVHR.  IL-13, interleukin-13; GVHR, graft-versus-host reaction  
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Figure 5.4 Correlation between GVHR grade in the human skin explant model and IL-13 
expression (pg/ml) in allogeneic MLC supernatants.  A. The mean (± SEM) IL-13 level 
was significantly higher for GVHR grades II-IV (n=73, P=0.002).  B. The mean (± 
SEM) IL-13 level was significantly higher for GVHR grades III-IV (n=61, P=0.008).  
IL-13, interleukin-13; P, P value; GVHR, graft-versus-host reaction   
 
 
 
Cytokine Profile of MLC Supernatants 
 
To establish if the IL-13 expression observed was affected by other cytokines 
implicated in the pathogenesis of acute GVHD, the cytokine profile of the allogeneic 
MLC supernatants was determined.  Cytokine quantification was achieved using the 
Human Soluble Protein CBA kit described in section 3.14.  The cytokines measured 
were IL-2, IL-4, IL5, IL-10, TNFα and IFNγ.  The mean (± SEM) levels (pg/ml) were 
18.40 ± 1.50, 2.46 ± 0.92, 11.02 ± 2.88, 24.52 ± 4.38, 97.50 ± 16.50, 49.61 ± 11.49 and 
56.44 ± 10.66 for IL-2, IL-4, IL-5, IL-10, IL-13, TNFα and IFNγ respectively (Figure 
5.5).  IL-13 expression was demonstrated to be significantly higher than IL-2, IL-4, IL-5 
and IL-10 in the MLC supernatants (P<0.0001).  The levels were also higher when 
compared to those of TNFα and IFNγ, but for these cytokines the difference did not 
reach significance (P=0.070).   
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Figure 5.5 Cytokine profile of allogeneic MLC supernatants.  The mean (± SEM) IL-13 level 
(pg/ml) was significantly higher than the mean (± SEM) levels of IL-2, IL-4, IL-5 and 
IL-10 (P<0.0001).  IL-13 expression was also higher than that of TNFα and IFNγ, 
although the difference did not reach significance (P=0.070).  P, P value; IL, 
interleukin; TNF, tumour necrosis factor alpha; IFNG, interferon gamma 
 
 
 
To ensure that the IL-13 expression observed in the allogeneic MLC supernatants was 
independent of IL-2, IL-4, IL-5, IL-10, TNFα and IFNγ expression, the Spearman’s 
Rank Correlation test was also performed.  This test was used to determine the 
individual relationship between IL-13 and each of the other cytokines examined.  
Following the analyses, no significant correlation could be demonstrated between the 
levels of IL-13 and the levels of IL-2 (P=0112 r=0.219 r
2
=0.048), IL-4 (P=0.231 
r=0.139 r
2
=0.019), IL-5 (P=0150 r=0.178 r
2
=0.031), IL-10 (P=0.472 r=0.098 r
2
=0.009), 
TNFα (P=0.155, r=0.156, r2=0.024) or IFNγ (P=0.342, r=0.106, r2=0.011) in the 
allogeneic MLC supernatant samples.  Thus, the IL-13 expression observed was 
independent of all other cytokines tested. 
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The Relationship between IL-13 Expression in MLC Supernatants and GVHD  
 
IL-13 expression in MLC supernatants was also correlated with acute and chronic 
GVHD in the clinical setting.  In contrast to the findings of the human skin explant 
model, where IL-13 levels increased with GVHR severity; when correlated with clinical 
acute GVHD, IL-13 expression was found to decrease with GVHD severity (Figure 
5.6A).  In addition, mean (± SEM) IL-13 levels (pg/ml) were found to be lower in 
overall acute GVHD (grades I-IV;  mean (± SEM) IL-13 level: grade 0, 109.60 ± 28.06 
grades I-IV, 98.02 ± 20.53), clinical acute GVHD (grades II-IV; mean (± SEM) IL-13 
level: grades 0-I, 115.20 ±281 grades II-IV, 90.76 ± 19.63) and severe acute GVHD 
(grades III-IV, mean (± SEM) IL-13 level: grades 0-II, 108.40 ± 18.70 grades III-IV, 
65.66 ± 25.96) (Figure 5.6B-C).  However, none of these observed associations reached 
significance (P=0.677, P=0.905 and P=0.394 respectively).  
 
 
Figure 5.6 Correlation between IL-13 expression (pg/ml) in MLC supernatants and clinical acute 
GVHD.  A. IL-13 levels decrease with increasing GVHD severity.  B. The mean (± 
SEM) IL-13 level was lower for overall acute GVHD (grades I-IV (n=53), P=0.677).  
C. The mean (± SEM) IL-13 level was lower for clinically significant acute GVHD 
(grades II-IV (n=36), P=0.905).  D. The mean IL-13 level was lower for severe acute 
GVHD (grades III-IV (n=12), P=0.394).  IL-13, interleukin-13; P, P value; GVHD, 
graft-versus-host disease 
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In terms of chronic GVHD, IL-13 expression was found to be lower for HSCT patients 
with the condition than those without it.  The mean (± SEM) IL-13 level (pg/ml) for 
patients with chronic GVHD was only 85.57 ± 21.25 compared to 101.10 ± 30.85 for 
unaffected individuals (Figure 5.7).  Again, the difference did not reach significance 
(P=0.681). 
 
 
 
 
 
Figure 5.7 Correlation between IL-13 expression (pg/ml) in MLC supernatants and Chronic 
GVHD.  The mean (± SEM) IL-13 level was lower for patients with chronic GVHD 
(n=41) than those without the condition (n=30, P=0.681).  IL-13, interleukin-13; P, P 
value; GVHD, graft-versus-host disease 
 
 
 
IL-13 expression in MLC supernatants was also correlated with overall survival, relapse 
incidence and TRM in our HSCT cohort.  No significant associations were observed 
with any of these clinical outcomes (P=0.361, P=0.404 and P=0.319 respectively). 
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5.5.3 IL-13 Serum Expression and Acute and Chronic GVHD 
 
Serum samples were obtained from HSCT patients at eight time points across the 
transplant period (section 3.12).  The time points employed for sampling were day -7 
(pre-HSCT, taken prior to the administration of any conditioning regimens), day 0 
(taken immediately prior to stem cell infusion), day 7, day 14, day 28, 3 months, 6 
months and 12 months.  These time points were chosen to allow intensive monitoring of 
peri-transplant IL-13 expression with respect to both acute and chronic GVHD.  Serum 
samples were also obtained from 18 laboratory staff volunteers at the same eight time 
points.  These individuals were employed as controls in this aspect of the study (section 
5.6.1). 
 
The cohort examined comprised of 30 of the original 90 HSCT patients with complete 
sets of serum samples (8 samples) and clinical data on acute and chronic GVHD.  Acute 
GVHD was assessable in all 30 patients and developed in 24.  The severity of GVHD 
ranged from grades 0-III; 6 patients developed no GVHD, 10 grade I, 10 grade II and 4 
grade III.  Chronic GVHD was assessable in 20 patients and developed in 12.  IL-13 
quantification was achieved using the Human IL-13 Low Level ELISA Kit described in 
section 3.13. 
 
Comparison of IL-13 Serum Expression in HSCT Patients and Healthy Controls 
 
To determine the effects of HSCT on IL-13 expression, IL-13 serum levels in patients 
and healthy controls were compared.  IL-13 expression was found to be significantly 
higher in the HSCT cohort (P<0.0001 at all time points, Figure 5.8).  Mean (± SEM) 
patient IL-13 levels (pg/ml) were over 5 times greater than those of the healthy controls 
at all time points examined.  Age and gender were found to have no effect on IL-13 in 
either group.  Mean (± SEM) IL-13 serum levels in the healthy controls remained 
relatively constant (0.86 ± 0.22 ,0.77 ± 0.21, 0.89 ± 0.21, 0.91 ± 0.20, 0.90 ± 0.22, 0.86 
± 0.22, 0.87 ± 0.21 and 0.85 ± 0.21 pg/ml respectively), thus, the variability observed in 
patient IL-13 expression (5.85 ± 0.63, 8.50 ± 0.89, 5.46 ± 0.70, 8.42 ± 1.04, 8.09 ± 0.98, 
9.37 ± 0.73, 5.83 ± 0.41 and 5.06 ± 0.35 pg/ml respectively) is likely to be transplant 
and/or treatment related rather than a naturally occurring phenomenon.  The mean (± 
SEM) IL-13 expression level observed in the transplant patients on day -7 was not 
however transplant or treatment related; as all serum samples utilised at this time point 
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were obtained on the day of hospital admission and prior to the administration of any 
conditioning, transplant or treatment modalities (pre-transplant), it is more likely that 
the higher expression observed was patient or disease related.  The IL-13 serum levels 
demonstrated for the transplant patients on day -7 ranged from 1.07-13.82pg/ml.  As no 
clear cause was obvious, the high degree of variability observed at this time point was 
of great interest and warranted further investigation.  As previously published studies 
have correlated pre-transplant release of inflammatory cytokines, such as TNFα and IL-
10 with HSCT outcome (Holler et al. 1995; Holler et al. 2000), it is possible that similar 
associations exist with IL-13.  Consequently, the prognostic significance of IL-13 serum 
expression prior to transplantation will be examined in the following chapter. 
 
 
 
 
 
 
Figure 5.8 Comparison of IL-13 serum expression (pg/ml) in HSCT patients (n=30) and healthy 
volunteers (n=18).  Mean (± SEM) IL-13 expression was significantly higher in the 
HSCT patients at day -7, day 0, day 7, day 14, day 28, 3 months, 6 months and 12 
months (P<0.0001).  IL-13, interleukin-13; HSCT, haematopoietic stem cell 
transplantation; D, day; M, months 
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The Relationship between IL-13 Serum Expression and Acute GVHD 
 
IL-13 serum expression was analysed between day -7 and 3 months amongst HSCT 
patients who did and did not develop GVHD grades I-III post-transplant; the traditional 
window for acute GVHD (Figure 5.9).  IL-13 levels in the GVHD (grades I-III) patients 
were found to be higher than those without the disease (grade 0) at all time points.  
Despite this, the difference between the two groups only reached significance at day 28 
and 3 months (P=0.043 and P=0.037 respectively).  Mean (± SEM) IL-13 levels (pg/ml) 
at these time points were 9.24 ± 1.30 and 9.76 ± 0.69 respectively for patients with 
acute GVHD (grades I-III) compared to 6.02 ± 1.08 and 6.43 ± 1.23 respectively for 
those with no acute GVHD.      
 
 
 
Figure 5.9 Comparison of IL-13 serum expression (pg/ml) in HSCT patients with grades I-III 
acute GVHD (n=24) and those with no acute GVHD (n=6).  Mean (± SEM) IL-13 
expression was higher in the HSCT patients with grades I-III acute GVHD at day -7, 
day 0, day7, day14, day 28 and 3 months.  An asterisk denotes a significant difference 
between the two groups at the designated time point (P=0.043 and P=0.37 respectively).  
IL-13, interleukin-13; GVHD, graft-versus-host disease; D, day; M, months 
    
 
 
IL-13 serum expression was also analysed amongst HSCT patients who did and did not 
develop clinical acute GVHD (grades II-III) between day -7 and 3 months post-
transplant (Figure 5.10).  Again, IL-13 levels were found to be higher between day 0 
and 3 months in the patients with clinical acute GVHD (grades II-III) compared to those 
with minimal or no disease (grade 0-I), although, the difference between the two groups 
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was considerably reduced and consequently did not reach significance at any point.  In 
contrast, pre-transplant levels (day -7) were found to be higher in the patients with 
grades 0-I GVHD compared to those with grades II-III.  However, the difference 
between the two groups at this time point was minimal.  Mean (± SEM) pre-transplant 
IL-13 levels (pg/ml) for patients with acute GVHD grades 0-I was 6.08 ± 0.93 
compared to 5.58 ± 0.86 for those with grades II-III.     
   
 
 
Figure 5.10 Comparison of IL-13 serum expression (pg/ml) in HSCT patients with grades II-III 
acute GVHD (n=14) and those with minimal or no acute GVHD (n=16).  Mean (± 
SEM) IL-13 expression was higher in the HSCT patients with grades II-III acute 
GVHD at all time points except day -7.  IL-13, interleukin-13; GVHD, graft-versus-
host disease; D, day; M, months 
 
 
 
Correlations could not be made between IL-13 serum expression and severe acute 
GVHD (grades III-IV) in this study.  No patients in our HSCT cohort developed grade 
IV acute GVHD and only 4 developed grade III. 
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The Relationship between IL-13 Serum Expression and Chronic GVHD 
 
IL-13 serum expression was compared amongst HSCT patients who did and did not 
develop chronic GVHD between 3 and 12 months post-transplant; the traditional 
window for this condition.  IL-13 levels were found to be higher at 3 months, 6 months 
and 12 months for the patients with chronic GVHD (Figure 5.11A-C).  However, the 
difference between the two groups only reached significance for the latter two time 
points (P=0.008 and P=0.016 respectively).  Mean (± SEM) IL-13 levels (pg/ml) at 6 
and 12 months were 6.93 ± 0.41 and 6.00 ± 0.38 respectively for the patients with 
chronic GVHD compared to 4.17 ± 0.27 and 3.66 ± 0.18 respectively for those without 
chronic GVHD. 
 
 
 
 
 
 
Figure 5.11 Comparison of IL-13 serum expression (pg/ml) in HSCT patients with chronic GVHD 
(n=12) and those without chronic GVHD (n=8).  A. Mean (± SEM) IL-13 expression 
was slightly higher at 3 months post-transplant in the patients with chronic GVHD 
(P=0.779).  B & C. Mean (± SEM) IL-13 expression was significantly higher in chronic 
GVHD patients at 6 months and 12 months post-transplant (P=0.008 and P=0.016 
respectively).  IL-13, interleukin-13; P, P value; GVHD, graft-versus-host disease 
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The Relationship between Serum IL-13 Expression and Other HSCT Outcomes 
 
IL-13 serum expression was also correlated with overall survival and relapse incidence 
in this study.  No significant associations were observed between IL-13 levels and these 
two clinical outcomes at any of the time points analysed (data not shown).  IL-13 
expression could not be correlated with TRM, as all the observed deaths in our cohort 
were relapse related. 
 
5.5.4 The Relationship between IL-13 Expression and the IL13 +2044 G/A 
Polymorphism 
 
Patient and donor PHA stimulated PBMC supernatants (section 3.11) were used to 
determine if the elevated IL-13 expression observed in patients with acute and chronic 
GVHD (section 5.6.3) was attributable to the IL13 +2044 G/A polymorphism (section 
5.5.4).  The previously examined serum cohort (section 5.6.3) was not employed in this 
aspect of the study due to its small nature (n=30).  All PBMCs employed in the mitogen 
stimulation assays were obtained before patients received any preparative treatments 
and prior to transplantation, thus IL-13 levels in these samples were not affected by 
conditioning regimens, the transplant process or GVHD prophylaxis drugs.     
 
The cohort examined comprised 60 of the original 90 HSCT patients with PHA 
stimulated supernatants for both patients and donors, IL13 +2044 G/A genotypes and 
clinical data on acute and chronic GVHD.  Acute GVHD was assessable in all 60 
patients and developed in 38.  The severity of GVHD ranged from grade 0-IV; 20 
patients developed no GVHD, 9 grade I, 23 grade II, 5 grade III and 1 patient developed 
grade IV acute GVHD.  Chronic GVHD was assessable in 51 patients and developed in 
33.  IL-13 quantification was achieved using the Human IL-13 Development ELISA kit 
described in section 3.13. 
 
Comparison of IL-13 Expression in Supernatant from PHA Stimulated and 
Unstimulated PBMCs 
 
Prior to any correlation with the IL13 +2044 G/A polymorphism, IL-13 release from 
PHA stimulated PBMCs was compared to spontaneous IL-13 release from unstimulated 
PBMCs (medium alone control samples).  This was to ensure that IL-13 expression was 
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a consequence of PHA activation.  Expression was found to be significantly higher in 
the stimulated samples.  In some cases, IL-13 release from PHA stimulated PBMCs was 
over 20 times greater than that from unstimulated cells.  The mean (± SEM) IL-13 level 
(pg/ml) in PHA stimulated supernatants was 1292.00 ± 112.10 compared to only 129.10 
± 20.45 in unstimulated supernatants (P<0.0001). 
 
Correlation between IL-13 Expression and Patient and Donor IL13 +2044 G/A 
Alleles 
 
Correlation of IL-13 levels in PHA stimulated supernatants with patient IL13 +2044 
G/A demonstrated that even though IL-13 levels were slightly higher for patients with 
IL13 +2044 A, there was no significant difference in IL-13 expression between the G 
and A alleles (P=0.171, Figure 5.12A).  The mean (± SEM) IL-13 level (pg/ml) for 
patient IL13 +2044 A was 1312.00 ± 227.40 compared to 1174.00 ± 213.50 for patient 
IL13 +2044 G.  Similar findings were also observed for donor IL13 +2044 G/A.  Donors 
with IL13 +2044 A were shown to have slightly higher IL-13 levels than those with 
IL13 +2044 G, however, the difference between the two groups did not reach 
significance (P=0.479, Figure 5.12B).  The mean (± SEM) IL-13 level (pg/ml) for donor 
IL13 +2044 A was 1384.00 ± 231.20 compared to 1242.00 ± 189.90 for donor IL13 
+2044 G.  It therefore seems unlikely that the IL13 +2044 G/A polymorphism was 
responsible for the higher IL-13 expression observed in the HSCT patients with acute 
and chronic GVHD.     
 
Figure 5.13 Correlation between IL-13 expression (pg/ml) in PHA stimulated supernatants and 
patient and donor IL13 +2044 G/A alleles.  Mean (± SEM) IL-13 expression was higher 
for both patients (A. n=60) and donors (B. n=60) with the IL13 +2044 A allele 
(P=0.171 and 0.479 respectively).  IL-13, interleukin-13; P, P value  
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In the genetic aspect of this study, patients with the IL13 +2044 A allele were shown to 
be more susceptible to acute GVHD (section 5.5.4); similar findings were demonstrated 
in this HSCT cohort.  62% of the patients with IL13 +2044 A developed clinical acute 
GVHD (grade II-IV) post-transplant, whereas only 46% of those with the G allele 
developed the condition (P=0.010 OR=7.991).  Furthermore, 14% of the IL13 +2044 A 
patients had severe acute GVHD (grade III-IV) compared to only 8% of the IL13 +2044 
G patients (P=0.037 OR=3.219).  The genetic study also demonstrated that the HSCT 
patients receiving stem cell transplants from donors with the IL13 +2044 A allele were 
more susceptible to chronic GVHD.  In this cohort, 67% of the patients with IL13 
+2044 A donors developed chronic GVHD post-transplant, whilst only 59% of the 
patients with IL13 +2044 G donors developed the condition (P=0.026 OR=5.016). 
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5.6 Discussion 
 
Polymorphisms in the gene encoding IL13 have been widely studied for associations 
with disease susceptibility.  IL13 +2044 G/A is of particular interest because it occurs in 
approximately 25% of the general population and results in an amino acid substitution 
(Vladich et al. 2005).  Consequently, association studies have mainly been focused on 
this polymorphism.  Asthma and allergy phenotypes have been thoroughly investigated 
due to the role that IL-13 plays in these biological pathways.  In asthma, the IL13 +2044 
A allele has been strongly linked with disease occurrence.  Heinzmann et al 
demonstrated an association between IL13 +2044 A and allergic and non-allergic 
asthma in British and Japanese subjects (Heinzmann et al. 2000).  The association was 
later confirmed by Arima et al (2002) and Heinzmann et al (2003) in children with 
bronchial asthma.  IL13 +2044 G/A has also been linked with elevated serum IL-13 
levels in asthmatics.  IL13 +2044 A homozygous individuals have been shown to have 
significantly higher serum IL-13 levels than G homozygous individuals (Heinzmann et 
al. 2000; Arima et al. 2002).     
 
The IL13 +2044 G/A polymorphism has also been linked with IgE, a crucial pathogenic 
component of allergy (Punnonen et al. 1993; Minton 2008).  The IL13 +2044 A allele 
has been correlated with elevated total serum IgE levels, a characteristic seen in a 
number of allergic phenotypes (Graves et al. 2000; Liu et al. 2000; Heinzmann et al. 
2003; Wang et al. 2003; Kabesch et al. 2006; Maier et al. 2006; Hunningshake et al. 
2007).  This allele has also been shown to strongly associate with atopy (He et al. 
2003), atopic dermatitis (Liu et al. 2000; Tsunemi et al. 2002), food sensitization 
(Zitnik et al. 2009) and a grouped phenotype that includes eosinophilia, elevated IgE 
and positive skin tests (DeMeo et al. 2002).  In terms of transplantation, no studies 
associating IL13 polymorphisms and disease susceptibility have been published to date.  
Elevated IL-13 levels have however, been linked to chronic lung allograft rejection and 
acute GVHD (Jordan et al. 2004; Keane et al. 2007).    
 
Polymorphism analysis of IL13 +2044 G/A in this study has demonstrated a significant 
association with the development of acute GVHD following HSCT.  Transplant patients 
possessing the A allele were more susceptible to severe acute GVHD (grades III-IV) 
than those with the G allele.  This association was observed in the whole HSCT cohort 
(n=600, P=0.028 OR=3.977) and a smaller validation cohort that consisted of 50% of 
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the original transplant population selected at random (n=300, P=0.018 OR=6.762).  The 
association also retained its significance when established clinical risk factors for acute 
GVHD were entered into the analysis (P=0.023 OR=2.260) and when the cohort was 
stratified into HLA-matched sibling and unrelated donor transplants (P=0.042 
OR=1.794 and P=0.024 OR=3.722 respectively).  It therefore seems likely that the IL13 
+2044 G/A polymorphism is an independent risk factor for severe acute GVHD 
following HLA-matched sibling and unrelated donor HSCT. 
 
Our hypothesis from the outset was that, as acute GVHD is considered as a Th1 disease 
(Antin and Ferrara 1992; Ferrara 1998), IL-13; a Th2 cytokine, would have anti-
inflammatory actions and therefore the IL13 +2044 G/A polymorphism would be 
beneficial to the patient.  However, the results were surprising and seem to challenge the 
notion that acute GVHD is purely a Th1 cytokine driven response.  As IL-13 up-
regulates MHC class II expression on monocytes, macrophages and B cells (Punnonen 
et al. 1993; Zurawski and de Vries 1994; de Vries 1998), it is possible that this cytokine 
could augment acute GVHD through enhanced antigen presentation to host reactive 
donor T cells.  IL-13 may also contribute to the pathogenesis of acute GVHD through 
the activation and recruitment of immune cells, such as eosinophils, mast cells, 
monocytes and B cells (Hershey 2003).  
 
The development of chronic GVHD was also shown to be significantly associated with 
the IL13 +2044 G/A polymorphism in this study.  Patients receiving stem cells 
transplants from donors with the IL13 +2044 A were more susceptible to chronic 
GVHD than patients with IL13 +2044 G donors.  This association was observed in the 
whole HSCT cohort (n=600, P=0.010 OR=5.808), the smaller validation cohort (n=300, 
P=0.011 OR=10.107) and when established clinical risk factors for chronic GVHD were 
included in the analysis (P=0.013 OR=6.848).  The association also retained its 
significance when the cohort was stratified into HLA-matched sibling and unrelated 
donor transplants (P=0.034 OR=5.063 and P=0.015 OR=9.851 respectively).  It is 
therefore likely that the IL13 +2044 G/A polymorphism is also an independent risk 
factor for chronic GVHD following HLA-matched sibling and unrelated donor HSCT.    
 
Unlike acute GVHD, the pathophysiology of chronic GVHD remains largely unclear 
(Joseph et al. 2008).  However, animal and human studies have demonstrated the 
presence of Th2 CD4+ allo-reactive T cells, a predominance of Th2 cytokines and B 
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cell rather than T cell activation in chronic GVHD (Allen et al. 1993; Tanaka et al. 
1996; Slayback et al. 2000; Horwitz and Sullivan 2006).  In addition, the elevation of 
Th2 cytokines has been shown to be consistent with the clinical manifestations of the 
condition (Ratanatharathorn et al. 2001).  It therefore seems completely feasible that IL-
13, a Th2 cytokine, could play a role in the development of chronic GVHD, a Th2 
disease.  Furthermore, as IL-13 is involved in the activation and proliferation of B cells 
(Punnonen et al. 1993; Chomarat and Banchereau 1998), a role for this cytokine in the 
development of the autoimmune component of chronic GVHD is plausible. 
 
Polymorphism analysis of IL13 +2044 G/A with respect to transplant type, also 
demonstrated significant associations between the IL13 +2044 A allele and the 
development of acute and chronic GVHD.  In both HLA-matched sibling and unrelated 
donor transplants, patients with IL13 +2044 A were more susceptible to severe acute 
GVHD (grades III-IV) and those with IL13 +2044 A transplant donors were more likely 
to develop chronic GVHD (acute GVHD III-IV, P=0.042 OR=1.794 and P=0.024 
OR=3.722 respectively; chronic GVHD, P=0.034 OR=5.063 and P=0.015 OR=9.851 
respectively), however the associations were much more significant in the latter group.  
This was further supported when HLA-matched sibling and unrelated donor transplants 
were tested against each other using multivariate analysis.  The demonstrated 
associations between patient IL13 +2044 A and acute GVHD (III-IV) and donor IL13 
+2044 A and chronic GVHD were again observable in both groups (acute GVHD III-
IV: P=0.091 OR=0.798, P=0.020 OR=5,451; chronic GVHD: P=0.076 OR=0.703, 
P=0.011 OR=11.087 respectively), however, they were found to be significantly 
stronger in the unrelated donor HSCT cohort.  Although this data requires replication, 
the stronger associations demonstrated in the unrelated donor population seem to 
suggest that the IL13 +2044 G/A polymorphism is of greater importance in this 
transplant setting.  The variation in association strengths observed for the HLA-matched 
sibling and unrelated donor cohorts is likely to result from differences in the biology 
(unrelated donor HSCT is typically associated with a greater degree of HLA disparity, 
enhanced allo-recognition and a heightened immune response compared to HLA-
matched sibling transplantation) and clinical protocols of the two transplant types.  As 
discussed previously (section 4.11), these differences also highlight the need for non-
HLA polymorphisms to be analysed independently in both transplant populations, as 
significant associations identified in one may not necessarily be reflective of the other. 
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The origins of the genetic associations demonstrated further substantiate the findings of 
this study.  In all groups analysed, patient IL13 +2044 A correlated with acute GVHD 
and donor IL13 +2044 A correlated with chronic GVHD, both of which fit with the 
biology of HSCT and the time-scale for GVHD development post-transplant.  Cells 
typically switch from patient to donor origin between 3-6 months post-HSCT, the time 
period traditionally used to differentiate between acute and chronic GVHD.      
 
Polymorphism analysis of IL13 +2044 G/A failed to demonstrate any significant 
associations with overall survival or TRM in this study.  Although the associations did 
not reach significance, the incidence of disease relapse was however shown to be lower 
at 12, 24, 36, 48 and 60 months post-transplant for patients and donors with the IL13 
+2044 A allele (patient, P=0.336; donor, P=0.453).  As the relapsed population analysed 
comprised of only 172 HSCT patients, the small nature of this cohort may have 
prevented these findings reaching significance (type II error).  It would therefore be of 
interest to examine IL13 +2044 G/A in a larger cohort of relapsed patients.  Sample 
collection for this European study is ongoing and should facilitate such an investigation 
in the future.  Confirmation of these findings would however, further support the 
observed associations between IL13 +2044 A and GVHD in our HSCT cohort.  Animal 
and human studies have demonstrated that acute and chronic GVHD lower the 
incidence of relapse via the GVL effect (Weiden et al. 1979; Weiden et al. 1981; 
Horowitz et al. 1990).  Host reactive donor T cells that produce GVHD are also capable 
of destroying residual malignant cells, thereby reducing the possibility of the disease 
reoccurring (Kolb 2008).  The potency of the GVL effect is illustrated by the ability of 
DLI to induce a durable remission in patients with relapsed leukaemia following 
transplantation (Kolb et al. 1995; Collins et al. 1997).  Thus, if patients with the IL13 
+2044 A allele are more susceptible to acute and chronic GVHD it is possible that they 
will get less relapse through this mechanism.    
   
Currently, there is no solid link in the literature between the IL13 +2044 G/A 
polymorphism and altered IL-13 expression.  However, higher serum IL-13 levels in 
asthmatic individuals with the IL13 +2044 A,A genotype have been reported in two 
independent studies (Heinzmann et al. 2000; Arima et al. 2002).  Considering these 
findings, in combination with the genetic associations already demonstrated in this 
study, it would seem biologically plausible that polymorphic variation in the IL13 gene 
could influence IL-13 levels and the subsequent development of GVHD.   
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At present, IL-13 functional studies in the HSCT setting are extremely limited.  Only a 
single study examining IL-13 expression in relation to GVHD has been published to 
date.  In this study, Jordan et al (2004) demonstrated a significant association between 
high IL-13 production by donor T cells in allogeneic MLCs and the development of 
severe acute GVHD following HSCT.  In this current study, IL-13 expression in 
allogeneic MLCs was correlated with the severity of acute GVHD using an in vitro 
model (the human skin explants model of acute GVHD).  IL-13 expression by donor 
cells was found to increase with increasing GVHR severity (Figure 5.3) and the highest 
IL-13 levels were observed in the patients with the most severe GVHR grades (grades 
III-IV; P=0.008, Figure 5.4).  Thus, our findings agree with those of Jordan et al (2004) 
and seem to suggest that IL-13 production by donor T cells during the allo-response is 
accountable for at least some of the pathology associated with severe acute GVHD.  
However, the findings of these studies differ greatly to those of a recent murine study, 
where IL-13 was shown to abrogate acute GVHD by down-regulation of TNFα 
production (Hildebrandt et al. 2007).  Hildebrandt et al (2007) suggested that since allo-
reactive T cells are a significant source of IL-13, the observed correlation between IL-
13 expression in MLCs and GVHD simply reflected an overall allo-activation state of 
the donor T cells rather than a direct link between IL-13 and GVHD severity.      
 
IL-13 expression in allogeneic MLCs was also correlated with clinical acute and chronic 
GVHD in this study.  No significant associations were observed with either form of 
GVHD; however, the relationship between IL-13 expression and acute GVHD was 
seemingly opposite to that of the human skin explant model; IL-13 levels were found to 
decrease with increasing acute GVHD grades (Figure 5.6).  The most likely explanation 
for this discrepancy is that the human skin explant model is a clean system.  This in 
vitro model does not account for GVHD prophylaxis drugs that are routinely employed 
in the clinical setting to reduce the incidence and severity of acute GVHD.  Wang et al 
(2006) have demonstrated similar discrepancies, with human skin explant GVHR grades 
correlating significantly with clinical acute GVHD in HLA-matched sibling transplant 
patients treated with CsA alone, but not those treated with CsA + MTX.  In this current 
study, as a result of the administration of high intensity GVHD prophylaxis post-
transplant (CsA ± MTX or MM), 54 of the 61 patients with GVHR grades III-IV in the 
human skin explant model developed only grades 0-II acute GVHD in the clinical 
setting.  Consequently, the high in vitro production of IL-13 was not reflective of the 
markedly reduced acute GVHD observed in vivo.   Thus, the development of an in vitro 
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model of acute GVHD that includes the administration of GVHD prophylaxis drugs 
would be more representative of HSCT in vivo and may therefore be a more useful 
research tool.   
 
As previously described, Jordan et al (2004) demonstrated a significant association 
between high IL-13 production in allogeneic MLCs and the development of severe 
acute GVHD in the clinical setting.  This study, however, failed to reproduce the 
finding.  Instead our results showed an inverse relationship between high IL-13 
expression and acute GVHD severity.  Differences in methodology may account for this 
discrepancy.  In the present study, raw IL-13 expression data from 90 allogeneic MLCs 
was correlated with acute GVHD, whereas Jordan et al correlated positive and negative 
IL-13 expression in 24 allogeneic MLCs with the condition.  In addition to the 
noticeable difference in sample size, the transplant cohort in the latter study was divided 
into positive and negative IL-13 producers using a seemingly arbitrary cut-off value of 3 
standard deviations above the lowest level of detection (Jordan et al. 2004).  
Manipulation of the data in such a manner, especially considering the small nature of 
the cohort examined, may have introduced some degree of error into the study.  It is 
arguable that our approach, which relies on the direct comparison of IL-13 levels with 
clinical acute GVHD grades, is more accurate and sensitive to subtle differences in IL-
13 expression.  Despite this, due to the small nature of both studies the findings should 
be interpreted with caution, until either is confirmed in a larger allogeneic MLC cohort.  
 
In vivo IL-13 expression was also examined in this study.  Initially, IL-13 serum levels 
in HSCT patients and healthy controls were compared.  The significantly higher levels 
observed in the transplant patients at all eight time points (day -7, day 0, day 7, day 14, 
day 28, 3 months, 6 months and 12 months) investigated (P<0.0001, Figure 5.8) 
indicate that HSCT has a substantial affect on in vivo IL-13 expression, while, the 
extremely low IL-13 serum levels demonstrated in the healthy controls seem to suggest 
that IL-13 release is predominantly from activated cells.  As IL-13 levels in the healthy 
controls remained relatively constant, it is likely that the variability observed in patient 
IL-13 expression was transplant, treatment or outcome related rather than a naturally 
occurring phenomenon.  Noticeable decreases in IL-13 were observed on day 7, 6 
months and 12 months post-transplant in all 30 HSCT patients and most probably 
reflected the effects of the transplant procedure on patient and/or donor cell numbers.  
The administration of steroids, such as methylprednisone and prednisolone, can also 
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cause a similar reduction in cytokine expression by the suppression of immune (T) cells.  
However, as the decreases in IL-13 expression were observed in both patients with and 
without GVHD, the cause is unlikely to be steroid related.  A relatively sharp increased 
in IL-13 between day -7 (pre-transplant) and day 0 was also observed in all 30 HSCT 
patients.  This rise coincided with the period of conditioning prior to HSCT.  As 
conditioning regimens used to prepare the patient for transplantation cause tissue 
damage and activate host cells, the increase in IL-13 serum levels between these time 
points may reflect the release of this cytokine from activated T and other immune cells 
in response to the damage.  As IL-13 can up-regulate MHC expression (Punnonen et al. 
1993; Chomarat and Banchereau 1998), it is possible that the IL-13 produced during the 
conditioning period contributes to the first phase of the acute GVHD mechanism.  The 
higher expression observed between day -7 and day 0 in the patients with acute GVHD 
compared to those without the condition (Figures 5.9 and 5.10) seem to support this 
hypothesis.  However, it is also possible that the IL-13 expression observed between the 
two time points is merely a by-product from activated cells; particularly T cells and the 
higher IL-13 serum levels associated with acute GVHD are simply reflective of the 
heightened activation state in these patients. 
    
In vivo IL-13 expression was also examined with respect to HSCT outcomes.  
Correlations could not be made with TRM in this study, as all observed deaths were 
relapse related.  No associations were demonstrated with overall survival and relapse 
incidence.  However, elevated IL-13 serum expression was observed in HSCT patients 
with GVHD.  Transplant patients with overall acute GVHD (grades I-III) had higher IL-
13 serum levels than those with no acute GVHD at all time points tested (day -7, day 0, 
day 7, day 14, day 28 and 3 months; Figure 5.9).  Furthermore, HSCT patients with 
chronic GVHD had considerably higher IL-13 serum levels than those without the 
disease (Figure 5.11).   Although this data should be interpreted with some caution due 
to the small nature of the HSCT population examined (n=30), the findings of this in vivo 
expression study seem to suggest a role for IL-13 in both acute and chronic GVHD.  As 
IL-13 levels were higher at all time points across the transplant period it is unlikely that 
the expression of this cytokine is related solely to the onset of acute or chronic GVHD; 
a role in the maintenance of these conditions is more likely.  As IL-13-mediated Th2 
effector functions are capable of producing the inflammation associated with asthma 
(Grunig et al. 1998; Wills-Karp et al. 1998; Walter et al. 2001), it is possible that IL-13 
secreted from donor T cells during GVHD contributes similarly to this inflammatory 
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response.  Considering the associations already demonstrated between the IL13 +2044 
A allele and acute and chronic GVHD, it is possible that this allele is involved in the up-
regulation of IL-13 observed in GVHD.  
 
Possession of the IL13 +2044 A allele was demonstrated to associate with the 
development of severe acute (grades III-IV) and chronic GVHD in the HSCT cohort 
utilised in the functional study (P=0.037 OR=3.219 and P=0.026 OR=5.016 
respectively).  However, altered IL-13 expression could not be correlated with the IL13 
+2044 G/A polymorphism in this cohort; there was no significant difference in the IL-
13 levels of IL13 +2044 A or G individuals.  It therefore seems extremely likely that the 
IL13 +2044 G/A polymorphism is linked with acute and chronic GVHD susceptibility, 
although, it is unlikely that the IL13 +2044 A allele is directly responsible for the 
elevated IL-13 levels observed in patients with these conditions.  The increased stability 
of IL13 +2044 A encoded IL-13 molecules in serum and plasma (Arima et al. 2002) is a 
more plausible explanation for the slightly higher IL-13 levels observed in the 
individuals with the IL13 +2044 A allele (Figure 5.12).    
 
Given that the location of IL13 +2044 G/A is in exon 4, a gene coding region; it is more 
likely that the polymorphism will affect the structure and/or function of IL-13 rather 
than its expression.  In the single published study examining the structural and 
functional significance of IL13 +2044 G/A, the G→A acid substitution caused by the 
polymorphism was shown to occur in α helix D, a region that is critical for IL-13/IL-13 
receptor interactions and IL-13-mediated signalling (Vladich et al. 2005).  IL13 +2044 
A encoded IL-13 was also shown to be much more active than wild-type IL-13 at 
triggering the IL-13 signalling pathway (IL-4Rα-Stat6 pathway) and inducing IL-13-
mediated effector functions, such as CD23 expression and IgE synthesis (Vladich et al. 
2005).  Moreover, IL13 +2044 A encoded IL-13 was found to be neutralized less 
effectively by IL-13Rα2, a soluble receptor that normally restrains the activity of wild-
type IL-13 in vivo (Vladich et al. 2005).  Thus, the findings of this functional study 
seem to suggest that the IL13 +2044 A allele increases the biological activity of IL-13.  
As this cytokine is a potent effector of Th2-mediated responses it is therefore possible 
that IL13 +2044 A mediates its effects on GVHD through augmentation of these 
responses. 
 
152 
 
Despite the associations demonstrated between IL13 +2044 A and acute and chronic 
GVHD in this study, it is highly unlikely that a single polymorphic allele is solely 
responsible for any role IL-13 plays in the development of GVHD.  It is more likely that 
the effects of IL-13 are also mediated by other polymorphisms within IL13 or other 
genes in close proximity.  One such polymorphism is IL13 -1112 C/T.  This promoter 
polymorphism has been found to be in strong linkage disequilibrium with IL13 +2044 
G/A in several populations (Tarazona-Santos and Tishkoff 2005) and the IL13 -1112 T 
allele has been shown to increase IL-13 production through enhanced IL13 transcription 
(van der Pouw Kraan et al. 1999; Cameron et al. 2006).  Although the individual effects 
of IL13 +2044 G/A and IL13 -1112 C/T are relatively modest, any increase in IL-13 
activity caused by IL13 +2044 A combined with the enhanced IL13 transcription 
associated with IL13 -1112 T may synergize to amplify IL-13-dependent events (van 
der Pouw Kraan et al. 1999; Vladich et al. 2005).  Thus, individuals with both IL13 
+2044 A and IL13 -1112 T are expected to produce large amounts of an over-active 
form of IL-13 (Vercelli 2008).  It would therefore be of great importance to examine the 
IL13 -1112/+2044 T-A haplotype in the HSCT setting.  The investigation of other 
functional polymorphisms in linkage disequilibrium with IL13 +2044 G/A would also 
be of interest.   
 
The genetic associations demonstrated with severe acute and chronic GVHD in this 
study provide strong evidence that the IL13 +2044 G/A polymorphism is an 
independent risk factor for the development of these conditions following both HLA-
matched sibling and unrelated donor HSCT.  Thus, it is extremely likely that IL13 
+2044 G/A will provide key pre-transplant information and may strengthen the 
predictive value of a prognostic index for GVHD when included alongside other 
significant clinical and genetic parameters.  Although this polymorphism was examined 
in a relatively large cohort (n=600), the confirmation of our findings in an even larger 
independent transplant population would be of greater significance, as this would 
provide evidence of reproducibility and would allow the heterogeneous nature of HSCT 
cohorts to be accounted for more effectively (section 4.11).  The future analysis of 
polymorphisms in linkage disequilibrium with IL13 +2044 G/A is also of great 
importance.  As the modest influence that individual polymorphisms have on GVHD 
may become much more significant when considered in combination. 
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The functional significance of the IL13 +2044 G/A polymorphism in GVHD is 
however, less clear.  The higher IL-13 expression observed in patients with acute and 
chronic GVHD seems to implicate IL-13 in the pathogenesis of these conditions, but 
this altered expression could not be directly attributed to IL13 +2044 G/A.  IL-13 
production by allo-reactive donor T cells during GVHD and/or increased IL13 gene 
transcription by linked polymorphisms are more likely to be responsible.  Published 
functional data seems to suggest that IL13 +2044 A increases the activity and stability 
of IL-13 rather than its expression.  Thus, carriers of this allele will have enhanced IL-
13-mediated Th2 effector functions.  Further functional studies are required to confirm 
this heightened activity, however, verification of the finding would suggest specific 
blocking of IL-13 as a possible future GVHD treatment for patients with IL13 +2044 A. 
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Chapter 6. Prognostic Significance of Elevated IL-13 Serum Levels 
Prior to HSCT 
 
It is well established that the production of inflammatory cytokines following HSCT 
strongly associates with the development of transplant complications, particularly 
GVHD (Antin and Ferrara 1992; Allen et al. 1993; Via and Finkelman 1993; Hempel et 
al. 1997; Liem et al. 1998; Remberger et al. 2003; Schot et al. 2003; Visentainer et al. 
2003).  However, the release of these cytokines prior to transplantation may also 
correlate with HSCT outcome.  Studies have shown elevated TNFα production during 
the course of pre-transplant conditioning to be highly predictive of acute GVHD (Holler 
et al. 1995), whilst increased production of IL-10 at the time of hospital admission has 
been found to predict an uneventful course, with the absence of acute GVHD (Holler et 
al. 2000).  Such findings seem to suggest that cytokine monitoring prior to 
transplantation may be a means of gaining valuable prognostic information, that in the 
future may allow the identification of high risk patients and the early detection of major 
complications in these individuals. 
 
Considering the high degree of variability observed in the pre-transplant (day -7) IL-13 
serum levels obtained for the Newcastle HSCT patients examined in the previous 
chapter, it is possible that altered expression of this cytokine prior to transplantation 
may also inform on outcome following HSCT.  As a result, this current study aims to 
establish the prognostic significance, if any, of IL-13 serum expression prior to 
transplantation.   
 
6.1 Study Aims 
 
v) To establish and compare pre-transplant IL-13 serum levels in Newcastle and 
Regensburg HSCT patients. 
 
vi) To compare HSCT outcome, in terms of acute GVHD incidence and severity, 
chronic GVHD incidence, relapse incidence and overall survival with pre-
transplant IL-13 serum levels in Newcastle and Regensburg HSCT patients. 
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vii) To determine the effects of clinical and patient parameters on pre-transplant IL-13 
serum levels. 
 
6.2 Statistical Analysis 
 
As the two HSCT cohorts examined in this study were small (Newcastle n=30, 
Regensburg n=36), normality tests were not performed and all correlations were 
examined using non-parametric methods.  The Mann-Whitney U test was employed 
when comparing two groups and the Kruskal-Wallis test was utilised when three or 
more groups were present.  Data analysed with respect to age, gender and CMV status 
were tested using Fisher’s exact test.  In all cases, P values <0.05 were considered 
statistically significant and values between 0.05 and 0.1 were indicative of a trend.    
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6.3 Experimental Design 
 
6.3.1 Inclusion and Exclusion Criteria 
 
All patients recruited as part of a European Commission FP5 biotechnology project 
(Eurobank QLRI-CT-2000-00010, PI Professor A M Dickinson), that were transplanted 
between November 1983 and December 2006 and had pre-transplant serum samples and 
1 year’s clinical follow-up available, were included in the analyses.  The study was 
given JLEC approval (Appendix B) and informed consent was obtained from all 
patients.  Exclusion criteria were as follows:  
 
i) Transplantation not performed 
ii) Incomplete HSCT outcome data 
iii) Incomplete HLA typing data  
iv) Below the age of 16 at the time of transplant   
v) Transplantation for an immunological disease  
vi) Transplantation with a source other than PBSC or bone marrow 
vii) Two or more transplants performed 
 
Once the inclusion and exclusion criteria had been taken into account, the Newcastle, 
UK (cohort 1) and Regensburg, German (cohort 2) HSCT populations examined in this 
study consisted of 30 and 36 patients respectively. 
 
6.3.2 Control Measures 
 
To exclude treatment related effects, all serum samples employed were obtained at the 
time of hospital admission and prior to the administration of any conditioning regimens.  
IL-13 quantification was achieved using the Human IL-13 Low Level ELISA Kit 
described in section 3.13.  All ELISAs performed included an appropriate standard 
dilution series and a negative control.  Samples and standards were tested in duplicate 
and the mean value for each set was used for quantification.  Samples were re-assayed if 
the values for the two replicates varied by more than 15%.  The quantification of IL-13 
in all serum samples was performed whilst blinded to clinical outcome. 
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6.3.3 Method of Analysis    
 
In an attempt to prevent spurious results, pre-transplant IL-13 serum levels were 
examined in two independent HSCT cohorts.  In order to demonstrate that selection bias 
was absent, the IL-13 levels determined for each of these cohorts were compared prior 
to any correlations with HSCT outcome.  The prognostic significance of IL-13 was then 
established by examining for associations between pre-transplant IL-13 levels and the 
incidence and severity of acute GVHD, incidence of chronic GVHD, relapse incidence, 
and overall survival.  Correlations with TRM could not be carried out in this study, as 
only 5 patients died from causes other than relapse.  The affect of clinical and patient 
factors, including age, gender, CMV status, underlying disease, disease stage at the time 
of HSCT and IL13 +2044 G/A alleles on IL-13 expression was also established.   
 
The two HSCT cohorts employed in this study were mixed for transplant type (HLA-
matched sibling/unrelated donor), underlying disease, disease stage (early/advanced), 
conditioning regimen (low intensity/myeloablative), prophylaxis intensity (low/high) 
and graft manipulation (T cell replete/T cell deplete); all of which have the potential to 
influence HSCT outcome.  The most accurate and reliable means of accounting for this 
heterogeneity is cohort stratification.  However, due to the small nature of both 
populations, this approach could not be performed.   
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6.4 Study Populations 
 
6.4.1 Cohort 1  
 
Newcastle HSCT Patients 
 
Pre-transplant IL-13 serum levels were examined in 30 allogeneic HSCT patients.  This 
was an adult cohort (≥16 at the time of transplant) comprising of 26 HLA-matched 
sibling HSCT patients and 6 unrelated donor transplant patients.  HLA matching was 
performed by high resolution DNA-based typing for HLA-A, B, C, DRB1 and DQB1.  
Complete matching at all 5 loci was observed in all transplant pairs. 
 
Cohort characteristics: 
The 30 HSCT patients included in this cohort were transplanted between November 
1983 and December 2006 at the Royal Victoria Infirmary, Newcastle upon Tyne, UK.  
All patients and donors were recruited and consented as part of the previously described 
‘Eurobank Project’ (section 6.3.1).  
  
Acute GVHD was assessable in all 30 patients and developed in 24.  The severity of 
GVHD ranged from 0-III; 6 patients developed no GVHD, 10 grade I, 10 grade II and 4 
grade III.  Chronic GVHD was assessable in 20 patients and developed in 12 cases.  All 
transplant patients were prepared for HSCT with low intensity (n=18) or myeloablative 
conditioning (n=12) regimens and 57% (n=17) were transplanted with T cell depleted 
stem cell grafts.  The survival rate for this cohort was 77% (n=23).  The cause of death 
(n=7) in all cases was disease relapse.  Table 6.1 shows the demographic characteristics 
of the HSCT patients included in this study.      
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Table 6.1 Characteristics of the Newcastle HSCT Patients (cohort 1 n=30). 
CMV, cytomegalovirus; TCD, T cell depletion 
 
 
 
TRANSPLANT PATIENTS 
 
Median Age      40 years (range 19-57) 
      Number in each group 
Gender 
 Male       21 
 Female         9 
 
CMV Status 
 Positive      16 
 Negative      14 
 
Underlying Disease 
 Acute Lymphoblastic Leukaemia      3 
 Acute Myeloid Leukaemia       9 
 Chronic Myeloid Leukaemia       3 
 Hodgkin disease        5 
 Non-Hodgkin Lymphoma       4 
  Plasma Cell Neoplasm        3 
  Aplastic Anaemia        1 
  Myelodysplastic Syndrome       2 
 
Conditioning Therapy 
  Low intensity       18 
  Myeloablative       12 
 
  TCD         17 
 
HSCT Outcome 
  Acute GVHD        24 
  Chronic GVHD        12 
  Relapse         10 
  Survival        23 
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6.4.2 Cohort 2 
 
Regensburg HSCT Patients 
 
Pre-transplant IL-13 serum levels were examined in 36 allogeneic HSCT patients.  This 
was an adult cohort (≥16 at the time of transplant) comprising of 15 HLA-matched 
sibling HSCT patients and 21 unrelated donor transplant patients.  HLA matching was 
performed by high resolution DNA-based typing for HLA-A, B, C, DRB1 and DQB1.  
Complete matching at all 5 loci was observed in all transplant pairs. 
 
Cohort characteristics: 
The 36 HSCT patients included in this cohort were transplanted between November 
1983 and December 2006 at the University Medical Centre, Regensburg, Germany.  All 
patients and donors were recruited and consented as part of the previously described 
‘Eurobank Project’ (section 6.3.1).  
  
Acute GVHD was assessable in all 36 patients and developed in 20.  The severity of 
GVHD ranged from 0-IV; 16 patients developed no GVHD, 11 grade I, 4 grade II, 4 
grade III and 1 grade IV.  Chronic GVHD was assessable in 30 patients and developed 
in 15 cases.  All transplant patients were prepared for HSCT with low intensity (n=29) 
or myeloablative conditioning (n=7) regimens and 61% (n=22) were transplanted with T 
cell depleted stem cell grafts.  The survival rate for this cohort was 75% (n=27) and 
causes of death (n=9) included disease relapse, infection and GVHD.  Table 6.2 shows 
the demographic characteristics of the HSCT patients included in this study.      
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Table 6.2 Characteristics of the Regensburg HSCT Patients (cohort 2 n=36). 
CMV, cytomegalovirus; TCD, T cell depletion 
 
 
 
TRANSPLANT PATIENTS 
 
Median Age      42 years (range 20-67) 
      Number in each group 
Gender 
 Male      21 
 Female      15 
 
CMV Status 
 Positive      19 
 Negative      17 
 
Underlying Disease 
 Acute Lymphoblastic Leukaemia      3 
 Acute Myeloid Leukaemia     21 
 Chronic Myeloid Leukaemia       2 
 Hodgkin disease        3 
 Non-Hodgkin Lymphoma       3 
  Plasma Cell Neoplasm        2 
  Aplastic Anaemia        1 
  Myelodysplastic Syndrome       1 
 
Conditioning Therapy 
  Low intensity        29 
  Myeloablative          7 
 
  TCD         22 
 
HSCT Outcome 
  Acute GVHD        20 
  Chronic GVHD        15 
  Relapse           9 
  Survival        27 
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6.5 Comparison of Pre-transplant IL-13 Serum Expression in Two Independent 
HSCT Cohorts 
 
Prior to any correlations with HSCT outcome, pre-transplant IL-13 serum levels for the 
two independent cohorts (cohort 1 and 2) examined in this study were compared.  
Although IL-13 expression in general was found to be slightly lower for cohort 2, there 
was no significant difference in the two populations (P=0.175, Figure 6.1).  The mean 
(± SEM) IL-13 level (pg/ml) in cohort 1 was 5.85 ± 0.63 compared to 4.84 ± 0.43 in 
cohort 2.  In addition, low, intermediate and high IL-13 producers were observed in 
both cohorts.  These data therefore demonstrate that selection bias was absent and the 
prognostic significance of pre-transplant IL-13 expression could be determined in both 
cohorts. 
 
 
 
Figure 6.1 Comparison of pre-transplant IL-13 expression (pg/ml) in two independent populations 
of HSCT patients.  No significant difference was observed in the mean (± SEM) IL-13 
serum level for cohort 1 (n=30) and cohort 2 (n=36, P=0.175).  IL-13, interleukin-13; P, 
P value 
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6.6 Correlation of Pre-Transplant IL-13 Serum Expression with HSCT Outcome 
 
6.6.1 Correlation of IL-13 Serum Expression with Acute GVHD 
 
Pre-transplant IL-13 serum levels were correlated with overall acute GVHD in cohort 1 
and 2.  No significant difference was observed between IL-13 levels in patients with or 
without the condition after transplantation (cohort 1 P=0.979; cohort 2 P=0.689, Figure 
6.2).  Mean (± SEM) IL-13 levels (pg/ml) in cohort 1 and 2 were 5.90 ± 0.71 and 4.33 
±0.47 respectively for patients with overall acute GVHD (grades I-IV) compared to 5.66 
± 1.50 and 4.75 ± 0.95 respectively for those with no acute GVHD. 
 
 
 
Figure 6.2 Correlation of pre-transplant IL-13 serum expression (pg/ml) with overall acute GVHD 
(grades I-IV) in two independent HSCT cohorts.  No significant difference was 
demonstrated between the mean (± SEM) IL-13 level for patients with and without 
overall acute GVHD (grades I-IV) in cohort 1 or cohort 2 (P=0.979 and P=0.689 
respectively).  IL-13, interleukin-13; P, P value; GVHD, graft-versus-host disease 
 
 
 
Pre-transplant IL-13 serum levels were also correlated with clinical acute GVHD 
(grades II-IV) in cohort 1 and cohort 2.  Again, no significant difference was observed 
between IL-13 levels in patients with or without the condition after transplantation 
(cohort 1 P=0.819; cohort 2 P=0.661, Figure 6.3).  Mean (± SEM) IL-13 levels (pg/ml) 
in cohort 1 and 2 were 5.58 ± 0.86 and 4.96 ± 1.04 respectively for patients with clinical 
acute GVHD (grades II-IV) compared to 6.08 ± 0.93 and 4.27 ± 0.47 respectively for 
those with minimal or no acute GVHD (grades 0-I). 
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Figure 6.3 Correlation of pre-transplant IL-13 serum expression (pg/ml) with clinical acute GVHD 
(grades II-IV) in two independent HSCT cohorts.  No significant difference was 
observed between the mean (± SEM) IL-13 level for patients with and without clinical 
acute GVHD (grades II-IV) in cohort 1 or cohort 2 (P=0.819 and P=0.661 respectively).  
IL-13, interleukin-13; P, P value; GVHD, graft-versus-host disease 
 
 
 
Finally, pre-transplant IL-13 serum levels were correlated with severe acute GVHD 
(grades III-IV) in cohort 1 and cohort 2.  No significant difference was observed 
between IL-13 levels in patients with severe (grades III-IV) or mild (grades 0-II) forms 
of the condition after transplantation (cohort 1 P=0.342; cohort 2 P=0.468, Figure 6.4).  
Mean (± SEM) IL-13 levels (pg/ml) in cohort 1 and 2 were 4.30 ± 0.77 and 4.78 ± 1.01 
respectively for patients with severe acute GVHD (grades III-IV) compared to 5.89 ± 
0.71 and 4.25 ± 0.51 respectively for those with mild acute GVHD (grades 0-II). 
      
 
 
Figure 6.4 Correlation of pre-transplant IL-13 serum expression (pg/ml) with severe acute GVHD 
(grades III-IV) in two independent HSCT cohorts.  No significant difference was 
observed between the mean (± SEM) IL-13 level for patients with and without severe 
acute GVHD (grades III=IV) in cohort 1 or cohort 2 (P=0.342 and P=0.468 
respectively).  IL-13, interleukin-13; P, P value; GVHD, graft-versus-host disease 
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6.6.2 Correlation of IL-13 Serum Expression with Chronic GVHD 
 
Correlation of pre-transplant IL-13 serum levels with chronic GVHD following 
transplantation revealed that there was no significant difference between IL-13 levels in 
the patients with or without the condition (cohort 1 P=0.472; cohort 2 P=0.772, Figure 
6.5).  Mean (± SEM) IL-13 levels (pg/ml) in cohort 1 and 2 were 5.33 ± 0.80 and 4.55 ± 
0.63 respectively for patients with chronic GVHD compared to 6.49 ± 1.17 and 4.37 ± 
0.64 respectively for those without chronic GVHD. 
 
 
Figure 6.5 Correlation of pre-transplant IL-13 serum expression (pg/ml) with chronic GVHD in 
two independent HSCT cohorts.  No significant difference was observed between the 
mean (± SEM) IL-13 level for patients with and without chronic GVHD in cohort 1 or 
cohort 2 (P=0.472 and P=0.772 respectively).  IL-13, interleukin-13; P, P value; 
GVHD, graft-versus-host disease 
 
 
 
6.6.3 Correlation of IL-13 Serum Expression with Relapse Incidence 
 
Comparison of pre-transplant IL-13 serum levels with the incidence of relapse revealed 
a correlation in both cohort 1 and cohort 2.  IL-13 levels were demonstrated to be higher 
for the patients who had disease relapse following HSCT (cohort 1 P=0.012; cohort 2 
P<0.0001, Figure 6.6).  Mean (± SEM) IL-13 levels (pg/ml) in cohort 1 and 2 were 8.61 
± 1.17 and 7.83 ± 0.88 respectively for relapsed patients compared to only 4.47 ± 0.53 
and 3.31 ± 0.24 respectively for those with no relapse. 
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Figure 6.6 Correlation of pre-transplant IL-13 serum expression (pg/ml) with the incidence of 
relapse in two independent HSCT cohorts.  The mean (± SEM) IL-13 level was 
significantly higher for patients with disease relapse following transplantation in cohort 
1 and cohort 2 (P=0.012 and P<0.0001 respectively).  IL-13, interleukin-13; P, P value 
 
 
6.6.4 Correlation of IL-13 Serum Expression with Post-Transplant Survival 
 
Correlation of pre-transplant IL-13 serum levels with post-transplant survival 
demonstrated an association with increased mortality in cohort 1.  IL-13 levels were 
found to be higher for patients who died following transplantation (P=0.019, Figure 
6.7).  The mean (± SEM) IL-13 level (pg/ml) for patients alive after HSCT was only 
4.91 ± 0.61 compared to 8.94 ± 1.27 for those who died.  However, this association 
could not be replicated in cohort 2.  No significant difference in IL-13 expression was 
observed between the patients who were alive or died post-transplant in this cohort 
(P=0.465, Figure 6.7).  The mean (± SEM) IL-13 level (pg/ml) for patients alive after 
HSCT was 4.08 ± 0.39 compared to 5.51 ± 1.25 for those that died.   
 
In terms of the cause of death, all 7 patients in cohort 1 died from disease relapse.  In 
cohort 2, 4 patients died from disease relapse; the highest IL-13 producers, 3 died from 
infection and 2 patients died from GVHD.   
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Figure 6.7 Correlation of pre-transplant IL-13 serum expression (pg/ml) with post-transplant 
survival in two independent HSCT cohorts.  In cohort 1, the mean (± SEM) IL-13 level 
was significantly higher for patients who died following transplantation (P=0.019).  In 
cohort 2, no significant difference was demonstrated in the mean (± SEM) IL-13 level   
for patients who were alive or died post-transplant (P=0.465).  IL-13, interleukin-13; P, 
P value 
 
 
 
6.7 Analysis of Risk Factors of Elevated IL-13 Serum Expression 
 
A variety of clinical and patient parameters were analysed in order to identify factors 
associated with elevated IL-13 serum expression prior to transplantation.  The 
parameters included in this aspect of the study were age, gender, CMV status, 
underlying disease, stage of disease at the time of HSCT and IL13 +2044 G/A alleles.  
 
6.7.1 Patient Age 
 
As patient age over 40 years is a considerable clinical risk factor in HSCT (Gratwohl et 
al. 1998; Cavet et al. 2001), pre-transplant IL-13 serum levels were compared amongst 
patients aged ≤40 years and >40 years in both cohort 1 and cohort 2.  No significant 
difference was demonstrated for IL-13 levels in either age group (cohort 1 P=0.125; 
cohort 2 P=0.610).  Mean (± SEM) IL-13 levels (pg/ml) in cohort 1 and 2 were 6.86 ± 
1.03 and 4.92 ± 0.76 respectively for patients ≤40 years compared to 5.85 ± 0.66 and 
4.06 ± 0.48 for patients >40 years.      
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6.7.2 Patient Gender 
 
Pre-transplant IL-13 serum levels were compared amongst male and female HSCT 
patients.  No significant correlation was demonstrated between the level of this cytokine 
and either gender (cohort 1 P=0.469; cohort 2 P=0.352).  Mean (± SEM) IL-13 levels 
(pg/ml) in cohort 1 and 2 were 5.47 ± 0.70 and 4.08 ± 0.53 respectively for male HSCT 
patients compared to 6.73 ± 1.33 and 4.95 ± 0.72 respectively for female patients.   
 
 
6.7.3 Patient CMV status 
 
As CMV infection is a considerable clinical risk factor in HSCT (Nichols et al. 2002), 
pre-transplant IL-13 serum levels were compared amongst CMV positive and negative 
patients in both cohort 1 and cohort 2.  No significant difference was demonstrated for 
IL-13 levels in either group (cohort 1 P=0.787; cohort 2 P=0.296).  Mean (± SEM) IL-
13 levels (pg/ml) in cohort 1 and 2 were 5.62 ± 0.77 and 5.07 ± 0.70 respectively for 
CMV positive patients compared to 6.12 ± 1.05 and 4.74 ± 0.43 respectively for CMV 
negative patients. 
 
 
6.7.4 Underlying Disease and Stage at the Time of HSCT 
 
 
Both HSCT cohorts examined in this study were heterogeneous for disease.  Diagnoses 
included acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), 
chronic myeloid leukaemia (CML), Hodgkin disease (HD), plasma cell neoplasm 
(PCN), aplastic anaemia (AA), myelodysplastic syndrome (MDS) and non-Hodgkin 
lymphoma (NHL, section 6.4).  As the biology of each of these haematological diseases 
differs greatly, disease specific IL-13 expression was examined in this study.  As 
expected, pre-transplant IL-13 serum levels were found to vary for each disease, 
however, IL-13 levels for patients with HD were demonstrated to be significantly higher 
than those with any other disease diagnoses (cohort 1 P=0.004; cohort 2 P=0.015, 
Figure 6.8).  In both cohorts, the IL-13 levels observed for HD patients were over twice 
as high as the levels observed for most of the other diseases.  Mean (± SEM) IL-13 
levels (pg/ml) for the patients with HD, AML, ALL, CML, PCN, AA, MDS and NHL 
were 11.94 ± 0.68, 6.12 ± 0.61, 2.10 ± 0.28, 4.48 ± 1.11, 3.94 ± 0.75, 1.49, 6.06 ± 0.34 
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and 3.88 ± 1.16 respectively in cohort 1 and 11.02 ± 0.32, 4.39 ± 0.36, 3.31 ± 0.92, 4.14 
± 0.38, 1.51 ± 0.31, 1.16, 2.56 and 3.21 ± 0.59 respectively in cohort 2. 
 
 
 
 
 
Figure 6.8 Correlation of pre-transplant IL-13 serum expression (pg/ml) with underlying disease in 
two independent HSCT cohorts.  The mean (± SEM) IL-13 level was significantly 
higher for the patients with Hodgkin disease in both cohort 1 and cohort 2 (P=0.004 and 
P=0.015 respectively).  IL-13, interleukin-13; P, P value; AML, acute myeloid 
leukaemia; ALL, acute lymphoblastic leukaemia; CML, chronic myeloid leukaemia; 
HD, Hodgkin disease; PCN, plasma cell neoplasm; AA, aplastic anaemia; MDS, 
myelodysplastic syndrome; NHL, non-Hodgkin lymphoma 
 
 
 
Considering the correlation between relapse incidence and pre-transplant IL-13 levels 
already demonstrated in this study (section 6.6.3), disease specific IL-13 expression was 
also examined in the patients who relapsed post-transplant.  In cohort 1, disease relapse 
was observed in 10 HSCT patients; 2 had AML, 1 had CML, 5 had HD and 2 had PCN.  
In cohort 2, disease relapse occurred in 9 patients; 5 had AML, 1 had CML and 3 had 
HD.  Again, pre-transplant IL-13 serum expression was found to be significantly higher 
for the patients with HD (cohort 1 P=0.042; cohort 2 P=0.040, Figure 6.9).  In cohort 1, 
the mean (± SEM) IL-13 level (pg/ml) for the HD patients was 11.94 ± 0.68 compared 
to only 6.04 ± 0.90, 4.97 and 4.69 ± 0.11 for those with AML, CML and PCN 
respectively.  In cohort 2, the mean (± SEM) IL-13 level for the HD patients was 11.02 
± 0.32 compared to only 6.58 ± 0.54 and 4.52 for those with AML and CML 
respectively.        
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Figure 6.9 Correlation of pre-transplant IL-13 serum expression (pg/ml) with underlying disease in 
two independent relapse cohorts.  Pre-transplant IL-13 expression was demonstrated to 
be significantly higher for the patients with Hodgkin disease (cohort 1 P=0.042, cohort 
2 P=0.040).  IL-13, interleukin-13; P, P value; AML, acute myeloid leukaemia; CML, 
chronic myeloid leukaemia; HD, Hodgkin disease; PCN, plasma cell neoplasm 
 
 
 
The affect of disease stage on pre-transplant IL-13 expression was also examined in this 
study.  IL-13 serum levels were compared amongst patients with early (first chronic 
phase, first complete remission or plateau 1) and advanced (accelerated phase, second or 
third complete remission or plateau 2) disease at the time of HSCT.  No significant 
difference was demonstrated for IL-13 levels in either group (cohort 1 P=0.197; cohort 
2 P=0.183, Figure 6.10), although, the mean (± SEM) expression (pg/ml) for the 
patients with advanced disease in cohort 1 and 2 was 7.59 ± 1.36 and 5.04 ± 0.68 
respectively compared to only 4.85 ± 0.51 and 3.77 ± 0.47 respectively for the patients 
with early disease.  The elevated mean (± SEM) IL-13 expression observed for the 
advanced disease groups was not truly representative, but rather was a consequence 
(falsely skewed) of the higher pre-transplant IL-13 serum levels associated with the 
patients with HD (cohort 1 n=5; cohort 2 n=3).           
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Figure 6.10 Correlation of pre-transplant IL-13 serum expression (pg/ml) with disease stage at the 
time of HSCT in two independent HSCT cohorts.  No significant difference was 
observed in the mean (± SEM) IL-13 level for patients with early or advanced stage 
disease at the time of HSCT in cohort 1 or cohort 2 (P=0.196 and P=0.183 
respectively).  IL-13, interleukin-13; P, P value 
 
 
 
6.7.5 IL13 +2044 G/A Polymorphism 
 
Pre-transplant IL-13 serum levels were correlated with the allelic variants of the 
previously examined IL13 +2044 G/A polymorphism (chapter 5, section 5.5).  Although 
in both cohorts, mean (± SEM) IL-13 levels for the patients with the IL13 +2044 A 
allele were found to be higher than those with the IL13 +2044 G allele, the difference 
between the two groups did not reach significance (cohort 1 P=0.619; cohort 2 P=0.296, 
Figure 6.11).  Mean (± SEM) IL-13 levels (pg/ml) for cohort 1 and 2 were 6.61 ± 1.12 
and 5.23 ± 0.95 respectively for the patients with IL13 +2044 A compared to only 5.09 
± 0.56 and 3.88 ± 0.38 respectively for those with IL13 +2044 G.  The highest pre-
transplant IL-13 levels observed for both cohorts, were however, for the 8 HD patients 
included in this study (cohort 1 n=5; cohort 2 n=3); all of which possessed the IL13 
+2044 A allele.    
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Figure 6.11 Correlation of pre-transplant IL-13 serum expression (pg/ml) with the IL13 +2044 G/A 
polymorphism in two independent HSCT cohorts.  No significant difference was 
observed in the mean (± SEM) IL-13 level for patients with the A or G allele in cohort 1 
or cohort 2 (P=0.196 and P=0.183 respectively).  IL-13, interleukin-13; P, P value 
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6.8 Discussion  
 
In an attempt to prevent spurious results, pre-transplant IL-13 serum levels were 
examined in two independent patient cohorts; Newcastle HSCT patients (cohort 1) and 
Regensburg HSCT patients (cohort 2).  As this was not a case-controlled study, the two 
patient populations examined were compared prior to any correlations with HSCT 
outcome.  In terms of patient demographics, both populations were similar for size 
(cohort 1 n=30, cohort 2 n=36), age (median age: cohort 1, 40(19-57); cohort 2, 42(20-
67)) and gender (cohort 1 M=21 F=9, cohort 2 M=21 F=15).  In addition, all patients 
had haematological diseases and all samples were collected at the time of hospital 
admission and prior to the administration of any preparative treatments.  With respect to 
IL-13 levels, although expression in general was found to be slightly lower for cohort 2, 
there was no significant difference in the mean (± SEM) IL-13 level observed for the 
two cohorts (P=0.175).  Furthermore, expression levels were representative of the whole 
population, with high, intermediate and low IL-13 producers being observed in both 
groups.  Thus, the two HSCT cohorts employed in this study were unbiased and 
comparable.            
 
The mean (± SEM) IL-13 serum levels (pg/ml) observed in cohort 1 and cohort 2 were 
5.85 ± 0.63 and 4.84 ± 0.43 respectively.  These levels were considerably higher than 
the mean (± SEM) IL-13 serum levels determined previously (section 5.6.3) for a cohort 
of healthy Newcastle controls (range 0.77 – 0.91 pg/ml).  Thus, the elevated expression 
observed in cohort 1 and 2 was related to the patient and/or the underlying disease 
rather than being naturally occurring.  This elevated expression was however relatively 
unexpected; IL-13 release in HSCT is thought to be predominantly from activated cells 
(Jordan et al. 2004; Hildebrandt et al. 2007), although at this time point (pre-transplant) 
the transplant patients had not yet received any form of intervention to have caused such 
activation.  Only a small number of ELISA-based studies have been published for IL-13 
detection in serum and the expression observed in these studies is variable.  The mean 
IL-13 serum level amongst an Iranian control population in a study of ischemic heart 
disease was 7.31pg/ml (Jafarzadeh et al. 2009), whilst the mean level for controls in an 
American burns study was only 0.9pg/ml (Gauglitz et al. 2008).  In another American 
study, IL-13 serum levels were reported to be undetectable for the control population 
and at least 30pg/ml for the disease population (Fiumara et al. 2001).  Although, 
differences in ELISA-based studies are often caused by inter-assay variation, it is also 
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possible that IL-13 serum levels are affected by ethnic differences; which would 
account for the variation in expression between cohort 1 and 2 in this current study.  
 
The examination of pre-transplant IL-13 serum levels with respect to HSCT outcome 
failed to demonstrate any significant associations with overall acute GVHD (grades I-
IV; cohort 1 P=0.979, cohort 2 P=0.689), clinical acute GVHD (grades II-IV; cohort 1 
P=0.819, cohort 2 P=0.661), severe acute GVHD (grades III-IV; cohort 1 P=0.342, 
cohort 2 P=0.468) or chronic GVHD (cohort 1 P=0.472; cohort 2 P=0.772, Figure 6.2, 
6.3, 6.4 and 6.5).  Even though elevated IL-13 serum levels were observed over the 
transplant period in patients with acute and chronic GVHD in the previous chapter, the 
pre-transplant levels demonstrated for both groups were very similar; thus the lack of 
associations in this study were not totally unexpected.  If allo-reactive donor T cells are 
the primary source of IL-13 in HSCT, as proposed (Jordan et al. 2004; Hildebrandt et 
al. 2007), then any link that may exist between IL-13 and GVHD is only likely to 
become apparent once the stem cell graft had been infused and donor T cells have 
become activated.  
 
A significant association was however demonstrated between pre-transplant IL-13 
serum levels and the incidence of relapse.  Patients who had disease relapse following 
HSCT were shown to have elevated IL-13 serum levels prior to transplantation (cohort 
1 P=0.012; cohort 2 P<0.0001, Figure 6.6).  Although sample populations were small, 
demonstration of this finding in both HSCT cohorts examined seems to suggest that pre-
transplant IL-13 serum expression is predictive of relapse post-transplant in this study.  
The use of this cytokine as a marker of relapse, however, currently seems questionable.  
The considerable overlap between the lowest IL-13 levels observed for the relapsed 
patients and the highest levels observed for the non-relapsed patients in this study 
indicates a lack of sensitivity for relapse at the lowest extreme.  It is possible, however, 
that the measurement of pre-transplant IL-13 serum levels in a larger HSCT cohort may 
reduce the standard error and increase the potential of this cytokine as a predictive 
marker.   
 
The elevated expression observed in the relapsed patients may also reflect the role of 
IL-13 in this disease process, as the cytokine has been demonstrated to promote the 
growth and survival of tumour cells.  Studies using murine models have proposed a 
novel pathway in which IL-13 down-regulates CD8+ cytotoxic T cell-mediated tumour 
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immunosurveillance (Terabe et al. 2000).  IL-13 released from CD4+ natural killer T 
(NKT) cells in response to tumour antigens has been demonstrated to suppress the 
tumour killing actions of cytotoxic T cells through the IL-13 signalling pathway (IL-
4Rα-Stat6 pathway) (Kacha et al. 2000; Ostrand-Rosenberg et al. 2000; Terabe et al. 
2000).  It still however, remains unclear how IL-13 actually represses cytotoxic T cells, 
since T cells do not express the IL-13 receptor (type II IL-4 receptor).  A possible 
mechanism involves the release of TGF-β from intermediary cells.  In tumour-bearing 
mice, IL-13 released by NKT cells has been shown to activate myeloid cells to produce 
TGF-β, which acts directly on CD8+ T cells to down-regulate tumour-specific cytotoxic 
T cell induction (Terabe et al. 2003).  
 
 
Pre-transplant IL-13 serum levels were also shown to correlate with post-transplant 
survival.  Patients who died following HSCT were shown to have elevated IL-13 serum 
levels prior to transplantation.  However, this association was only demonstrated for 
cohort 1 (P=0.019, Figure 6.7).  No significant difference in IL-13 expression was 
observed between the patients who were alive or died post-transplant in cohort 2 
(P=0.465, Figure 6.7).  Due to the extremely small number of deaths observed in both 
populations (cohort 1 n=7, cohort 2 n=9), these findings should be interpreted with 
caution until either is confirmed in a larger cohort.  Nevertheless, considering that 
relapse was the cause of all deaths in cohort 1, it is highly likely that the association 
observed in this population merely reflects the correlation already described between 
pre-transplant IL-13 expression and post-transplant disease relapse (section 6.6.3). 
 
A variety of clinical and patient parameters were also analysed in this study.  No 
associations were demonstrated between pre-transplant IL-13 serum levels and age, 
gender or CMV status in either cohort examined (cohort 1 P=0.125, P=0.469 and 
P=0.787 respectively; cohort 2 P=0.610, P=0.352 and P=0.296 respectively).  A 
significant correlation was however, observed with underlying disease.  In both cohorts, 
pre-transplant IL-13 serum levels for patients with HD were shown to be substantially 
higher than the levels observed for patients with any other disease diagnoses (cohort 1 
P=0.005; cohort 2 P=0.015, Figure 6.8).  A similar finding has been described by 
Fiumara et al (2001).  In a study examining IL-13 serum expression in HD and healthy 
volunteers, IL-13 levels of at least 30pg/ml were detected in patients with HD, whilst 
IL-13 expression was undetectable in all controls (Fiumara et al. 2001).  Although the 
number of HD patients examined in this current study was extremely small (cohort 1 
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n=5, cohort 2 n=3), the disease specific IL-13 expression demonstrated echoes the role 
of IL-13 in the pathogenesis of HD.  Hodgkin and Reed-Sternberg (H/RS) cells of HD 
have been demonstrated in vitro and in vivo to substantially express both IL-13 and IL-
13 receptors (Kapp et al. 1999; Skinnider et al. 2001) and have been shown to use this 
cytokine as an autocrine growth factor to enhance their own survival (Skinnider et al. 
2002a; Skinnider et al. 2002b).  Blocking of IL-13 has also been demonstrated to induce 
apoptosis in H/RS cells in vitro (Kapp et al. 1999).  This latter finding, not only 
emphasises the importance of IL-13 in the disease mechanism of HD, but implicates 
this cytokine as potential target for future treatment strategies.  
 
HD specific IL-13 expression was confirmed when pre-transplant IL-13 serum levels 
were examined in the context of post-transplant disease relapse.  The HD patients who 
relapsed following HSCT were shown to have significantly elevated IL-13 serum levels 
prior to transplantation (cohort 1 P=0.042; cohort 2 P=0.040, Figure 6.9).  In fact, the 
IL-13 levels observed for relapsed HD were almost twice as high as the levels observed 
for any of the other relapsed diseases.  Although the HD population examined in this 
study was extremely small (n=8; cohort 1=5 cohort 2=3), this finding seems to suggest 
that high IL-13 serum expression in HD patients prior to HSCT reflects a poor 
prognosis in terms of disease relapse.  From the data presented, it is not clear however, 
if this elevated expression is simply a marker of post-transplant relapse or is somehow 
involved in the development of the outcome.  It must also be considered however, that 
allogeneic transplantation for HD is often only performed when chemotherapy and 
autologous HSCT has failed and hence the demonstrated correlation between pre-
transplant IL-13 expression and HD relapse in this study may merely reflect the 
advanced nature of the disease at the time of transplantation.  Further investigations into 
the role of pre-transplant IL-13 in HD and post-transplant relapse in a larger patient 
population are therefore warranted.  In addition, while no significant correlations could 
be made between pre-transplant IL-13 expression and the IL13 +2044 G/A 
polymorphism when all patients were examined, the possession of the IL13 +2044 A 
allele by all 8 HD patients seems to suggest that an association may also exist between 
this polymorphism and post-transplant HD relapse.  As the  IL13 +2044 A allele is 
unlikely to influence cytokine expression, it is possible that the increased IL-13 activity 
proposed to associated with this allele (Vladich et al. 2005) plays a role HD relapse.  
Again, due to the extremely small nature of the HD subgroup examined in this study, 
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further investigations into the IL13 +2044 G/A polymorphism in a larger patient 
population are warranted.   
 
The examination of pre-transplant IL-13 serum levels with respect to disease stage 
(early/advanced) at HSCT failed to demonstrate an association in this current study 
(Figure 6.10).  Although the mean (± SEM) expression levels observed for the patients 
with advanced disease were elevated, they were not demonstrated to be significantly 
higher than those for the patients with early stage disease.  In a previously published 
study examining pre-transplant IL-10 levels, low expression of this cytokine prior to 
HSCT was found to correlate with advance disease stage.  The explanation for this 
finding was a decreased capacity for cytokine production in macrophages derived from 
patients with advanced disease at the time of transplant.  Exhaustion of immune 
regulation or an effect from more aggressive previous cytotoxic treatment were 
suggested causes (Holler et al. 2000).  This is seemingly not the case for IL-13 in this 
study.  However, on closer inspection of the data obtained, 6/11 and 16/19 of the 
patients with advanced disease in cohort 1 and 2 respectively had IL-13 levels that were 
comparable with those of the early stage groups.  Thus, the elevated means (± SEM) 
associated with advanced disease in both patient cohorts were therefore solely 
attributable to the remaining 8 patients (cohort 1 n=5; cohort 2 n=3); all of which were 
transplanted for HD.  In the context of this disease, an association between high IL-13 
serum levels and advanced disease should be expected.  Considering the role IL-13 
plays in the disease mechanism of HD, serum levels of this cytokine will increase as the 
disease progresses.                   
 
The observed relationship between HD and IL-13 expression in this study, not only 
confirms the role of IL-13 in the disease, but brings the validity of the previously 
demonstrated correlation between pre-transplant IL-13 expression and post transplant 
relapse (section 6.6.3) into question.  As the HD patients accounted for the highest IL-
13 levels observed in the relapsed groups and these levels were significantly higher than 
those for all of the other patients, it is extremely likely that the elevated IL-13 
expression associated with HD had a substantial influence on the mean (± SEM) IL-13 
level detected for relapse in both HSCT cohorts.  As a result, exclusion of the HD 
patients from the relapse analyses is likely to reduce the difference in IL-13 serum 
expression between the relapsed and non-relapsed patients considerably and result in the 
loss of the correlation.  Although confirmation of this is required in a larger cohort, it 
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now seems unlikely that pre-transplant IL-13 expression is a predictive marker for post-
transplant relapse.  It is more likely that the data presented in this study simply reflects 
the significance of IL-13 in HD.    
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Chapter 7. Conclusions 
 
 
The findings of this study clearly demonstrate that the genetic make-up of transplant 
patients and their donors can strongly influence GVHD development following HSCT.  
In the unrelated donor transplant setting, patient carriage of the VDR intron 8 A,A and 
IFNG intron 1 3,3 genotypes were associated with the development of severe acute 
GVHD (grades III-IV), whilst patient carriage of the IL6 -174 G,G genotype was a risk 
for chronic GVHD.  In both the HLA-matched sibling and unrelated donor settings, 
patient carriage of the IL13 +2044 A allele was associated with an increased 
susceptibility to severe acute GVHD (grade III-IV) and donor carriage of this allele was 
associated with an increased risk of chronic GVHD.  Although these associations 
require replication in a large independent validation cohort, they do provide further 
evidence for the employment of non-HLA polymorphisms pre-transplant as predictive 
markers of HSCT outcome; particularly GVHD development.  The findings of this 
study, in combination with previously published data, also highlight the need for non-
HLA polymorphisms to be analysed independently in both the HLA-matched sibling 
and unrelated donor transplant setting, as the differences in biology and clinical 
protocols employed significantly affect the genetic associations observed in each 
transplant type.     
 
The functional significance of IL-13 and the IL13 +2044 G/A polymorphism were also 
examined in this study.  Elevated IL-13 serum levels across the transplant period were 
demonstrated in patients with both acute and chronic GVHD, suggesting a role for IL-
13 in the pathogenesis of these conditions.  However, this altered expression could not 
be directly attributed to IL13 +2044 G/A.  A published functional study seems to 
suggest that this polymorphism increases the biological activity of IL-13 rather than its 
expression (Vladich et al. 2005), although, further studies are necessary to confirm this.   
Elevated IL-13 serum levels were also demonstrated prior to transplantation.  These 
levels could not be correlated with GVHD, but were shown to be disease specific; 
patients with HD had significantly higher pre-transplant IL-13 serum expression than 
patients with any other disease diagnoses.  This finding substantiates published data 
demonstrating a role for IL-13 in the disease mechanism of HD (Kapp et al. 1999; 
Skinnider et al. 2001; Skinnider et al. 2002a; Skinnider et al. 2002b).  Elevated IL-13 
expression prior to transplantation was also shown to correlate with post-transplant 
relapse.  Although our finding seems to implicate IL-13 as a predictive marker of this 
180 
 
outcome, it is likely that the elevated IL-13 expression associated with HD patients had 
a substantial influence on the correlation, thus further studies are warranted.                  
 
This study has also highlighted some of the problems associated with investigations in 
the field of HSCT.  The number of transplant procedures undertaken, particularly at 
single centres, is relatively small; thus laboratory sample and clinical data accrual is 
slow.  The collection of samples, including blood and skin biopsies is highly dependent 
on the consent and co-operation of the patient.  Consequently, study numbers are 
reduced if the patient with-holds consent or does not attend clinic appointments.  In 
addition, complete clinical information is often unavailable for patients eligible for 
inclusion in retrospective studies that were transplanted many years before the 
investigation was initiated; thus exclusion of these individuals reduces sample numbers 
even further.  
 
As HSCT is a potential treatment for a wide range of malignant and non-malignant 
haematological diseases with a variety of options available to the transplant patient and 
their treating clinician, population heterogeneity is another problem encountered in the 
transplant setting.  In addition to the underlying diagnosis of the patient, variations in 
transplant type, conditioning regimen and GVHD prophylaxis therapy have the potential 
to impact on HSCT studies.  As a result only large registry-based studies allow the 
stratification of patients with respect to these variations (Gratwohl et al. 1998; van 
Beisen et al. 2003).  In terms of genetic association studies such as this one, 
heterogeneity is extremely problematic, as the existence of multiple confounding 
variables is likely to prevent all possible disease associations from being observed.  The 
extrapolation of data from different heterogeneous studies should therefore be examined 
with caution. 
 
There is little doubt that the adoption of a limited number of conditioning regimens and 
GVHD prophylaxis therapies for transplant procedures would ease the interpretation of 
scientific studies.  At the present time, however, this would be difficult to instigate.  
Despite extensive research and advances in the HSCT setting, clinical outcome is 
unfortunately still relatively poor.  Thus, clinicians are keen to implement results from 
phase II studies as quickly as possible. 
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Despite the difficulties associated with HSCT studies, there is clearly a need for greater 
knowledge in the setting, as there is little doubt that acute and chronic GVHD remain a 
major cause of morbidity and mortality.  The ability to predict these conditions would 
therefore be invaluable.  The ideal predictive factor for GVHD would be assessable pre-
transplant.  This would permit the selection of the best possible donor if several were 
available, allow the patient to make more informed decisions about their therapeutic 
options and would possibly allow clinicians to modify conditioning and prophylaxis 
therapies in those patients at the lowest or highest risk of GVHD.  The ideal predictive 
factor would also be highly sensitive and specific and unaffected by post-transplant 
factors, such as conditioning regimen induced-toxicity and infection.  Although the 
VDR intron 8 A/C, IFNG, intron 1 (CA)n, IL6 -174 G/C and IL13 +2044 G/A 
polymorphisms were shown to be independent risk factors for GVHD in this study, it is 
unlikely that any of these alone will be the ‘ideal predictive factor’.  The identification 
of a single easily measurable factor that is highly predictive for GVHD is an attractive 
goal.  However, given the complexity of GVHD and the existence of numerous clinical 
risk factors associated with the condition, achievement of this seems extremely 
doubtful.  Much more likely, is the development of a prognostic index that consists of 
both clinical and genetic risk factors for GVHD.   
 
The data presented in this investigation have provided the basis for future non-HLA 
polymorphism studies included as part of a multicentre European project investigating 
potential risk factors for GVHD.  The study, co-ordinated in Haematological Sciences, 
Newcastle University and lead by Professor A M Dickinson is ongoing and will provide 
the opportunity to accrue a greater number of DNA samples, skin biopsies and serum 
samples from participating centres.  This will allow potential GVHD risk factors to be 
examined in much larger transplant populations, will permit the stratification of HSCT 
cohorts into more informative homogeneous disease, treatment and transplant specific 
groups and will facilitate the creation of independent validation cohorts, that are 
required to address reproducibility problems (Colhoun et al. 2003).   With regard to the 
non-HLA polymorphisms investigated in this study; IL2 -330 T/G, IL4 -590 C/T, IL6 -
174 G/C, IL10 -592 A/C, IL10 -1082 G/A, IL1RN intron 2 VNTR, TNFA intron 3 
(GA)n, TNFRSF1B -196 M/R, IFNG intron 1 (CA)n, VDR intron 8 A/C, VDR exon 9 
T/C, ESR1 intron 1 A/G and ESR1 intron 1 C/T, future aims will mainly focus on cohort 
expansion and association confirmation.  However, analysis of these polymorphisms 
with respect to HSCT outcome in larger separate HLA-matched sibling and unrelated 
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donor transplant cohorts will also be performed.  As previously mentioned, due to the 
differences in biology and clinical protocols employed, it is unlikely that exactly the 
same genetic associations will exist for both transplant settings. 
 
Cohort expansion and association confirmation in the HLA-matched sibling and/or 
unrelated donor transplant setting would not only provide substantial evidence that any 
association observed was the result of a true genetic risk factor for HSCT outcome, but 
would also permit the development of the previously outlined prognostic index.  Such 
an index would consist of the established European Group for Blood and Marrow 
Transplantation (EBMT) clinical risk score (Gratwohl et al. 1998) for all patients 
undergoing HSCT for a haematologic disorder (Gratwohl et al. 2009) combined with 
any identified genetic risk factor(s) using the approach adopted by Dickinson et al 
(2010).  Using prediction error and concordance index statistics this group demonstrated 
that the integration of three genetic factors (TNFRSFIB -196 M/R, IL10 -592/-819/-
1082 haplotype and IL1RN intron 2 VNTR) into the EBMT clinical risk score (five 
clinical factors: patient age, stage of disease, time interval from diagnosis to 
transplantation, histocompatibility and gender mismatch (female to male) 
transplantation) significantly improved this predictive model in a cohort of CML 
patients and donors (Dickinson et al. 2010).   
 
In addition to the development of a prognostic index, expansion of our existing 
transplant cohorts would also allow Genome Wide Association Studies (GWAS) to be 
performed.  These studies employ high throughput genotyping technologies to analyse 
the maximum number of genomic polymorphisms in a single assay; current microarray-
based platforms can parallel genotype almost 2 million markers dispersed throughout 
the human genome.  The employment of GWAS technologies in the transplant setting 
would be extremely valuable, as it is highly unlikely that a single genetic factor or 
inflammatory mediators alone are responsible for the complex clinical picture 
associated with GVHD and any other HSCT outcome.  However, a major drawback 
exists with the GWAS approach, the requirement for vast sample sizes; the achievement 
of which is likely to be problematic in the field of transplantation as sample accrual is 
notoriously slow.      
 
Future studies with respect to IL-13, will again mainly be focused on the confirmation 
of the genetic associations demonstrated in this study.  However, the IL13 -1112/+2044 
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T-A haplotype will be also be examined in the context of GVHD, as further definition 
of linked polymorphisms is likely to increase the predictive power of this cytokine.  The 
preliminary investigations into IL-13 expression prior to and across the transplant 
period will be ongoing.  Continued serial serum sample collection is expanding the 
cohort considerably.  Larger numbers will not only allow the heterogeneous nature of 
HSCT to be accounted for, but will permit the more accurate definition of the role of IL-
13 in GVHD.  Blocking experiments employing the human skin explants assay as a 
HSCT model will also be performed.  Blocking of IL-13 using soluble receptors or 
receptor antagonists may down-regulate the heightened biological activity possibly 
associated with the IL13 +2044 A allele and thus diminish GVHD.  In addition, 
expansion of our existing HD population (n=8) will be undertaken, as larger numbers 
will allow the role of IL-13 and the IL13 +2044 G/A polymorphism in both the disease 
mechanism of HD and post-transplant HD relapse to be explored more thoroughly.    
 
The ultimate goal of this collaborative European project is the creation of a prognostic 
index for GVHD.  This index will comprise the most informative clinical and genetic 
risk factors and will be employed pre-transplant to predict the risk of GVHD on an 
individual basis.  The successful prediction of GVHD prior to transplantation would 
lead to several immediate and long term benefits, such as better donor selection, 
improved or tailored prophylaxis therapies, shorter hospital stays and most importantly, 
reduced GVHD morbidity and mortality.  It is therefore essential that research into 
GVHD risk factors continues and encompasses all potential genetic candidates. 
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Appendix A 
 
List of Suppliers 
 
Company Name  Address of Supplier 
(shortened)     
 
AB Applied Biosystems, Lingley House, Cheshire UK 
Alpha Innotech GRI Ltd, Queenborough Lane, Braintree, Essex UK 
Axis-Shield  Axis-Shield Plc, Luna Place, The Technology Park, Dundee UK 
BDH/Merck Merck Ltd, North East Laboratory Supplies, Newton Aycliffe UK 
BD   BD Biosciences, Between Town Road, Cowely, Oxford UK 
Bioline  Bioline UK Ltd, The Edge Business Centre, London UK 
Bio-Rad Bio-Rad Laboratories Ltd, Maylands Avenue, Hemel Hempstead 
UK 
Fisher Scientific Thermo Fisher Scientific, Bishop Meadow Road, Leicestershire 
UK 
Flow Laboratories ICN Biomedicals, Wenman Road, Thame, Oxfordshire UK 
Flowgen  Flowgen Instruments Ltd, Lichfield, Staffordshire UK  
Gelman Sciences Pall Gelman Laboratories, Havant Street, Portsmouth UK 
Gibco Invitrogen Life Technologies, Inchinnian Business Park, Paisley 
UK 
Greiner Greiner Bio-One Ltd, Stroudwater Business Park, Gloustershire 
UK 
Inverness Medical Inverness Medical Innovations, Bio-Stat House, Cheshire UK 
Lonza Lonza Sales Ltd, Muenchchensteiner Strasse, Basel Switzerland 
MWG MWG Eurofins Genetic Services Ltd, Worple Park, London UK 
NBS Biologicals NBS Biologicals Ltd, Edison House, Hertfordshire UK 
NEB New England Biolabs Inc, Knowl Place, Hertfordshire UK 
Nunc Thermo Fisher Scientific, Kamstrupvej, Roskilde Denmark 
PAA PAA Laboratories Ltd, Houndstone Business Park, Somerset UK 
PeproTech  PeproTech EC Ltd, Margravine Road, London UK 
Promega  Promega Ltd, Chilworth Research Centre, Southampton UK 
Rathburn Chemicals Rathburn Chemicals Ltd, Caberston Road, Peebleshire UK 
RayBiotech  RayBiotech Inc, Parkway Lane, Norcross, Georgia USA  
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Roche   Roche Diagnostic Ltd, Bell Lane, Lewes, East Sussex UK 
Sigma  Sigma-Aldrich Chemical Company, Fancy Road, Poole, Dorset 
UK 
SLS Scientific Laboratories Supplies Ltd, Elm Road, Tyne and Wear 
UK 
ThermoLabsystems Thermo Electron Corporation, The Ringway Centre, Basingstoke 
UK  
VWR   VWR International Ltd, Magna Park, Leicestershire UK 
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Appendix C 
 
Personal Publications and Communications 
 
Publications: 
 
JL Harrold, EA Leitch, GH Jackson and AM Dickinson.  Prognostic significance of 
elevated interleukin-13 levels in patients prior to haematopoietic stem cell 
transplantation.  Bone Marrow Transplantation 2009; 43 (Supplement 1): 141. 
 
BE Turner, JL Harrold, J Norden, EA Douglas and AM Dickinson.  Cytokine 
expression and genotype can affect outcomes after haematopoietic stem cell 
transplantation.  Bone Marrow Transplantation 2009; 43 (Supplement 1): 135. 
 
EA Leitch, JL Harrold, A Ironside, J Norden, GH Jackson, E Holler, V Rocha, G 
Socie, I Hromadnikova, P Sedlacek, H Greinix, A Urbano, D Wolff and AM Dickinson.  
IL13 +2044 (Arg130Gln) associates with acute and chronic graft-versus-host disease 
following haematopoietic stem cell transplantation.  Biology of Blood and Marrow 
Transplantation 2008; 14 (Supplement 2): 13.  
 
AM Dickinson, JL Harrold and H Cullup.  Haematopoietic stem cell transplantation: 
Can our genes predict clinical outcome?  Expert Reviews in Molecular Medicine 2007; 
9: 29. 
 
U Holtick, PG Middleton, JL Harrold E Holler, E Gluckman, I Hromadnikova, AM 
Dickinson and MP Collin.  The MyD88 Adapter-Like (MAL) protein variant Leu 180, a 
candidate polymorphism for protection against graft versus host disease.  Blood 2006; 
108: 3243. 
 
JL Harrold, E Holler, I Hromadnikova, P Sedlacek, V Rocha, PG Middleton and AM 
Dickinson.  Non-HLA polymorphism risk factor analysis in unrelated haematopoietic 
stem cell transplants.  Bone Marrow Transplantation 2006; 37: 82 
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Oral Communications: 
 
European Group of Blood and Marrow Transplantation (EBMT), March 2008; 
Florence, Italy 
 
American Society for Blood and Marrow Transplantation (ASBMT), February 2008; 
San Diego, USA 
 
TRANSNET consortium meeting, October 2006; Dusseldorf, Germany 
 
Poster Presentations: 
 
European Group of Blood and Marrow Transplantation (EBMT), March 2009; 
Gothenburg, Sweden 
 
American Society of Hematology (ASH), December 2006; Orlando, USA 
 
European Group of Blood and Marrow Transplantation (EBMT), March 2006; 
Hamburg, Germany 
 
European School of Haematology - European Group of Blood and Marrow 
Transplantation (ESH-EBMT), June 2005; Sesimbra, Portugal 
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